Conjugates consisting of or comprising at least one beta-glucan or mannan

By covalently coupling β-glucan or mannan with α-synuclein epitope polypeptides and combining lithoglycan adjuvant, the problem of vector-specific antibody response in existing vaccines has been solved, achieving high efficiency , safe target-specific immune responses improve the safety and effectiveness of the vaccine.

CN119053345APending Publication Date: 2024-11-29TRIDEM BIOSCIENCE GMBH & CO KG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380034931.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-08-19
Filing Date
2023-02-28
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

When existing vaccines use β-glucan or mannan as CLEC conjugates, it is difficult to induce target-specific immune responses, and may trigger vector-specific antibody responses, affecting the safety and efficacy of the vaccine.

Method used

By covalently coupling B-cell or T-cell epitopic peptides of β-glucan or mannan with α-synuclein, a vaccine composition with high specificity and affinity is formed, using lithozolilan as C lectin adjuvant improves skin selectivity and immunogenicity and reduces vector-specific antibody response.

Benefits of technology

A target-specific immune response to α-synuclein is achieved, which reduces the antibody response to CLEC or carrier proteins, improves the safety and efficacy of the vaccine, and avoids the risk of vector-induced immune rejection in traditional vaccines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119053345A_ABST
    Figure CN119053345A_ABST
Patent Text Reader

Abstract

The present invention relates to the use of beta-glucan or mannan as a C-type lectin (CLEC) polysaccharide adjuvant of a B-cell or T-cell epitope polypeptide of alpha synuclein.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to polysaccharide adjuvants belonging to the class of C-type lectins (CLECs). Background Art

[0002] Vaccination is considered one of the most effective means of saving lives and reducing the burden of disease. Through active immunization, vaccines are administered, causing the host's immune system to produce a nonspecific innate immune response as well as specific antibodies, B and T memory cells that can act against the immunogen used.

[0003] Mannan is a polysaccharide derived from yeast cell walls, whose backbone is mainly composed of β-(1,4)-linked mannose and a small amount of α-(1,6)-linked glucose and galactose side chain residues. In addition, the protein content detected in conventional mannan preparations is about 5%. As an important component of fungal cell walls, mannan has been widely used as a component of carbohydrate-based vaccines for candidiasis (Han and Rhew, Arch Pharm Res 2012, Vol 35, No 11, 2021-2027; Cassone, Nat Rev Microbiol. 2013 Dec; 11 (12): 884-91; Johnson and Bundle, Chem. Soc. Rev., 2013, 42, 4327). In addition, different examples of vaccines based on mannan carrier-antigen complexes / conjugates have been developed, including mannan-mucin 1 (MUC1) fusion protein conjugates for tumor therapy, or conjugates of mannan with model allergens such as ovalbumin (OVA), papain, or Betv1.

[0004] Mucins are highly glycosylated proteins expressed on the cell surface. MUC1 is a prototypical mucin that has been found to be overexpressed on a wide variety of tumor cells. Along these lines, a MUC1 fusion protein containing five tandem repeats of human MUC1 (containing the immunodominant epitope: APDTRPAPGSTAPPAHGVTS) and a peptide (Cpl3-32) was made and conjugated to mannan under oxidative or reduced conditions, resulting in distinct immune responses: oxidized mannan-MUC1 stimulated a Th1-type response mediated by CD8+ T cells, with IFN-γ secretion and a predominant IgG2a antibody response, whereas reduced mannan-MUC1 stimulated a Th2-type response with IL-4 production and a high level of IgG1 antibody response. The fusion proteins used represent a single protein displaying both T-cell and B-cell epitopes.

[0005] Protein-carbohydrate / mannan complexes of papain and OVA have also recently been generated to analyze their sensitizing potential. It was found that coupling mannan to the protein surface reduced the binding and cross-linking of anti-papain IgE antibodies. Interestingly, in these experiments, coupling of mannan, dextran, or maltodextrin only reduced the sensitizing potential of papain, but not OVA, indicating the importance of carbohydrate choice for vaccine design (Weinberger et al. J. Control. Release 2013;165:101–109). These experiments also showed that mannan coupling resulted in the generation of elevated anti-OVA IgG titers after intradermal immunization.

[0006] Similar to the new sugar conjugate vaccine for MUC1, Ghochikyan et al. (DNA and CELL BIOLOGY, Volume 25, Number 10, 2006, 571-580) and Petrushina et al. (Journal of Neuroinflammation 2008, 5:42) used amyloid beta (Aβ) 28 (a 28 aa residue peptide that carries a combination of B cell epitopes and T cell epitopes of the human Aβ42 peptide) coupled to mannan to induce low-level anti-Aβ responses in mice. These responses were also demonstrated to reduce amyloid deposition in the cortex and hippocampus after subcutaneous immunization of APP transgenic mice. Immunization also resulted in the induction of increased anti-mannan titers in animals treated with Aβ28-mannan and BSA-mannan. However, the treatment failed to progress further, most likely due to increased microbleeding in the brains of treated animals, which was attributed to the potential deleterious effects of mannan as it can induce adverse vascular events, emphasizing the importance of carbohydrate selection for the design of effective and safe vaccines.

[0007] To date, no conjugates of single B-cell epitope peptides or T-cell epitope peptides conjugated to mannan or other related CLECs are known.

[0008] Beta-glucans comprise a group of beta-D-glucose polysaccharides. These polysaccharides are the main structural component of fungal cell walls and are also found in bacteria, yeast, algae, lichens, and plants such as oats and barley. Depending on the source, beta-glucans vary in the type of linkage, degree of branching, molecular weight, and tertiary structure.

[0009] β-glucan is a source of soluble, fermentable fiber (also known as prebiotic fiber), which provides substrate for the microflora in the large intestine, increases stool volume, and produces short-chain fatty acids as byproducts with a wide range of physiological activities. For example, people with normal or elevated blood cholesterol levels who consume at least 3 grams of cereal-based β-glucan from oats per day can reduce total cholesterol and low-density lipoprotein cholesterol levels by 5-10%.

[0010] Typically, β-glucans form a linear backbone with 1-3 β-glycosidic bonds, but vary in molecular weight, solubility, viscosity, branching structure, and gel properties. Yeast and fungal β-glucans are usually built on a β-(1,3) backbone with β-(1,6) side branches, while cereal β-glucans contain both β-(1,3) and β-(1,4) backbone bonds with or without side branches.

[0011] β-glucans are recognized by the innate immune system as pathogen-associated molecular patterns (PAMPs). The PRR dectin-1 has emerged as a major receptor for these carbohydrates, and β-glucans bind to dectin-1, inducing multiple cellular responses via the Syk / CARD9 signaling pathway, including phagocytosis, respiratory burst, and cytokine secretion. In addition, complement receptor 3 (CR3, CD11b / CD18) is also considered a receptor for β-glucans. Stimulation via dectin-1 has been reported to elicit responses from Th1, Th17, and cytotoxic T lymphocytes.

[0012] Members of the beta-glucan family include:

[0013] β-Glucan peptide (BGP) is a high molecular weight (~100 kDa) branched polysaccharide extracted from the fungus Trametes versicolor. BGP consists of a highly branched glucan portion containing a β-(1,4) backbone and β-(1,3) side chains, with β-(1,6) side chains covalently linked to a polypeptide portion rich in aspartic acid, glutamic acid, and other amino acids.

[0014] Curdlan is a high molecular weight linear polymer composed of β-(1,3) linked glucose residues from Agrobacterium spp.

[0015] Laminarin is derived from the brown alga Laminaria digitata (Dactyl kelp) and is a linear β-(1,3)-glucan with β-(1,6) linkages. Laminarin is a low molecular weight (5-7 kDa) water-soluble β-glucan that acts as a dectin-1 antagonist or agonist. It binds to dectin-1 without stimulating downstream signaling and can block the binding of dectin-1 to particulate β-(1,3)-glucans such as zymosan.

[0016] Pustulan is a medium molecular weight (20 kDa) linear β-(1,6) linked β-D-glucan from the lichen Lasallia pustulata. It can also bind to dectin-1 as a major receptor and activate signal transduction through dectin-1.

[0017] Lichenan is a high molecular weight (approximately 22-245 kDa) linear β-(1,3)β-(1,4)-β-D glucan from Cetraria islandica (Icelandic lichen), similar in structure to the β-glucans of barley and oats. Lichenan has a much higher ratio of 1,3-phase to 1,4-β-D bonds than the other two glucans. The ratio of β-(1,4)-phase to β-(1,3)-β-D bonds is approximately 2:1.

[0018] β-glucan from oats and barley is a linear β-(1,3)β-(1,4)-β-D glucan, which is available on the market with different molecular weights (medium molecular weight fraction is 35.6 kDa and high molecular weight fraction is up to 650 kDa).

[0019] Schizophyllan (SPG) is a gel-forming β-glucan from Schizophyllm commune. SPG is a high molecular weight (450 kDa) β-(1,3)-D-glucan with one β-(1,6) monoglucosyl branch for every three β-(1,3)-glucosyl residues on the backbone.

[0020] Scleroglucan is a high molecular weight (>1000 kDa) polysaccharide produced by fermentation of the filamentous fungus Sclerotium rolfsii. Scleroglucan consists of a linear β-(1,3)D-glucose backbone with one β-(1,6)D-glucose side chain every three main residues.

[0021] Whole Glucan Particles (WGP) are β-glucans known for their ability to modulate immune responses. Dispersible, Biothera) is a granular preparation of Saccharomyces cerevisiae β-glucan. It consists of hollow yeast cell wall "ghosts" and mainly contains long polymers of β-(1,3) glucose obtained from the cell wall of Saccharomyces cerevisiae after a series of alkali and acid extractions. Compared with other dectin-1 ligands (such as Zymosan), WGP dispersible lacks TLR stimulatory activity. In contrast, soluble WGP binds dectin-1 without activating this receptor. And it can significantly block the binding of WGP dispersible to macrophages and its immunostimulatory effects.

[0022] Zymosan (zymosan) is an insoluble preparation of yeast cells that activates macrophages via TLR2. TLR2 collaborates with TLR6 and CD14 to respond to Zymosan. Zymosan is also recognized by dectin-1, a phagocytic receptor expressed on macrophages and dendritic cells, which collaborates with TLR2 and TLR6 to enhance the immune response triggered by the recognition of Zymosan by each receptor.

[0023] As the main component of fungal cell wall, different β-glucans have been used as antigens to generate anti-glucan antibodies against fungal infection (e.g., Torosantucci et al. J Exp Med. 2005 Sep 5; 202(5): 597-606., Bromuro et al., Vaccine 28 (2010) 2615–2623, Liao et al., Bioconjug Chem. 2015 Mar 18; 26(3): 466-76).

[0024] Torosantucci et al. (2005) and Bromuro et al. (2010) disclosed conjugates of branched β-glucan laminarin and linear β-glucan caldran gum with diphtheria toxoid CRM197. These conjugate vaccines induced high IgG titers against β-glucan and conferred protection against fungal infection in mice. In addition, high titers against CRM197 were detected using such conjugates (Donadei et al., Mol Pharm. 2015 May 4; 12(5): 1662-72). These authors also generated a β-glucan-CRM197 vaccine with synthetic linear β-(1,3)-oligosaccharides or β-(1,6)-branched β-(1,3)-oligosaccharides, combined with a human-acceptable adjuvant MF59. All conjugates induced high titers of anti-β-(1,3)-glucan IgG and / or also anti-β-(1,6)-glucan antibodies, as well as anti-β-(1,3)-glucan IgG, indicating the immunogenicity of different glucan combinations with traditional carrier proteins. Interestingly, Torosantucci et al. failed to demonstrate higher anti-CRM titers after immunization with CRM-dextran conjugates than with unconjugated CRM alone.

[0025] Donadei et al. (2015) also analyzed conjugates of the diphtheria toxoid CRM197 with either the linear β-(1,3) glucan Curdlan or synthetic β-(1,3) oligosaccharides. These conjugates were immunogenic and produced comparable anti-CRM197 antibody responses. Interestingly, these authors showed that intradermal administration of the CRM Curdlan conjugate produced higher antibody titers than intramuscular (im) immunization. However, intradermal application of CRM-Curdlan did not show different immunogenicity compared to subcutaneous application. Furthermore, the in vivo effects of CRM-Curdlan and non-Curdlan conjugated CRM (with Alum as adjuvant) were comparable. Therefore, no additive benefit of CLEC conjugation on the overall immune response was detected in this system.

[0026] Liao et al. (2015) disclosed a series of linear β-(1,3)-β-glucan oligosaccharides (hexa-, octa-, deca-, and dodeca-β-glucans) that were conjugated to KLH to generate glycoconjugates. These conjugates were shown to elicit strong T cell responses and were highly immunogenic, inducing high levels of anti-glucan antibodies. Mice immunized with this vaccine also elicited a protective immune response against the virulent pathogen Candida albicans. Anti-KLH titers were not compared to unconjugated KLH, so no information is available on the potential benefits of β-glucan in this experimental system.

[0027] These findings are very important for the suitability of glucan-based neoglycoconjugates as novel vaccines: potential anti-glucan antibodies induced by initial glucan conjugate immunization can lead to a rapid disappearance of the same β-glucan vaccine in subsequent booster immunizations or can attenuate the immune response to neoglycoconjugate vaccines for other indications, which is a well-known vector vaccine effect. The presence or even (re)stimulation of high levels of anti-glucan antibodies, as demonstrated above for mannan and β-glucan (Petrushina et al. 2008, Torosantucci et al. 2005, Bromuro et al., 2010, Liao et al., 2015), can therefore reduce or eliminate potential immune responses induced by the conjugate vaccine. Therefore, for new sustainable platforms using CLEC (especially β-glucan) as a backbone for immunization, it is crucial to ensure that the polysaccharides / oligosaccharides used induce very low levels of glucan antibodies or no glucan antibodies at all.

[0028] Glucan particles (GP) are highly purified 2-4 μm hollow porous cell wall microspheres consisting primarily of β-(1,3)-D-glucan with minor amounts of β-(1,6)-D-glucan and chitin, typically isolated from Saccharomyces cerevisiae using a series of hot alkaline, acid, and organic extractions. They interact with their receptors dectin-1 and CR3 (there is also evidence implicating toll-like receptors and CD5 as other factors in GP function) and upregulate cell surface presentation of MHC molecules, leading to altered expression of co-stimulatory molecules and induction of proinflammatory cytokine production. Due to their immunomodulatory properties, GP have been developed for vaccine delivery.

[0029] There are three common approaches to using GPs in vaccines: (i) as adjuvants co-administered with antigens to enhance T-cell and B-cell mediated immune responses, (ii) chemically cross-linked with antigens, and most commonly (iii) as physical delivery vehicles for antigens trapped within the hollow GP cavity to provide targeted antigen delivery to APCs.

[0030] Benefit (i): Antigen-specific adaptive immune responses can be enhanced by co-administering GP with antigens. In this traditional adjuvant strategy, both innate and adaptive immune responses are activated to exert a protective response against pathogens. For example, Williams et al. (Int J Immunopharmacol. 1989; 11(4): 403-10) provided an adjuvant for an inactivated Trypanosoma cruzi vaccine by co-administering GP. The immune response elicited using this formulation resulted in 85% survival of mice challenged with Trypanosoma cruzi. In contrast, the mortality rate of the control group that received only glucose, dextran or vaccine was 100%.

[0031] Benefit (ii): The carbohydrate surface of GP can also be covalently modified by coupling the antigen to the GP shell using NaIO4 oxidation, carbodiimide cross-linking, or 1-cyano-4-dimethylaminopyridinium tetrafluoroborate-mediated coupling of the antigen. Using this approach, the coupling efficiency is very low (about 20%, see, for example, Pan et al. Sci Rep 5, 10687 (2015)), which significantly limits the applicability and number of candidate vaccines compared to antigen encapsulation in GP or the platform technology proposed in this application. Such covalently linked antigen-GP conjugates have been used in the study of cancer immunotherapy and infectious diseases. For example, Pan et al. (2015) subcutaneously immunized mice with OVA cross-linked with periodate-oxidized GP. When mice were challenged with E.G7 lymphoma cells expressing OVA, a significant reduction in tumor size was observed. Twelve and 36 hours after subcutaneous injection, DCs (CD11c + MHC-II + GP-OVA was detected in 144 samples of 147 ...

[0032] Benefit (iii): The most effective way to use GPs in vaccines is to use them to encapsulate vaccines / antigens into hollow cores. GPs can encapsulate one or more antigens / DNA / RNA / adjuvants / drugs / combinations thereof with high loading efficiency, depending on the type of payload and the intended mode of delivery.

[0033] Antigens can be encapsulated in the cavity of GP using polymer nanocomposite approaches, such as using bovine or mouse serum albumin and yeast RNA / tRNA to load and complex the payload, or adding alginate-calcium or alginate-calcium-chitosan mixtures. For example, Huang et al. (Clin. Vaccine Immunol. 2013; 20: 1585–91) reported that using these strategies, mice vaccinated with GP-OVA showed strong CD4+ T cell lymphocyte proliferation against ovalbumin (a Th1- and Th17-biased T cell-mediated immune response) and high levels of IgG1- and IgG2c-specific antibody responses. Non-covalent encapsulation strategies triggered stronger immune responses than GP co-administered with antigens.

[0034] An example of a GP-encapsulated subunit vaccine is GP encapsulating a soluble alkaline extract of the non-capsulated strain of Cryptococcus neoformans (cap59), which provided protection (60% survival) to mice challenged with a lethal dose of highly virulent Cryptococcus neoformans by inducing an antigen-specific CD4+ T cell response (IFN-γ, IL-17A positive) that reduced fungal colony-forming units (CFU) by more than 100-fold compared to the initial challenge dose (Specht CA et al. Mbio 2015;6:e01905–e1915. and Specht CA et al., mBio 2017;8:e01872–e1917.). In addition, vaccination of mice with GP-encapsulated antigens has been shown to be effective against Histoplasma capsulatum (Deepe GS et al., Vaccine 2018; 36: 3359-67), F. tularensis (Whelan AO et al., PLOS ONE 2018; 13: e0200213), Blastomyces dermatitidis (Wuthrich M et al., Cell Host Microbe 2015; 17: 452-65) and C. posadasii (Hurtgen BJ et al., Infect. Immun. 2012; 80: 3960-74).

[0035] In addition to cancer and infectious diseases, there are still a few studies using autoantigens that use GP as an encapsulation agent for vaccine delivery. Along these lines, Rockenstein et al. (J. Neurosci., 2018-01-24, 38 (4): 1000-1014) describe the application of GP loaded with recombinant human α-synuclein (aSynuclein) (comprising B cell epitopes and T cell epitopes suitable for inducing anti-aSyn immune responses) and rapamycin (known to induce antigen-specific regulatory T cells (Treg) in mouse synuclein disease models). As expected from previous studies using full-length α-synuclein as an immunogen, the use of GP containing aSyn leads to the induction of strong anti-α-synuclein antibody titers and reduces the pathological changes caused by α-synuclein in animals, the extent of which is similar to that previously published. The addition of rapamycin effectively induced the formation of iTregs (CD25 and FOXP3+) cells, because the number of such Treg cells increased significantly after rapamycin exposure. Thus, GP loaded with the antigens α-synuclein and rapamycin triggered neuroprotective humoral and iTreg responses in a mouse model of synucleinopathy, and the combined vaccine (aSyn+rapamycin) was more effective than either humoral immunization (GP aSyn) or cellular immunization (GP rapamycin) alone. Comparative information on the effects of immunization with conventional non-α-synuclein-containing GP has not been reported.

[0036] β-glucan neoglycoconjugates effectively target dendritic cells via the C-type lectin receptor dectin-1, enhancing their immunogenicity. Specifically, certain β-glucans are also used as potential carriers for vaccination using model antigens such as OVA (Xie et al., Biochemical and Biophysical Research Communications 391 (2010) 958–962; Korotchenko et al., Allergy. 2021; 76: 210–222.) or fusion proteins based on MUC1 (Wang et al., Chem. Commun., 2019, 55, 253).

[0037] Xie et al. and Korotchenko et al. used the branched β-glucan laminarin as the backbone for OVA conjugation. These new glucose conjugates were then applied to mice via the epidermal or subcutaneous route. Xie et al. showed that laminarin / OVA conjugates, but not unconjugated mixtures of these compounds, induced an anti-OVA CD4+T cell response that was increased compared to ovalbumin alone. Importantly, co-injection of unconjugated laminarin blocked this enhancement, supporting the APC targeting function mediated by laminarin. As expected, native OVA and a mixture of OVA and laminarin stimulated low levels of anti-OVA antibody production. In contrast, OVA / laminarin conjugates significantly enhanced antibody responses. Similarly, Korotchenko et al. demonstrated that laminarin conjugation to OVA significantly increased the absorption and induced activation of BMDCs, as well as the secretion of proinflammatory cytokines. These properties of LamOVA conjugates also lead to enhanced stimulation of OVA-specific naive T cells co-cultured with BMDCs. In the preventive immunization experiments, the authors could demonstrate that LamOVA immunization had reduced allergenic properties but induced approximately threefold higher IgG1 antibody titers compared to OVA after two immunizations. However, this effect disappeared in all treatment groups after the third immunization, when all groups showed similar antibody titers. Lam / OVA conjugates and OVA / Alum conjugates showed comparable therapeutic effects in the mouse allergic asthma model. Therefore, these experiments failed to provide a clear superiority of the dextran-based conjugates over conventional vaccines.

[0038] Wang et al. (2019) analyzed the efficacy of β-glucan-based MUC1 cancer vaccine candidates. Again, the MUC1 tandem repeat sequence GVTSAPDTRPAPGSTPPAH (a well-studied cancer biomarker) was selected as a peptide antigen, providing T cell and B cell epitopes within the repeat sequence. Ethylene glycol (i.e., PEG) spacers were used to link β-glucan and MUC1 peptides to yeast β-(1,3)-β-glucan polysaccharide, applying 1,1'-carbonyl-diimidazole (CDI)-mediated conditions. The size of β-glucan-MUC1 nanoparticles was in the range of 150nm (actual average 162nm), while unmodified β-glucan formed particles of approximately 540nm. The β-glucan-MUC1 conjugate elicited high titers of anti-MUC1 IgG antibodies, which were significantly higher than the control group. Further analysis of the isotype and subtype of the antibodies generated showed that IgG2b was the major subtype, indicating that a Th1-type response was activated, as the IgG2b / IgG1 ratio was > 1. The large amounts of IgM antibodies observed indicated the involvement of the C3 component of the complement system, which typically induces cytotoxic activity and could be problematic for vaccine applications of this type of backbone, as vaccines should avoid cytotoxic activity, for example for chronic or degenerative diseases.

[0039] US2013 / 171187 A1 discloses an immunogenic composition comprising glucan and a pharmaceutically acceptable carrier to elicit protective anti-glucan antibodies. Metwali et al. (Am. J. Respir. Crit. Care Med. 185 (2012), A4152; Poster link C31 Regulation of pulmonary inflammation) studied the immunomodulatory effects of glucan derivatives in pulmonary inflammation. WO 2021 / 236809 A2 discloses a multi-epitope vaccine comprising amyloid-β and tau peptides for the treatment of Alzheimer's disease (AD). US2017 / 369570 A1 discloses β-(1,6)-glucan linked to antibodies against cells present in the tumor microenvironment. US2002 / 077288 A1 discloses synthetic, immunogenic, but non-amyloidogenic peptides homologous to amyloid β, used alone or in combination to treat AD. US2013 / 171187 A1 discloses anti-glucan antibodies as protective agents against Candida albicans fungal infections. WO 2004 / 012657 A2 discloses microparticulate β-glucan as a vaccine adjuvant. CN113616799A discloses a vaccine carrier composed of oxidized mannan and a cationic polymer. CN 111514286A discloses a Zika virus E protein conjugate vaccine with glucan. US 4,590,181 A discloses a solution of viral antigen mixed with mycoglucan or mycoglucan. Lang et al. (Front.Chem.8(2020):284) reviewed carbohydrate conjugates in vaccine development. Larsen et al. (Vaccines 8(2020):226) reported that mycoglucan activated chicken bone marrow-derived dendritic cells in vitro and promoted ex vivo CD4 +T cell memory response. US 2010 / 266626A1 discloses dextran, preferably laminarin and curdlan gum, as antigens coupled to adjuvants for antifungal immunization. Mandler et al. (Alzh.Dement.15(2019), 1133-1148) reported the effects of single and combined immunotherapy targeting amyloid beta protein and alpha synuclein in a Lewy body dementia model. Mandler et al. (Acta Neuropathol.127(2014), 861-879) reported a next-generation active immunization method for synucleinopathy, which uses immunogenic (B cell response) short peptides that are too short to induce T cell responses (autoimmunity) and do not carry natural epitopes, but carry a sequence that mimics the original epitope (e.g., oligomeric alpha synuclein), as well as the application of this method in clinical trials for Parkinson's disease (PD). Mandler et al. (Mol. Neurodegen. 10 (2015), 10) reported that active immunization against alpha-synuclein improved degenerative pathology and prevented demyelination in a multiple system atrophy (MSA) model. Jin et al. (Vaccine 36 (2018), 5235-5244) reviewed β-glucan as a potential immune adjuvant, mainly on adjuvant properties, structure-activity relationship and receptor recognition properties. WO 2022 / 060487 A1 discloses a vaccine containing a specific α-synuclein peptide for the treatment of neurodegenerative diseases. WO 2022 / 060488 A1 discloses a multi-epitope vaccine containing amyloid β protein and α-synuclein peptide for the treatment of AD. US2009 / 169549 A1 discloses a modified conformational isomer of α-synuclein, which is produced by introducing cysteine ​​into α-synuclein polypeptide and disrupting disulfide bonds to form a stable and immunogenic isomer. WO 2009 / 103105 A2 discloses a vaccine having a mimetic epitope of an α-synuclein epitope (extending from amino acid D115 to amino acid N122 of the natural α-synuclein sequence).

[0040] So far, no one has reported the construction or use of coupling a single B cell or T cell epitope peptide to β-glucan, especially linear β-glucan and / or pyruvic acid with high binding specificity / capacity to dectin-1 to form the novel glucose conjugate of the present application. Summary of the invention

[0041] It is therefore an object of the present invention to provide improved vaccines, being conjugate vaccines of a vaccination antigen and a carbohydrate-based CLEC adjuvant, particularly said vaccines which provide an improved immune response in vaccinated individuals over existing conjugate vaccines, particularly carbohydrate-based CLEC-peptide / protein conjugate vaccines.

[0042] Another object of the present invention is to provide vaccine compositions that utilize the CLEC backbone to confer immunity to short, readily interchangeable, highly specific B / T cell epitopes with potency, specificity, and affinity not previously achieved by traditional vaccines.

[0043] It is a particular object of the present invention to provide CLEC-based vaccines with improved selectivity and / or specificity for the dermal compartment.

[0044] Another object of the present invention is to provide a vaccine which induces target-specific immune responses as exclusively as possible, while inducing no or only very limited CLEC- or carrier protein-specific antibody responses.

[0045] Another object of the present invention is to provide vaccine compositions that utilize the CLEC backbone to confer immunity to short, readily interchangeable, highly specific B / T cell epitopes of alpha synuclein with potency, specificity, and affinity previously unmet by traditional vaccines for appropriate prevention and treatment of synucleinopathies.

[0046] A specific object of the present invention is to provide an alpha synuclein vaccine for use in the dermis which has improved selectivity and / or specificity over CLEC-based vaccines.

[0047] Another object of the present invention is to provide a vaccine which induces as exclusively as possible an alpha-synuclein-specific immune response while inducing no or only very limited CLEC- or carrier protein-specific antibody responses.

[0048] Another object of the present invention is to provide peptide immunogen constructs of alpha synuclein (aSyn) and their preparations for use in the treatment of synucleinopathies.

[0049] Therefore, the present invention provides a conjugate, which consists of or comprises at least one β-glucan or mannan and at least one B cell or T cell epitope polypeptide, wherein the β-glucan or mannan is covalently coupled to the B cell and / or T cell epitope polypeptide to form a conjugate of β-glucan or mannan and B cell and / or T cell epitope polypeptide, and wherein the B cell and / or T cell epitope polypeptide is an α-synuclein polypeptide. Alternatively, the conjugate according to the present invention consists of or comprises at least one β-glucan or mannan and at least one α-synuclein B cell epitope polypeptide, wherein the β-glucan or mannan is covalently coupled to the B cell epitope polypeptide to form a conjugate of β-glucan or mannan and the B cell epitope polypeptide.

[0050] Preferably, the β-glucan is pachysan, lichenan, laminarin, curdlan gum, β-glucan peptide (BGP), schizophyllan, scleroglucan, whole glucan particles (WGP), zysoman or lentinan, preferably pachysan, laminarin, lichenan, lentinan, schizophyllan or scleroglucan, especially wherein the β-glucan is pachysan.

[0051] According to a preferred embodiment of the present invention, β-glucan is a C-type lectin (CLEC) polysaccharide adjuvant used as a B cell and / or T cell epitope polypeptide, in particular, wherein the β-glucan is covalently coupled to the B cell and / or T cell epitope polypeptide to form a conjugate of β-glucan and the B cell and / or T cell epitope polypeptide, wherein the β-glucan is mainly linear β-(1,6)-glucan, and the ratio of the β-(1,6)-coupled monosaccharide part to the non-β-(1,6)-coupled monosaccharide part is at least 1:1, preferably at least 2:1, more preferably at least 5:1, and especially at least 10:1.

[0052] The present invention successfully solves one or more of the above-mentioned goals. This is surprising to those skilled in the art, because no one in the art has reported the construction and use or efficacy of compounds similar to the novel, small, modular glucose conjugates of the present invention.

[0053] Surprisingly, the present invention shows that by coupling (i.e. covalently binding; synonymous herein) a peptide / protein to a selected CLEC-carrier of the present invention, wherein the coupling can be based on current chemistry, a superior pharmaceutical preparation is obtained that achieves an immune response. In the prior art, a large number of different coupling methods are available. In the process of establishing the present invention, hydrazone formation or coupling via a heterobifunctional linker is a particularly preferred method. Generally, activation of the CLEC prior to coupling (e.g. formation of a reactive aldehyde on the ortho-OH group of the sugar moiety) and the presence of a reactive group (e.g. N- or C-terminal hydrazide residue, SH group (e.g. via N- or C-terminal cysteine)) on the selected peptide / protein are necessary. The reaction can be a single step reaction (e.g. mixing the activated CLEC with the hydrazide peptide leads to hydrazone formation), or a multi-step process (e.g. reaction of the activated CLEC with the hydrazide from the heterobifunctional linker followed by coupling of the peptide / protein via the respective reactive groups).

[0054] Thus, the individual components of the conjugate of the invention can be directly coupled to each other, for example by coupling the B cell epitope and / or T cell epitope to β-glucan or mannan and / or a carrier protein, or by coupling β-glucan or mannan to a carrier protein (in all possible orientations). The "B cell epitope polypeptide" or "T cell epitope polypeptide" described herein refers by default to the B cell or T cell epitope of the "B cell epitope polypeptide" or "T cell epitope polypeptide", rather than the B cell or T cell epitope of the carrier protein (if present), unless the B cell or T cell epitope of the carrier protein is explicitly mentioned. According to a preferred embodiment, the connection of the B-cell epitope and / or T-cell epitope to the β-glucan or mannan and / or the carrier protein is preferably achieved via a linker, more preferably a linker comprising a cysteine ​​residue or a cysteine ​​or glycine residue, a linker resulting from a hydrazide-mediated coupling, a linker resulting from a coupling via a heterobifunctional linker, such as N-β-maleimidopropionic acid hydrazide (BMPH), 4-[4-N-maleimidophenyl]butyric acid hydrazide (MPBH), N-[ε-maleimidohexanoic acid ] hydrazide (EMCH) or N-[κ-maleimidoundecanoic acid] hydrazide (KMUH), by imidazole-mediated coupling, by reductive amination, by carbodiimide coupling -NH-NH2 linker; NRRA, NRRA-C or NRRA-NH-NH2 linker, peptide linker, such as a di-, tri-, tetra-(or more)-peptide group, such as CG or CG, or a cleavage site, such as a cathepsin cleavage site; or a combination thereof, in particular a cysteine ​​or NRRA-NH-NH2 linker. Obviously, "linker resulting from (for example) hydrazide-mediated coupling" refers to the chemical structure in the conjugate resulting from coupling, i.e., the chemical structure that appears in the resulting conjugate after coupling. Amino acid linkers can have peptide bonds (such as glycine-containing linkers) or via functional groups of amino acids (such as disulfide bonds of cysteine ​​linkers) in the coupled form.

[0055] By using the CLEC backbone of the present invention, the novel conjugates of the present invention have been shown to confer immunity to short, easily interchangeable, highly specific B / T cell epitopes, exhibiting potency, specificity and affinity previously unmet by conventional vaccines: in fact, the conjugates of the present invention are the first to use short B cell / T cell epitopes in CLEC-based vaccines, avoiding the need to present alpha synuclein epitopes in the form of fusion proteins, including the formation of tandem repeats of these epitopes or fusions of different tandem repeats to form stable and effective immunogens.

[0056] With the present invention, the necessity of using full-length proteins (i.e. payload in glucan particles (GP)) in CLEC vaccines can also be avoided. Furthermore, autoimmune reactions caused by (unwanted) T-cell epitopes present in the immunogen, like self-proteins such as alpha-synuclein, can also be avoided.

[0057] According to the present invention, for the first time short epitopes (B- and / or T-cell epitopes, mainly peptides, modified peptides) can be linked to functional CLEC-based scaffolds using covalent coupling techniques based on well-established chemistry, wherein the possible coupling methods can be adapted to the requirements of the specific epitope based on methods well known in the art.

[0058] The presentation of the short peptides of the present invention can be made as individually coupled moieties, in combination with a single foreign T cell epitope (as a short peptide or long protein), or as a complex / conjugate with a larger carrier molecule, providing the T cell epitope to induce a sustainable immune response. The vaccine design of the present invention allows the preparation of multivalent conjugates, which is a prerequisite for inducing an effective immune response by efficient B cell receptor (BCR) cross-linking.

[0059] Furthermore, by means of the present invention, a CLEC-based vaccine with excellent dermal selectivity / specificity can be provided. In fact, the conjugate design of the present invention is built on CLEC, with CLEC as a carrier of target-specific α-synuclein epitopes, which exhibit high binding specificity for PRRs on dermal APC / DC, especially for dectin-1 (or MR and DC-SIGN in the case of mannan), to allow skin-selective / specific and receptor-mediated uptake (= targeted vaccine delivery).

[0060] The CLEC polysaccharide used as a carrier according to the present invention is used to concentrate the carrier-peptide conjugate into the preferred dermal / skin DC and elicit an immune response. This is mainly due to epidermal or dermal (rather than subcutaneous) specificity. The CLEC backbone of the present invention and the effective dermal immune response elicitation also help to avoid the mandatory use of adjuvants, which are commonly used in conventional vaccines and are also used in exemplary CLEC-based vaccines (e.g., using Alum, MF59, CFA, PolyI:C or other adjuvants). According to a preferred embodiment of the present invention, the use of adjuvants can be significantly reduced or omitted, for example, when the addition of adjuvants is not specified.

[0061] Several CLECs have been used in previous applications, but none of the proposed conjugated structures could confer skin selectivity (i.e., high dectin-1 binding capacity for dermal application compared to all other routes (i.e., subcutaneous, intramuscular, and ip (intraperitoneal) injection), efficient dermal DC targeting, and excellent immunogenicity).

[0062] The present invention selects CLEC in order to provide a novel solution to efficiently target skin-specific DC and skin-specific immunity. The conjugates of the present invention also exert limited activity in other classical tissues (such as muscle or subcutaneous tissue) immunity, which is contrary to the previously described CLEC-based vaccines / candidates applied im (muscle) or sc (subcutaneous). As a result of the experiments conducted during the present invention, the vaccines of the present invention, especially the vaccines with pyralidin as CLEC, have been shown to be surprisingly selective for skin immunity.

[0063] By using the present invention, it is possible to focus on inducing an alpha synuclein-specific immune response without inducing or only inducing a very limited CLEC- or carrier-protein-specific antibody response. The conjugate of the present invention thus solves the problem of traditional conjugate vaccines, which must rely on the use of foreign carrier proteins to induce a sustainable immune response. Existing conjugate vaccine development is mainly based on carrier molecules, such as KLH, CRM197, tetanus toxoid or other suitable proteins, which form complexes with target-specific short antigens and provide them to the immune response to resist alpha synuclein in synuclein diseases such as Parkinson's disease.

[0064] The preferred polypeptide immunogen constructs of the present invention comprise a B cell epitope from alpha-synuclein (aSyn, alpha Syn) and a heterologous T helper cell (Th) epitope coupled to CLEC. The present invention provides surprisingly superior new conjugates that surpass traditional vaccines in immunogenicity, cross-reactivity to aSyn, selectivity to aSyn species / aggregates, affinity, affinity maturation, and inhibitory capacity.

[0065] Covalent coupling of alpha synuclein polypeptides to beta-glucan or mannan according to the present invention unexpectedly enhances the immune response to such polypeptides. This is particularly impressive when directly compared with traditional vaccine formulations, such as described in Rockenstein et al. (2018), as also shown in the Examples section below.

[0066] Rockenstein et al. (2018) disclosed the application of yeast glucan whole particles (GP) with aSyn and rapamycin as non-covalent complexes as Parkinson's disease immunotherapeutics. These GPs are produced from Saccharomyces cerevisiae after a series of hot alkaline, organic and aqueous extraction steps. The final product consists of a highly purified yeast cell wall preparation with a diameter of 3-4 microns, free of cytoplasmic contents, and is coated with porous, insoluble β-glucan (mainly β1-3β-glucan).

[0067] Importantly, the vaccine composition disclosed by Rockenstein et al. (January 24, 2018, 38(4): 1000-1014) consists of GP and ovalbumin and mouse serum albumin (MSA), human aSyn and MSA, or human aSyn, MSA and rapamycin in a non-covalent complex. This complexing method relies on the co-incubation of different payloads with GP, followed by diffusion into the hollow GP cavity without covalent linkage, and is therefore similar to a group of vaccines in Example 5 of the present application, which only use a mixture of multiple components rather than covalent linkage to formulate the vaccine, and has been shown to be less effective and unsuitable than the vaccine of the present invention.

[0068] 1) Rockenstein et al. showed that non-covalent mixing of aSyn and GP resulted in a detectable anti-aSyn immune response, thus indicating that GP can act as an adjuvant. However, Rockenstein et al. also showed that non-covalent addition / co-complexation of rapamycin was necessary to induce a significant increase in the function of such vaccines compared to controls. From this perspective, mixing of various adjuvants (GP and the mTOR inhibitor rapamycin) is required to provide a fully functional vaccine, such as the vaccine disclosed in the present invention.

[0069] 2) The vaccine disclosed by Rockenstein et al. is active in this aSyn overexpression model because it provides aSyn-specific T cell epitopes (as well as other T cell epitopes, such as MSA-derived epitopes) to exert their full functionality, i.e., inducing neuroprotective, anti-ASyn directed cellular (i.e.: T cell mediated) and humoral (i.e., antibody / B cell based) immune responses. This is in stark contrast to the teaching of the present invention, in which it is sufficient that only aSyn-specific B cell responses are elicited by the selected vaccine.

[0070] 3) The use of full-length aSyn also carries the risk of inducing / enhancing autoreactive aSyn-specific T cells, which could exacerbate the underlying neuropathology of PD and other synucleinopathies. Therefore, in this regard, the GP-aSyn-rapamycin vaccine proposed by Rockenstein et al. is also not suitable for human use.

[0071] 4) As shown in Example 5, similar to Rockenstein et al., non-covalent mixing of aSyn-derived peptides (e.g., SeqID2, i.e., B cell epitopes) and heterocompetent T cell epitopes (e.g., SeqID7) with β-glucan particles (e.g., unoxidized pyruvic polysaccharides) can also induce low-level anti-aSyn antibody responses. However, the vaccines of the present invention based on the covalent attachment of such peptides to suitable glucans produce significantly different and superior immune responses (see also Figure 5 ).

[0072] In addition, Example 6 and Figure 7It is also disclosed that such covalently linked vaccines also show a highly beneficial lack of anti-glucan antibody response compared to the non-covalent mixture vaccines based on glucan particles and peptides disclosed in the present invention.

[0073] Thus, the prior art of Rockenstein et al. does not suggest the claimed subject matter disclosed in the present invention.

[0074] Any α-synuclein polypeptide containing B cell and / or T cell epitopes can be used in the present invention, including polypeptide vaccine candidates proposed in the prior art, for example, see WO 2004 / 041067 A2, WO 2006 / 045037A2, WO 2009 / 103105 A2, WO 2011 / 020133 A1 or Mandler et al. (Mol. Neurodeg. 10 (2015), 10; Acta Neuropath. 127 (2014), 861-879). Therefore, an α-synuclein polypeptide having a natural amino acid sequence (according to human α-synuclein) or an αSyn-derived polypeptide containing a B cell and / or T cell epitope of αSyn (e.g., a mimetic or mimic epitope thereof) can be used as the α-synuclein polypeptide component in the conjugate of the present invention.

[0075] The particularly preferred aSyn polypeptide to be coupled in the present invention is selected from natural α-synuclein, or comprises or consists of the amino acid sequence of natural human α-synuclein MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYVGSKTKEGVVH GVATVAEKTK EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQEGILEDMPVDP DNEAYEMPSE a polypeptide consisting of amino acid residues 1-5, 1-8, 1-10, 60-100, 70-140, 85-99, 91-100, 100-108, 102-108, 102-109, 103-129, 103-135, 107-130, 109-126, 110-130, 111-121, 111-135, 115-121, 115-122, 115-123, 115-124, 115-125, 115-126, 118-126, 121-127, 121-140 or 126-135,

[0076] Preferably, a polypeptide comprising or consisting of amino acid residues 1-8, 91-100, 100-108, 103-135, 107-130, 110-130, 115-121, 115-122, 115-123, 115-124, 115-125, 115-126, 118-126, 121-127 or 121-140; or a mimotope selected from DQPVLPD, DQPVLPDN, DQPVLPDNE, DQPVLPDNEA, DQPVLPDNEAY, DQPVLPDNEAYE, DSPVLPDG, DHPVHPDS, DTPVLPDS, DAPVTPDT, DAPVRPDS, and YDRPVQPDR.

[0077] Weihofen et al. (Neurobiology of Disease 124 (2019) 276-288) disclosed that N-terminal residues aa1-10 (MDVFMKGLSK) are suitable aSyn epitopes. PRX002 (see Masliah et al. (PLoS One 6:e19338); Games et al. (2014, J Neurosci 34:9441-9454); Schenk et al. (Mov Disord. 2017 Feb; 32(2):211-218.); Jankovic et al. (JAMA Neurol. 2018 Oct 1; 75(10):1206-1214.)) targets the C-terminal region aa118-126 (VDPDNEAYE). Schofield et al. (Neurobiol Dis. 2019 Dec; 132: 104582.) disclosed aSyn-specific monoclonal antibody MEDI-1341, which targets a similar epitope in the C-terminal region of aSyn (aa 103-129, NEEGAPQEGILEDMPVDPDNEAYEMP). MEDI Ab (aa121-127; DNEAYEM) was disclosed in et al. (Neurobiology of Disease 161(2021)105543). Other epitopes in aSyn suitable for antibody / immunotherapy known to those skilled in the art include epitopes from autoantibodies (see Heinzel et al. (PLoS ONE 9(12):e114566.); Rabenstein et al. (Neurosci Lett. 2019 Jun 21;704:181-188); US2014 / 0377271 A1 and Li et al. (Acta Neuropathologica 137,825–836 (2019)) including aa60-100, aa60-95, aa73-82, aa91-100; aa74-79 and aa92-97, aa121-140 and aa111-121. In addition, Games et al. (2014) also disclosed suitable epitopes aa 91-99 and aa 118-126. In US2005 / 0037013 A1, immunogenic α-synuclein fragments are disclosed that can induce an immune response against a specific epitope within residues aa70-140. WO 2009 / 103105A2 and WO 2011 / 020133A1 disclose molecular mimetics of aa102-108 and aa115-121, respectively. WO 2016 / 062720 A1 provides modified VLPs comprising Th cell epitopes representing the middle region (aa102-109), and an N-terminal sequence (aa1-8) or a C-terminal sequence (i.e., aa131-140) that can induce a high anti-peptide response. The middle and C-terminal derived epitopes can also induce aSyn-specific titers that recognize different aSyn species (e.g., monomers and oligomers). Interestingly, none of the vaccines provided can reduce aSyn burden or behavioral changes in in vivo PD models. US2015 / 0232524 A1 discloses polypeptide immunogens, particularly aa10-14 and aa36-69, and epitopes are shown in aa85-99, aa109-126, and aa126-140. Interestingly, all constructs elicited an anti-aSyn immune response, but the epitope aa109-126 appeared to be less effective. WO 2018 / 232369A1 demonstrated the use of a target-specific B cell epitope (10-25aa, derived from the C-terminus of aSyn; region: aa111-135).

[0078] Although in principle, the present invention can improve all proposed aSyn vaccine peptides, selected epitopes were specifically evaluated for their suitability with the present platform. For example, aa1-8 (SeqID12+13) was shown to be superior to the KLH-based vaccine.

[0079] Although the nature of the α-synuclein polypeptide is not critical to the generation of β-glucan or mannan conjugates, there are preferred and less preferred α-synuclein epitopes, depending on the goal to be addressed by the conjugate (specificity for monomers or aggregates, selectivity, affinity, antibody generation, etc.).

[0080] For some embodiments of the present invention, B cell epitopes aa91-100, aa100-108, aa107-114 and aa131-140 are less preferred because of reduced anti-peptide response and reduced reactivity to α-synuclein (aa91-100); low cross-reactivity (CR) to α-synuclein (although anti-peptide titers are high), low selectivity for aggregates (aa100-108); low efficacy in inhibiting aggregation (aa107-114); altered selectivity (towards monomers rather than aggregates), reduced selectivity, and low effectiveness in reducing α-synuclein aggregates (aa131-140). In addition, epitope polypeptides with 5 or fewer amino acid residues (or with 6 or fewer amino acid residues) are generally less preferred because such short forms induce a lower immune response.

[0081] According to the present invention, particularly preferred α-synuclein epitopes include the above-mentioned epitopes, which include or consist of amino acid residues 1-5, 1-8, 1-10, 60-100, 70-140, 85-99, 91-100, 100-108, 102-108, 102-109, 103-129, 103-135, 107-130, 109-126, 110-130, 111-121, 111-135, 115-121, 115-122, 115-123, 115-124, 115-125, 115-126, 118-126, 121-127, 121-140 or 126-135 of the amino acid sequence of natural human α-synuclein.

[0082] For example, aa115-126 and its shorter sequences and mimetic epitopes described above are particularly suitable in terms of immunogenicity, selectivity, aggregation inhibition, etc.; generally, polypeptides having 7 or more amino acid residues show good immune response and cross-reactivity to α-synuclein; excellent immunoreactivity and cross-selectivity are shown for aa 115-121 (and polypeptides extending to the C-terminus (e.g., up to aa126) (even compared with the monoclonal LB509 binding epitope 115-122 (Jakes et al., Neurosci Lett. 1999 Jul 2; 269(1): 13-6)); unexpectedly, compared with the "classical constructs" using CRM197 or KLH as carrier proteins, the conjugates of the present invention show significantly improved selectivity for aggregates (whereas, for example, CRM-based vaccines generally lack selectivity for aggregates or are even selective for monomers, while the conjugates of the present invention show clear and significant activity against aggregates).

[0083] This is even more surprising in light of published experiments in which LB509 bound to α-synuclein aggregates but failed to inhibit aggregation (Breydo et al., Mol Neurobiol 53, 1949–1958 (2015)), indicating that not every antibody from this epitope is biologically active as described in the present invention.

[0084] It is widely accepted that the T cell compartment is differentially altered in patients with Parkinson's disease compared to healthy controls (e.g., Bas et al., J Neuroimmunol 2001;113:146-52 or Gruden et al., J Neuroimmunol 2011;233:221-7). Such phenotypic changes in T cells in PD include: decreased absolute lymphocyte counts, decreased absolute and relative total T cell counts, decreased absolute and relative CD4+ lymphocyte counts, and sometimes CD8+ lymphocyte counts, increased Th1 / Th2 and Th17 / Treg ratios, and increased expression of inflammatory cytokines. However, most of these changes are also seen during healthy aging, making it difficult to discern the impact of a disease such as PD, which has a wide age range of onset (approximately 30-90 years) and a variable rate of progression. With regard to absolute cell counts, there seems to be consensus that there is a net decrease in CD3+CD4+ T cells in patients with PD. This CD4 decrease is supported by the altered CD4:CD8 ratio described above.

[0085] Along these lines, for example, Bhatia et al. (J Neuroinflammation (2021) 18:250) showed that PD patients have an overall reduction in the total number of CD3+ T cells, which correlates with disease severity (e.g., as measured by H+Y stage). This suggests that systemic T cell dysfunction continues to worsen as the disease progresses, which may reflect the combined effects of ongoing inflammation, drug treatment, and lifestyle changes. In addition, Lindestam Arlehamn et al. (2020) showed that the highest T cell activity can be detected in PD patients in the prodromal or early clinical stages (duration <10 years, H+Y stage 0-2).

[0086] Therefore, a preferred embodiment of the present invention is to provide for increasing or maintaining the number of PD patient T cells (especially the number of T effector cells) and the treatment of T cell function. This preferably includes a combination of multiple immune checkpoint inhibitors or multiple vaccines using anti-immune checkpoint inhibitor epitopes to induce the immune response of anti-checkpoint inhibitors and the target-specific vaccine combination of the present invention to increase or maintain the number of PD patient T cells (especially the number of T effector cells) and T cell function.

[0087] Patients receiving / suitable for treatment are characterized by an overall decrease in CD3+ cells, especially a decrease in CD3+CD4+ cells, which is typical of PD patients at all stages of the disease. The preferred disease stages defining the patient groups suitable for this combination are H+Y stages 1-4, preferably H+Y stages 1-3, and most preferably H+Y stages 2-3, respectively.

[0088] In addition, affinity maturation of target-specific responses induced by repeated immunization with the carrier conjugate is also impaired due to overexpression of carrier-specific epitopes in the conjugate. As used and understood herein, immunological affinity maturation is the process by which T cells are attached to the target during an immune response. FH The process by which activated B cells produce antibodies with higher affinity for antigens. Through repeated exposure to the same antigen, the host will produce antibodies with gradually increasing affinity. The secondary response can elicit antibodies with affinity several times higher than the primary response. Affinity maturation occurs primarily on the surface immunoglobulins of germinal center B cells and is a process of somatic hypermutation (SHM) and T FHA direct result of cell selection (see also: https: / / en.wikipedia.org / wiki / Affinity_maturation). According to the Segen Medical Dictionary (https: / / medical-dictionary.thefreedictionary.com / affinity+maturation">affinitymaturation), affinity maturation refers to the increase in the average affinity of antibodies for antigens after immunization. Affinity maturation is due to an increase in specific and more homogeneous IgG antibodies, following the less specific and more heterogeneous early response of IgM molecules.

[0089] Existing CLEC vaccines are able to induce high titers against the carrier protein used (e.g., CRM197 or OVA). However, this high immunogenicity, as well as the structural complexity and heterogeneity of the carrier protein components, may lead to the induction of high levels of carrier / protein-specific antibodies at the expense of target-specific responses, which may therefore underrepresent the induced carrier response.

[0090] Furthermore, high anti-vector responses also pose the risk of immune rejection and related safety issues.

[0091] Thus, this challenge was successfully addressed by an innovative solution according to the present invention to identify effective constructs with high immunogenicity, high target specificity and high tolerability / safety and low or absent carrier reactivity (i.e., against the protein carrier). Furthermore, it is critical for the novel vaccines of the present invention that the provided immunotherapeutics do not induce or induce very weak immune responses against the sugar backbone. This is particularly important because high anti-CLEC antibody levels induced by immunization can inhibit or reduce the efficacy of repeated immunizations using the same CLEC-based vaccine due to vaccine neutralization, or can also negatively affect the use of such vaccines for continuous immunization against various different targets.

[0092] The vaccine platform of the present invention also meets the need to combine various epitopes against one or more targets in one formulation without the risk of reduced efficacy due to unintended epitope diffusion as with traditional vaccines. The modular design of the platform of the present invention allows for easy exchange of B-cell epitopes and T-cell epitopes without the negative impact of vector-induced responses.

[0093] The present invention is based on a CLEC that has a highly specific binding to a cognate receptor. This binding is critical, and only strong binders can be effective as vaccine vectors / backbones.

[0094] According to the present invention, CLEC conjugation enables an effective immune response with novel characteristics. The conjugation of the present invention excludes the formation of anti-CLEC (especially pyralidin) antibodies, which can be impressively demonstrated in the process of the present invention. This lack of anti-CLEC antibody stimulation is very important for the reusability and re-boosting of a single vaccine designed using the platform of the present invention - whether the antigens are the same or different.

[0095] In contrast to the conjugated embodiments of the present invention, merely mixing the CLEC polysaccharide adjuvant with a B-cell or T-cell epitope peptide does not produce a similar effect in vivo. However, if conjugated, the orientation of the peptide does not significantly affect the performance of the compounds of the present invention; thus CLEC conjugation is essentially independent of the orientation of the peptide in the construct. In the course of the present invention, it could be demonstrated that CLEC conjugation, especially with pyralidin, leads to improvements in new as well as existing peptide immunogens / alpha synuclein antigens: this improvement is achieved by higher, more target-specific and higher affinity antibody responses (as shown by antibody selectivity and functionality). This effect is most pronounced for pyrenoids or similar β-glucans, which are primarily linear β-(1,6)-glucans in which the ratio of β-(1,6)-conjugated monosaccharide moiety to non-β-(1,6)-conjugated monosaccharide moiety is at least 1:1, preferably at least 2:1, more preferably at least 5:1, and especially at least 10:1, which perform surprisingly much better than even KLH or CRM in direct comparison, and even better than mannan or lichenan conjugates or conjugates comprising barley β-glucan.

[0096] As used herein, the term "predominantly linear" β-(1,6)-glucan refers to a β-(1,6)-D-glucan in which there are no or only a small amount of cross-linked sugar monomer entities, i.e., less than 1%, preferably less than 0.1%, and especially less than 0.01% of the monosaccharide moieties have more than two covalently linked monosaccharide moieties.

[0097] As mentioned above, pyrifos is the most preferred CLEC of the present invention. Pyrifos generally does not contain cross-linked sugar moieties and is mainly β-(1,6)-coupled, so that the common pyrifos preparations used to prepare the conjugates of the present invention have less than 1%, preferably less than 0.1%, and especially less than 0.01% of monosaccharide moieties with more than two covalently linked monosaccharide moieties, and have a maximum of 10% of impurities with β-(1,3)- or β-(1,4)-coupled monosaccharides.

[0098] The fact that dactylan was shown to be the most potent CLEC in the present invention was unexpected, as various references indicate that dactylan should be less effective in dectin-1 binding (e.g., Adams et al., J Pharmacol Exp Ther. 2008 Apr;325(1):115-23); in the literature, linear 1,3 and branched (1,3 backbone and 1,6 side chains) have been reported to be the most potent dectin-1 binders. For example, Adams et al. 2008 reported that murine recombinant dectin-1 only recognized and interacted with polymers containing a β-(1,3)-linked glucose backbone. Dectin-1 did not interact with glucans containing only a β-(1,6)-glucose backbone (dactylan), nor with non-glucan carbohydrate polymers such as mannan.

[0099] Therefore, according to a preferred embodiment of the present invention, the β-glucan of the present conjugate is a dectin-1 binding β-glucan. The ability of any compound (especially a glucan) to bind to dectin-1 can be easily determined by the methods disclosed herein (especially in the Examples section). In case of doubt, "dectin-1 binding β-glucan" refers to a β-glucan whose IC50 value for binding to the soluble mouse Fc-dectin-1a receptor is less than 10 mg / ml as determined by competitive ELISA (as disclosed in the Examples).

[0100] The Dectin-1 binding β-glucan (e.g., linear β-(1,6)-glucan) of the present invention has advantages over other glucans (e.g., DC-SIGN β-glucan (e.g., β-(1,2)-glucan)) in that such Dectin-1 binding glucan can reach a wider range of DCs (immature, mature, myeloid, plasmacytoid; and APC), which significantly increases the possibility of eliciting an effective immune response in vivo, compared with non-Dectin-1 binding glucans with limited applicability (immature DC, myeloid DC).

[0101] WO 2022 / 060487 A1 and WO 2022 / 060488 A1 disclose conjugates linking peptide immunogens to immunostimulatory polymer molecules such as β-(1,2) glucans. β-(1,2) glucans (including cyclic variants) have previously been considered as potential adjuvants (Martirosyan A et al., doi:10.1371 / journal.ppat.1002983). They are a class of glucans that primarily bind to a specific PRR, namely DC-SIGN (Zhang H et al., doi:10.1093 / glycob / cww041), specifically binding to N-linked high mannose oligosaccharides and branched fucose structures. Importantly, β-1,2 glucans do not bind to dectin (Zhang H et al., doi:10.1093 / glycob / cww041), thereby limiting their activity on DC-SIGN-positive cells.

[0102] DC-SIGN (CD209) is the first SIGN molecule to be identified and is highly expressed only on a limited subset of DCs, including immature (CD83 negative) DCs and specialized macrophages in the placenta and lungs (Soilleux EJ et al., doi: 10.1189 / jlb.71.3.445). In the periphery, such as in the skin or mucosal sites, expression and therefore the potential for biological activity as a receptor of the present invention is only detectable in immature DC subsets. Mature plasmacytoid DCs and other APCs (such as epithelial DC-like Langerhans cells) do not express DC-SIGN (Engering A et al., doi: 10.4049 / jimmunol.168.5.2118).

[0103] In contrast, the target receptor of the β-glucan-based immunogen provided by the present invention is dectin-1. Dectin-1 is expressed on many different types of DCs, including not only immature DCs, myeloid DCs, but also plasmacytoid DCs that express dectin-1 at both mRNA and protein levels, and DC-like Langerhans cells in the skin (Patente et al., doi: 10.3389 / fimmu.2018.03176; Joo et al., doi: 10.4049 / jimmunol.1402276).

[0104] Therefore, the biological activity of DC-SIGN targeting polymers (such as β-(1,2) glucan) is limited to a specific DC target cell population, while the dectin-1 targeting polymers used in the present invention can function in a variety of other DC types. Therefore, compared with other conjugates, these new conjugates can exert significantly different and superior immune responses. Therefore, the content disclosed in the prior art does not suggest the claimed subject matter disclosed in the present invention.

[0105] According to a particularly preferred embodiment, the conjugate of the present invention comprises a β-glucan that strongly binds to dectin-1, preferably a β-glucan that binds to a soluble mouse Fc-dectin-1a receptor, with an IC50 value of less than 10 mg / ml, more preferably an IC50 value of less than 1 mg / ml, even more preferably an IC50 value of less than 500 μg / ml, in particular an IC50 value of less than 200 μg / ml, as determined by competitive ELISA, for example, see the Examples. Specifically preferably, as determined by competitive ELISA, the conjugate binds to a soluble mouse Fc-dectin-1a receptor with an IC50 value of less than 1 mg / ml, more preferably an IC50 value of less than 500 μg / ml, even more preferably an IC50 value of less than 200 μg / ml, in particular an IC50 value of less than 100 μg / ml; and / or

[0106] - β-glucan which binds to soluble human Fc-dectin-1 receptor with an IC50 value of less than 10 mg / ml, more preferably with an IC50 value of less than 1 mg / ml, even more preferably with an IC50 value of less than 500 μg / ml, in particular with an IC50 value of less than 200 μg / ml, as determined by competitive ELISA; and / or

[0107] - The conjugate binds to soluble human Fc-dectin-1a receptor with an IC50 value of less than 1 mg / ml, more preferably an IC50 value of less than 500 μg / ml, even more preferably an IC50 value of less than 200 μg / ml, in particular an IC50 value of less than 100 μg / ml, as determined by competitive ELISA, for example see the Examples.

[0108] In addition, the conjugates of the present invention also show that the ratio of antibodies reacting with the target polypeptide to antibodies reacting with the carrier molecule is much higher than that of non-CLEC vaccines (especially vaccines without pyruvic polysaccharides). This significantly increases the specific focus of the antibody immune response on the target rather than the carrier, resulting in increased efficacy and specificity of the response.

[0109] The CLEC conjugates of the invention, especially the conjugates with pyruvic acid, also resulted in increased affinity maturation (AM) for the target protein (AM was strongly increased, whereas the KLH / CRM conjugate showed only limited AM after repeated immunizations).

[0110] In the field of vaccines, suitable vaccines having only B cell epitopes or only T cell epitopes have been disclosed. In certain cases, vaccines having only T cell epitopes or only B cell epitopes are suitable and preferred. However, most vaccines on the market contain two epitopes, i.e., T cell epitopes and B cell epitopes.

[0111] For example, vaccines containing only B cell epitopes are ineffective in most cases, even if they do result in a detectable antibody immune response. However, in most cases, this immune response is usually much less effective than vaccines containing both B cell and T cell epitopes. This is also consistent with the examples given in the Examples section of the present invention where lower levels of responses can be detected.

[0112] On the other hand, vaccines containing only T cell epitopes (e.g., in vaccines in which a specific T cell response is the active component of the response) are of particular interest for certain applications, especially for cancer, where cancer-specific cytotoxic T lymphocyte and T helper cell epitopes or only CTL epitopes are combined with the vaccine platform of the present invention. In this case, the T cell epitopes with the CLEC polysaccharide adjuvant of the present invention are provided as only T cell epitopes. This is particularly preferred in cases where, for example, somatic mutations in cancer affect protein-coding genes (which can generate potential therapeutic new epitopes). These new epitopes can guide adoptive cell therapy and peptide-based (and RNA-based) new epitope vaccines to selectively target tumor cells using the patient's own cytotoxic T cells. For specific autoimmune diseases, the use of vaccines containing only T cell epitopes may also be preferred. The therapeutic effect of the corresponding conjugate containing only T cell epitopes is consistent with the reduction of effector T cells and regulatory T cells (T reg The development of autoimmune disease (such as multiple sclerosis or similar diseases) is associated with the inhibition of the corresponding autoimmune diseases (such as multiple sclerosis or similar diseases).

[0113] Since most commonly used vaccine combinations contain both B-cell and T-cell epitopes, the CLEC conjugates of the present invention also preferably contain both, separate B-cell and T-cell epitopes (minimum: at least one α-synuclein B-cell epitope and at least one T-cell epitope) to generate a sustained B-cell immune response. However, if desired, a weaker effect may demonstrate T-cell-independent immunity.

[0114] Therefore, the conjugates of the invention are not limited by possible vaccine antigens.Thus, the alpha synuclein vaccines of the invention may also comprise further antigens to provide bi-, tri-, tetra-, penta-, hexa-(etc.) or multi-specific vaccines.

[0115] Preferably, the vaccine antigen (ie, B cell and / or T cell epitope polypeptide) has a length of 6-50 amino acid residues, preferably 7-40 amino acid residues, and especially 8-30 amino acid residues.

[0116] Using the vaccine of the present invention, cross-linking of B cell receptors is also possible. According to a specific embodiment, the conjugate of the present invention is used for T cell-independent immunity. The T cell-independent response of polysaccharide vaccines is well known. These vaccines / polysaccharides produce immune responses by directly stimulating B cells without the assistance of T cells. T cell-independent antibody responses are short-lived. Antibody concentrations to pneumococcal capsular polysaccharides usually drop to baseline within 3-8 years, depending on the serotype. Typically, additional doses cannot be used to enhance vaccine responses because polysaccharide vaccines do not constitute immune memory. In children under two years old, polysaccharide vaccines are less immunogenic. The reason for direct stimulation here may be that B cells express a molecule called CR3 (complement receptor type 3). Macrophage-1 antigen or CR3 is a human cell surface receptor that can be found in B- and T-lymphocytes, polymorphonuclear leukocytes (mainly neutrophils), NK cells, and mononuclear phagocytes (such as macrophages). CR3 also recognizes iC3b when bound to foreign cells and β-glucan, meaning that direct uptake of the vaccine by B cells via the Pus-CR3 interaction could lead to cell stimulation and the generation of a low-level TI immune response.

[0117] The adjuvants, conjugates and vaccines of the present invention can fix complement and can be conditioned. The conditioned conjugates of the present invention can have enhanced B cell activation ability, which can lead to higher antibody titers and antibody avidity. This effect is known for C3d conjugates (Green et al., J. Virol. 77 (2003), 2046-2055) and can also be used in the process of the present invention unexpectedly.

[0118] Another unexpected advantage of the present invention is that the CLEC structure of the present invention allows for modular design of vaccines. For example, epitopes can be combined at will, and the platform does not rely on conventional carrier molecules. Although the main focus of the present invention is peptide-only vaccines, it is also applicable to proteins and peptides coupled independently to, and peptide-protein conjugates coupled to, the CLEC backbone of the present invention (Pyrgosaccharides). As shown in the Examples section involving Pyrgosaccharides, the present invention achieves significantly superior immune responses than traditional vaccines.

[0119] As mentioned above, the conjugate of the invention, if provided in the form of a pharmaceutical formulation (e.g. as a vaccine intended to be administered to a (human) subject in order to elicit an immune response to a specific polypeptide epitope coupled to a CLEC backbone, against which the immune response is to be directed), can be administered without the use (by co-administration) of a (additional) adjuvant in the formulation. According to a preferred embodiment, the pharmaceutical formulation comprising the conjugate of the invention is adjuvant-free.

[0120] A particularly preferred class of CLEC polysaccharide adjuvants of the present invention is β-glucan, especially chrysanthemum. Another preferred CLEC polysaccharide adjuvant is mannan. In contrast to the present invention, chrysanthemum has only been used in antifungal vaccines in the prior art (wherein chrysanthemum is used as an antigen, not as a carrier as in the present invention). Chrysanthemum also exhibits a different backbone, consisting only of β-(1,6) linked sugar moieties.

[0121] Pyran is a medium-sized linear β-(1,6) glucan. Pyran and synthetic forms of linear β-(1,6) glucans differ from all other glucans used as β-glucans, which usually consist of branched glucan chains (preferably β-(1,3) backbone with β-(1,6) side chains, such as yeast extract, GP, laminarin, schizophyllan, scleroglucan) or linear glucans that rely solely on β-(1,3) glucans, such as synthetic β-glucans, curdlan gum, Saccharomyces cerevisiae β-glucan (150 kDa) or linear β-(1,3:1,4) glucans, such as barley- and oat-β-glucans and lichenan.

[0122] As shown for the first time in the present invention, in vitro binding of dextran conjugates to the dectin-1 receptor is a proxy for subsequent in vivo efficacy: low-binding molecules can only exert a low level of immune response, medium binders are better, and high-efficiency binders induce a high-efficiency response (oat / barley BG < lichenan < pyracantha).

[0123] According to the present invention, CLECs are coupled to a single polypeptide (e.g., by standard techniques) to produce small nanoparticles with a low level of polydispersity (hydrodynamic radius (HDR) range: 5-15 nm), which are not cross-linked and do not aggregate to form larger particles similar to conventional CLEC vaccines, such as dextran particles (2-4 μm) or β-glucan particles disclosed in the literature, which are generally characterized by a size range of >100 nm (typical range (diameter; 150-500 nm, for example, Wang et al. (2019) provide particles with a diameter of 160 nm (DLS evaluation), a size of about 150 nm (TEM evaluation); Jin et al. (Acta Biomater. 2018 Sep 15; 78: 211-223) provides β-glucan particles (nanoparticles of aminated β-glucan-ovalbumin) with a size of 180-215 nm (assessed by DLS and SEM, respectively). These conjugates preferably contain at least one T cell epitope, especially a promiscuous linear or carrier peptide T cell epitope (e.g. from CRM197 or KLH).

[0124] By definition, the hydrodynamic radius measured by DLS is the radius of a hypothetical hard sphere that diffuses at the same rate as the particle being examined. The radius is calculated from the diffusion coefficient assuming a spherical shape of the molecule / particle and a given buffer viscosity. The HDR, also known as the Stokes radius, is a function of the Stokes-Einstein equation (see https: / / en.wikipedia.org / wiki / Stokes_radius ) calculated from the diffusion coefficient.

[0125] The preferred size range of the nanoparticles of the present invention can be those generally provided by the prior art, i.e. 1-5000 nm, preferably 1-200 nm, especially 2-160 nm, is the hydrodynamic radius (HDR) determined by dynamic light scattering (DLS). According to a preferred embodiment of the present invention, the particle size is smaller, such as 1-50 nm, preferably 1-25 nm, especially 2-15 nm, is the HDR determined by DLS. Therefore, these preferred particles are smaller, including peptide-only conjugates (about 5 nm average HDR) and CRM-pachysan conjugates (about 10-15 nm average HDR). Therefore, the preferred particles of the present invention are less than 100 nm, which is different from Wang et al.

[0126] Accordingly, the present invention also relates to a vaccine product designed for vaccination of an individual against a specific alpha synuclein antigen, the product comprising a compound comprising β-glucan or mannan as a C-type lectin (CLEC) polysaccharide adjuvant covalently coupled to said specific antigen.

[0127] Preferably, the vaccine product of the invention comprises a conjugate as described herein or obtainable or obtained according to the method of the invention.

[0128] According to a preferred embodiment, the vaccine product of the present invention comprises an α-synuclein antigen, which contains at least one α-synuclein B cell epitope and at least one T cell epitope. Preferably, the antigen is a polypeptide comprising one or more B cell epitopes and T cell epitopes.

[0129] According to a preferred embodiment, the covalently coupled antigen and CLEC polysaccharide adjuvant in the vaccine product of the present invention are present in the form of particles with a size of 1- to 5000 nm, preferably 1-200 nm, and especially 2-160 nm, the hydrodynamic radius (HDR) being determined by dynamic light scattering (DLS). As used herein, all particle sizes are median particle sizes, wherein the median separates the larger half of the particles from the smaller half. From the determined particle size, half of the particles are smaller than it, and the other half are larger than it.

[0130] According to a preferred embodiment, the covalently coupled antigen and CLEC polysaccharide adjuvant in the vaccine product of the present invention are present in the form of particles with a size of 1-50 nm, preferably 1-25 nm, especially 2-15 nm (HDR determined by DLS).

[0131] Preferably, the covalently coupled antigen and CLEC polysaccharide adjuvant in the vaccine product of the present invention are present as particles smaller than 100 nm, 50 nm, preferably smaller than 70 nm, especially smaller than 50 nm (HDR measured by DLS).

[0132] The vaccine product of the present invention has high storage stability. When stored in the form of liquid or frozen material (storage temperature: -80°C, -20°C, 2-8°C or stored at room temperature for a long time, at least 3 months), almost no aggregation occurs, as evidenced by the fact that the particle size does not increase significantly (i.e., more than 10%) during storage.

[0133] The extremely high potency of such small particles prepared using the medium molecular weight component dextrin of the present invention is surprising: for example, according to Adams et al. (J Pharmacol Exp Ther. 2008 Apr; 325(1): 115-23), the best dectin-1 substrates are linear β(1,3) glucan phosphate (about 150 kDa) and branched glucans (containing a β(1,3) main chain and β(1,6) side chains), such as scleroglucan or glucan from Candida albicans or laminarin. Furthermore, data from Adams et al., Palma et al. (J Biol Chem. 281(9)(2006) 5771-5779) and Willment et al. (J Biol Chem. 276(47)(2001), 43818-23) suggest that dectin-1 has no or only weak interactions with chalcone, and also no interactions with non-glucan carbohydrate polymers such as mannan. In fact, various references report that chalcone is poorly effective in binding dectin-1. However, in general, linear 1,3 and branched (1,3 backbone and 1,6 side chains) are the most effective dectin-1 binders; Adams et al. (2008) showed that mouse recombinant dectin-1 only recognizes and interacts with polymers containing a β(1,3)-linked glucose backbone. Dectin-1 does not interact with glucans containing only a β(1,6)-glucose backbone (such as pyrenoids) nor with non-glucan carbohydrate polymers (such as mannans).

[0134] In contrast to these findings, it was discovered during the course of the present invention that dactylin-based conjugates can strongly bind to dectin-1 in vitro and elicit cellular responses.

[0135] According to a preferred embodiment of the present invention, β-(1,6)-glucan is used. The prior art generally reports that large particles are more effective at activating PRRs than small ("soluble") monomer preparations, so particles containing large glucans are superior (and therefore preferred), while small soluble glucans can be used to block the activation of DCs, thereby interfering with the desired effect. It is well known that granulated β-glucans (such as the widely used yeast cell wall fraction zymosan) bind to and activate dectin-1, thereby inducing cellular responses. In contrast, the interaction of soluble β-glucans with dectin-1 remains controversial. Although there is a general consensus that soluble β-glucans, such as the small branched glucan laminarin (β-(1,3) and β-(1,6) side chains), bind to dectin-1 but fail to initiate signaling and induce cellular responses in DCs (Willment et al., J Biol Chem. 276(47) (2001), 43818-23, Goodridge et al., Nature. 2011, 472(7344):471–475.).

[0136] According to the present invention, it can be demonstrated that conjugates using high molecular weight glucans (10 times the size of schisan; for example: oat / barley 229 kDa / lichenan 245 kDa) perform less effectively than schisan particles (20 kDa). Korotchenko et al. showed that OVA / Lam conjugates are approximately 10 nm in diameter, bind dectin-1 and induce DC activation in vitro, but they are branched glucans, have no skin specificity, and are no more effective in vivo than OVA applied to the skin or OVA / alum applied subcutaneously. Wang et al. provided β-glucan particles >100 nm (average size: 160 nm). Jin et al. (2018) demonstrated aminated β-glucan-ovalbumin nanoparticles of 180-215 nm in size.

[0137] The present invention found that dapoxetine-based particles are potent dectin-1 binders, activate DC in vitro (with changes in surface marker expression) and elicit very strong immune responses, superior to a) other routes and b) comparable to KLH / CRM conjugate vaccines (which are also generally much larger particles) and c) larger glucans and mannans. This was true for Pep+Padre+dapoxetine (5 nm in size) and Pep+CRM+dapoxetine conjugates (11 nm in size).

[0138] In order to obtain an optimal immune response, the degree of activation of CLECs, especially pyrenoids, and the peptide / sugar ratio resulting from this degree of activation are crucial. Activation of the corresponding CLECs can be achieved by mild periodate oxidation. Thus, the degree of oxidation depends on the addition of periodate solution at a specified molar ratio: i.e. periodate:sugar subunit; 100% = 1 mole of periodate per mole of sugar monomer.

[0139] According to a preferred embodiment, the conjugate of the present invention comprises activated CLEC, wherein the ratio of periodate to β-glucan or mannan (monomer) part is 1 / 5 (i.e. 20% activation) to 2.6 / 1 (i.e. 260% activation), preferably 60% to 140%, especially 70% to 100%.

[0140] An optimal range of oxidation degrees between low / medium and high oxidation degrees (which will be proportional to the amount of epitope polypeptide in the final conjugate) can be defined as a reactivity with Schiff's fuchsin reagent similar to the reactivity of an equal amount of a given carbohydrate (e.g., pyrenoids) oxidized with periodate at molar ratios (sugar monomer:periodate) of 0.2-0.6 (low / medium), 0.6-1.4 (optimal range), and 1.4-2.6 (high), respectively.

[0141] The preferred ratio of glucan to peptide (especially pyruvate to peptide) is 10 to 1 (w / w) to 1 to 1 (w / w), preferably 8 to 1 (w / w) to 2 to 1 (w / w), especially 4 to 1 (w / w), but if the conjugate contains a carrier protein, the preferred ratio of β-glucan or mannan to B cell epitope-carrier polypeptide is 50:1 (w / w) to 0.1:1 (w / w), especially 10:1 to 0.1:1; that is, the molar ratio of sugar monomer to peptide is 24 to 1, which is lower than other reported effective vaccines (e.g. Liang et al., Bromuro et al.).

[0142] The degree of oxidation and the amount of reactive aldehydes available for sugar coupling are determined using existing methods such as: 1) gravimetric measurement, which allows determination of the total mass of the sample; 2) the anthrone method (according to Laurentin et al. 2003) - used to determine the concentration of intact, unoxidized sugars in the sample; in this case, dextran is dehydrated with concentrated H2SO4 to form furfural, which is reacted with anthrone (0.2% in H2SO4) to form furfural. )Condensation forms a green complex, which can be measured colorimetrically at 620nm) or 3) Schiff analysis: The oxidation state of the carbohydrate used for coupling is assessed using the Schiff fuchsin-sulfite reagent. Briefly, the fuchsin dye is decolorized by sulfur dioxide. Reaction with fatty aldehydes (on dextran) restores the purple color of the fuchsin, which can then be measured at 570-600nm. The color reaction produced is proportional to the degree of oxidation of the carbohydrate (the number of aldehyde groups). Other suitable analytical methods are also possible. Peptide ratios can be assessed using suitable methods, including UV analysis (205nm / 280nm) and amino acid analysis (aa hydrolysis, derivatization, and RP-HPLC analysis).

[0143] The conjugates of the invention can be used to induce a target-specific immune response without inducing or only inducing a very limited CLEC- or carrier protein-specific antibody response. The conjugates of the invention can also be used to induce an alpha synuclein-specific immune response while inducing no or only a very limited CLEC- or carrier protein-specific antibody response. As shown in the Examples section below, the present invention can also improve and focus the alpha synuclein-specific immune response because it triggers an immune response away from the reaction to the carrier protein or CLEC (e.g. in conventional peptide-carrier conjugates or in comparable settings without conjugation, especially also using non-oxidized CLEC, such as pyruvic acid).

[0144] Unless otherwise specified, "peptide" as used herein refers to a shorter polypeptide chain (2-50 amino acid residues), while "protein" refers to a longer polypeptide chain (more than 50 amino acid residues). Both are referred to as "polypeptides". According to the present invention, the B cell and / or T cell epitope polypeptide coupled to CLEC includes, in addition to polypeptides containing amino acid residues naturally used in normal gene expression and protein translation, all other forms of such polypeptide-based B cell and / or T cell epitopes, especially their natural or artificially modified forms, such as glycopeptides and all other post-translationally modified forms (e.g., the pyroglutamate form of Aβ disclosed in the Examples). In addition, the CLEC of the present invention is particularly suitable for presenting conformational epitopes, such as conformational epitopes that are part of a larger natural polypeptide, a mimetic epitope, a cyclic polypeptide, or a surface-bound construct.

[0145] According to a preferred embodiment, the conjugate of the present invention comprises a CLEC polysaccharide backbone and a B cell epitope. A "B cell epitope" is a portion of an alpha synuclein antigen that is bound by an immunoglobulin or antibody. B cell epitopes can be divided into two groups: conformational epitopes or linear epitopes. There are two main methods for epitope mapping: structural studies or functional studies. Methods for structural mapping of epitopes include X-ray crystallography, nuclear magnetic resonance, and electron microscopy. Methods for functional mapping of epitopes typically use binding assays such as western blots, dot blots, and / or ELISA to determine antibody binding. Competition methods determine whether two monoclonal antibodies (mAbs) can bind to an antigen simultaneously or compete with each other for binding at the same site. Another technique involves high-throughput mutagenesis, an epitope mapping strategy that aims to improve the rapid mapping of conformational epitopes of structurally complex proteins. Mutagenesis uses random / site-directed mutations at single residues to map epitopes. B cell epitope mapping can be used to develop antibody therapies, peptide-based vaccines, and immunodiagnostic tools (Sanchez-Trincado et al., J. Immunol. Res. 2017-2680160). For a variety of antigens, B cell epitopes are known and can be used in the current CLEC platform.

[0146] According to a particularly preferred embodiment, the conjugates of the invention comprise a CLEC polysaccharide backbone and a promiscuous T-cell epitope and / or an MHC II epitope known to function with several / all MHC alleles of a given species as well as other species.

[0147] According to another aspect, the present invention also relates to improving known T cell epitopes using the present CLEC technology. Therefore, the present invention also includes β-glucan or mannan as a C-type lectin (CLEC) polysaccharide adjuvant for T cell epitope polypeptides, wherein β-glucan or mannan is covalently coupled to the T cell epitope polypeptide to form a conjugate of β-glucan or mannan and the T cell epitope polypeptide.

[0148] A single T-cell epitope that binds to more than one HLA allele is called a "promiscuous T-cell epitope". Preferred promiscuous T-cell epitopes bind to 5 or more, preferably 10 or more, and in particular 15 or more HLA alleles. Promiscuous T-cell epitopes are applicable to different species, most importantly to several MHC / HLA haplotypes of a given species and other species (referring to MHC I and MHC II epitopes that are known to work with several / all MHC alleles). For example, the MHC II epitope PADRE (= non-natural pan-DR epitope (PADRE)) mentioned in the Examples section works in several human MHC alleles and mice (C57 / Bl6, but less effective in Balb / c). According to a preferred embodiment, the conjugate of the present invention comprises a T-cell epitope, preferably a T-cell epitope comprising the amino acid sequence AKFVAAWTLKAAA ("PADRE (polypeptide)") or a PADRE (polypeptide) variant.

[0149] Preferred PADRE polypeptides or PADRE polypeptide variants include a linker (also preferred for other polypeptide epitopes used herein), such as a cysteine ​​residue or a linker comprising a cysteine ​​residue ("-C" or "C-"; particularly useful for maleimide coupling), NRRA, NRRA-C or NRRA-NH-NH2 linkers. Preferred PADRE polypeptide variants include variants disclosed in the prior art (e.g., Alexander et al., Immunity 1 (1994), 751-761; U.S. Pat. No. 9,249,187; B2, or), preferably a shortened variant without a C-terminal A residue (AKFVAAWTLKAA), a variant in which the first residue alanine is replaced by an aliphatic amino acid residue (e.g., glycine, valine, isoleucine and leucine), a variant in which the third residue phenylalanine is replaced by L-cyclohexylalanine, a variant in which the thirteenth (last) amino acid residue alanine is replaced by an aliphatic amino acid residue (e.g., glycine, valine, isoleucine and leucine), a variant comprising aminocaproic acid, preferably coupled to the C-terminus of the PADRE variant, or a variant having the amino acid sequence AX1FVAAX2TLX3AX4A, wherein X1 is selected from W, F, Y, H, D, E, N, Q, I and K; X2 is selected from F, N, Y and W, X3 is selected from H and K, and X4 is selected from A, D and E (provided that the oligopeptide sequence is not AKFVAAWTLKAAA; US 9,249,187 B2); in particular, the T cell epitope is selected from AKFVAAWTLKAAANRRA-(NH-NH2), AKFVAAWTLKAAAN-C, AKFVAAWTLKAAA-C, AKFVAAWTLKAAANRRA-C, aKXVAAWTLKAAaZC, aKXVAAWTLKAAaZCNRRA (Seq ID7, 8, 87, 88, 89, 90, 91, 92), aKXVAAWTLKAAa, aKXVAAWTLKAAaNRRA, aA(X)AAAK TAAAAa, aA(X)AAATLKAAa, aA(X)VAAATLKAAa, aA(X)IAAATLKAAa, aK(X)VAAWTLKAAa, and aKFVAAWTLKAAa (Sequences 760.5, 760.57, 906.09, 906.11, 965.10, 1024.03 of Alexander et al. 1994), wherein X is L-cyclohexylalanine, Z is aminocaproic acid, and a is an aliphatic amino acid residue selected from alanine, glycine, valine, isoleucine and leucine.

[0150] T cell epitopes are presented on the surface of antigen presenting cells, where they bind to major histocompatibility complex (MHC) molecules. In humans, specialized antigen presenting cells exclusively present MHC class II peptides, while most nucleated somatic cells present MHC class I peptides. T cell epitopes presented by MHC class I molecules are typically peptides of 8–11 amino acids, while MHC class II molecules present longer peptides of 13–17 amino acids in length; nonclassical MHC molecules also present non-peptide epitopes, such as glycolipids. MHC class I and II epitopes can be reliably predicted by computational means alone, but not all T cell epitope in silico prediction algorithms are equally accurate. There are two main approaches to predict peptide-MHC binding: data-driven and structure-based. Structure-based approaches simulate peptide-MHC structures and require significant computational power. Data-driven approaches have higher prediction performance than structure-based approaches. Data-driven approaches predict peptide-MHC binding based on the sequence of the peptide that binds to the MHC molecule (Sanchez-Trincado et al., 2017). By identifying T cell epitopes, scientists can track, phenotype and stimulate T cells. For many antigens (including alpha synuclein), T cell epitopes are known and can be used in this CLEC platform.

[0151] Interestingly, recent breakthrough studies have shown that patients with Parkinson's disease (PD) have an increase in α-synuclein-specific T cells, which may be related to the risk haplotype of HLA, and also suggest that T cells are involved in autoimmunity in Parkinson's disease (Sulzer et al., Nature 2017;546:656–661 and Lindestamn Arlehamn et al., Nat Commun. 1875;2020:11). The causal role of α-synuclein-reactive T cells has also been recently confirmed by animal model studies [Williams et al., Brain. 2021;144:2047-2059]. A case study showed that the incidence of α-synuclein-reactive T cells increased several years before the onset of motor symptoms, and its frequency was highest around the time of motor symptoms and shortly thereafter in a large cross-sectional cohort of PD patients (Lindestam Arlehamn et al.). After the onset of motor symptoms, the T cell response to α-synuclein decreased with the duration of the disease. Thus, anti-aSyn T cell responses reach their highest levels before or shortly after PD diagnosis and gradually wane thereafter (i.e., maximal activity is detectable less than 10 years after diagnosis; Hoehn and Yahr (H+Y) stages 1 and 2 are preferred) (Lindestamn Arlehamn et al., 2020).

[0152] Thus, the human α-synuclein sequence contains common T cell epitopes. Examples are provided by Benner et al. (PLoS ONE 3(1):e1376.60), Sulzer et al. (2017), and Lindestam Arlehamn et al. (2020).

[0153] Benner et al. (Benner et al., (2008) PLoS ONE 3(1):e1376.) used a 60aa long, nitrated (at the Y residue) peptide containing the C-terminal portion of aSyn, which was emulsified in an equal volume of CFA containing 1 mg / ml Mycobacterium tuberculosis as an immunogen in a PD model. The article also disclosed the α-synuclein T cell epitope aa71-86 (VTGVTAVAQKTVEGAGNIAAATGFVK).

[0154] Sulzer et al. (Nature 2017; 546: 656-661) found two T cell antigenic regions in the N-terminal and C-terminal regions of α-synuclein in human PD patients. The first region is located near the N-terminus and contains MHCII epitopes aa31-45 (GKTKEGVLYVGSKTK) and aa32-46 (KTKEGVLYVGSKTKE), and also contains 9 peptides aa37-45 (VLYVGSKTK) as potential MHC class I epitopes. The second antigenic region disclosed by Sulzer et al. is located near the C-terminus (aa116–140) and requires phosphorylation of amino acid residue S129. Three phosphorylated aaS129 epitopes, aa116-130 (MPVDPDNEAYEMPSE), aa121-135 (DNEAYEMPSEEGYQD), and aa126-140 (EMPSEEGYQDYEPEA), generated significantly higher responses in PD patients than in healthy controls. The authors also demonstrated that the innate immune response to PD-associated α-synuclein has both MHC class I and class II restricted components.

[0155] In addition, Lindestam Arlehamn et al. (Nat Commun. 1875; 2020: 11) also disclosed α-synuclein peptide aa61-75 (EQVTNVGGAVVTGVT) as a T cell epitope (MHCII) for PD patients.

[0156] Accordingly, preferred T cell epitopes of the present invention include alpha synuclein polypeptide GKTKEGVLYVGSKTK

[0157] (aa31-45), KTKEGVLYVGSKTKE (aa32-46), EQVTNVGGAVVTGVT (aa61-75), VTGVTAVAQKTVEGAGNIAAATGFVK (aa71-86), DPDNEAYEMPSE (aa116-130), DNEAYEMPSEEGYQD (aa121-135), and EMPSEEGYQDYEPEA (aa126-140).

[0158] Regulatory T cells ("Treg cells" or "Tregs") are a subset of T cells that regulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune diseases. Treg cells have an immunosuppressive effect, usually inhibiting or downregulating the induction and proliferation of effector T cells. Tregs produced by the normal thymus are called "natural" Tregs. Selection of natural Tregs occurs on radioresistant hematopoietic-derived MHC class II expressing cells in the medulla or Hassal's corpuscles in the thymus. The process of Treg selection depends on the affinity of the interaction with the self-peptide-MHC complex. Selection to become a Treg is a "Goldilocks" process - not too high, not too low, but just right, T cells that receive very strong signals will undergo apoptosis; cells that receive weak signals will survive and be selected as effector cells. If a T cell receives an intermediate signal, it will become a regulatory cell. Due to the stochastic nature of the T cell activation process, all T cell populations with a given TCR will eventually become a mixture of Teffs and Tregs - the relative proportions are determined by the T cell's affinity for self-peptide-MHC. Tregs differentiated from immune naive T cells outside the thymus (ie, peripheral) or in cell culture are called "adaptive" or "induced" (ie, iTregs).

[0159] Natural Tregs are characterized by the expression of the CD4 T cell co-receptor and CD25, which is a component of the IL-2 receptor. Therefore, Tregs are CD4+CD25+. The expression of the nuclear transcription factor Forkhead box P3 (FoxP3) is a defining characteristic for the development and function of natural Tregs. Tregs inhibit the activation, proliferation, and cytokine production of CD4+ and CD8+ T cells and are thought to suppress B cells and dendritic cells, thereby inhibiting autoimmune responses.

[0160] Along these lines, several studies have shown that the number and function of Tregs in PD patients are reduced. For example, Hutter Saunders et al. (J Neuroimmune Pharmacol (2012) 7:927-938) and Chen et al. (MOLECULAR MEDICINE REPORTS 12:6105-6111, 2015) showed that the ability of regulatory T cells (Tregs) in PD patients to inhibit effector T cell function is impaired, and the proportion of Th1 and Th17 cells increases, while the proportion of Th2 and Treg cells decreases. Thome et al. (npj Parkinson's Disease (2021) 7:41) showed that decreased PD Treg function is associated with increased activation of proinflammatory T cells, which can directly lead to subsequent increase in proinflammatory signals by other immune cell populations. Treg inhibition of T cell proliferation is significantly associated with peripheral proinflammatory immune cell phenotypes. Using the H&Y disease scale, the ability of PD Tregs to inhibit the proliferation of T effector cells (such as CD4+) decreases with increasing PD disease burden, with the highest activity in H+Y 1 and 2 stages. Importantly, Lindestam Arlehamn et al. (2020) showed that anti-aSyn T cell responses were highest before or shortly after diagnosis of motor PD and gradually declined thereafter (i.e., maximal activity was detectable less than 10 years after diagnosis; and Hoehn and Yahr (H+Y) stages 1 and 2 were preferred) (Lindestamn Arlehamn et al., 2020).

[0161] Therefore, the vaccine of the present invention is combined with

[0162] 1) a vaccine containing an alpha synuclein-specific Treg epitope (e.g., a CD4 epitope, such as those disclosed by Brenner et al., Sulzer et al., and Lindestam Arlehamn et al. (aa31-45 (GKTKEGVLYVGSKTK), aa32-46 (KTKEGVLYVGSKTKE), aa61-75 (EQVTNVGGAVVTGVT), aa71-86 (VTGVTAVAQKTVEGAGNIAAATGFVK), aa116-130 (MPVDPDNEAYEMPSE), aa121-135 (DNEAYEMPSEEGYQD), and aa126-140 (EMPSEEGYQDYEPEA)); and / or

[0163] 2) Treg inducers, such as rapamycin, low-dose IL-2, TNF receptor 2 (TNFR2) agonists, anti-CD20 antibodies (such as rituximab), prednisolone, inosine pranobex, glatiramer acetate, sodium butyrate

[0164] It is preferred in the early stages of the disease (i.e., less than 10 years after diagnosis; and Hoehn and Yahr stages 1 and 2) to increase the number and activity of waning / declining Tregs, thereby reducing the autoimmune reactivity of aSyn-specific T effector cells and suppressing the autoimmune response in PD patients.

[0165] In addition, it has been found that Tregs are reduced and / or dysfunctional in a variety of diseases, especially chronic degenerative diseases or autoimmune diseases such as (active) systemic lupus erythematosus (SLE, aSLE), type 1 diabetes (T1D), autoimmune diabetes (AID), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD) as well as other degenerative diseases (ALS: Beers et al., JCI Insight 2, e89530 (2017); AD: Faridar et al., Brain Commun. 2, fcaa112 (2020); ALS: Beers et al., JAMA Neurol. 75, 656-658 (2018); MS: Haas et al., Eur. J. Immunol. 35, 3343-3352 (2005); T1D: Lindley et al., Diabetes 54, 92-99 (2005): AID: Putnamet al., J. Autoimmun. 24, 55-62 (2005); Autoimmune diseases: Ryba-Stanislawowska et al., Expert Rev. Clin. Immunol. 15, 777-789 (2019); aSLE: Valencia et al., J. Immunol. 178, 2579-2588 (2007); MS: Viglietta et al., J. Exp. Med. 199, 971-979 (2004); sLE: Zhang et al., Clin. Exp. Immunol. 153, 182-187 (2008); AD+MS: Ciccocioppo et al., Sci. Rep. 9, 8788 (2019)).

[0166] Therefore, it is also preferred to provide T cell epitopes suitable as Treg epitopes or Treg inducers in diseases where the Treg population is reduced or dysfunctional, as a combination with the vaccine of the present invention, so that the number and activity of reduced / decreased Tregs are increased, thereby reducing the autoimmune response of disease-specific T effector cells and inhibiting the patient's autoimmune response. Suitable Treg epitopes are defined as self-MHC epitopes (MHC II type), which are characterized by the ability to induce intermediate signals during T cell selection.

[0167] According to a preferred embodiment, the conjugate of the present invention comprises a polypeptide comprising or consisting of the amino acid sequence SeqID7, 8, 22-29, 87-131, GKTKEGVLYVGSKTK, KTKEGVLYVGSKTKE, ​​EQVTNVGGAVVTGVT, VTGVTAVAQKTVEGAGNIAAATGFVK, MPVDPDNEAYEMPSE), DNEAYEMPSEEGYQD, EMPSEEGYQDYEPEA or a combination thereof.

[0168] Therefore, preferred T cell epitopes are:

[0169]

[0170]

[0171]

[0172] wherein X is L-cyclohexylalanine, Z is aminocaproic acid, and a is an aliphatic amino acid selected from the group consisting of alanine, glycine, valine, isoleucine and leucine.

[0173] According to another preferred embodiment, the conjugate of the present invention comprises an alpha synuclein B cell epitope and a T cell epitope, preferably a fully specific / heterogamous T cell epitope, which are independently coupled to the CLEC polysaccharide backbone of the present invention, especially to alfalfa.

[0174] According to another preferred embodiment, the conjugate of the invention comprises an alpha synuclein B-cell epitope coupled to a "classical" carrier protein, such as CRM197, the construct also being coupled to a CLEC carrier of the invention, in particular pyrogallol.

[0175] For example, in the first step, a CRM conjugate can be formed by activating CRM such as GMBS or sulfo-GMBS; the maleimide group of the activated CRM then reacts with the SH group of the peptide (cysteine). The CRM conjugate is then treated with DTT to reduce the disulfide bond and generate an SH group on the cysteine. Subsequently, a one-pot reaction can be performed to mix the reduced CRM-conjugate with BMPH (N-β-maleimide-propionic acid hydrazide) and activated pyralidin (oxidized form) to generate a CLEC-based vaccine. The mechanism in the one-pot reaction may be that (in the case of pyralidin) oxidized pyralidin reacts with BMPH (having a hydrazide residue) and forms BMPH-hydrazone. The reduced CRM conjugate then reacts with the maleimide of BMPH-activated pyralidin via the SH group on the CRM-conjugate.

[0176] According to another preferred embodiment, the conjugate of the present invention comprises a "classical" carrier protein such as CRM197, which contains multiple T cell epitopes. The conjugate of the present invention also comprises a B cell epitope covalently coupled to a polysaccharide portion. In this embodiment, both polypeptides (B cell epitope and carrier molecule) are independently coupled to the CLEC carrier of the present invention (especially to Pseudomonas aeruginosa).

[0177] According to another preferred embodiment, the conjugate of the present invention further comprises a "classical" carrier protein such as CRM197, which contains multiple T cell epitopes. The conjugate of the present invention also comprises a B cell epitope covalently coupled to the "classical" carrier protein. The peptide-carrier conjugate of the present invention is also covalently coupled to the polysaccharide portion. In this embodiment, two polypeptides (B cell epitope and carrier molecule) are combined into a conjugate and coupled to the CLEC carrier of the present invention (especially to pyralidin). The carrier protein represents the connection between the β-glucan or mannan in the conjugate of the present invention and the B cell and / or T cell epitope polypeptide. The covalent coupling between the β-glucan or mannan and the B cell and / or T cell epitope polypeptide is then carried out by the carrier protein (as a functional linking part). Preferred conjugates of the invention may comprise a B cell epitope coupled to CRM197, the construct further coupled to a CLEC polymer of the invention, in particular to a β-glucan, wherein the β-glucan is pyralidin, lichenan, laminarin, curdlan gum, β-glucan peptide (BGP), schizophyllan, scleroglucan, whole glucan particles (WGP), zymosan, or lentinan, preferably pyralidin, laminarin, lichenan, lentinan, schizophyllan or scleroglucan, in particular pyralidin.

[0178] The present invention found that the novel B cell epitope-CRM197 conjugate coupled to pyralidin is a potent dectin-1 binder, which can induce a very strong immune response and is superior to the traditional CRM conjugate vaccine.

[0179] The present invention has found that the conjugation of CLEC with a novel B cell epitope-CRM197 conjugate, in particular the generation of a B cell epitope-CRM197-dextran, more preferably a B cell epitope-CRM197-linear β-(1,6)-glucan or a B cell epitope-CRM197-chalcone conjugate, is essential for inducing the immunogenicity of various peptide-CRM197-CLEC (in particular, a peptide-CRM197-β-glucan, more preferably a peptide-CRM197-linear β-(1,6)-glucan or a peptide-CRM197-linear chalcone conjugate) that is superior to traditional CRM conjugate vaccines (with or without adjuvant, prepared by mixing with β-glucan / chalcone).

[0180] Therefore, a preferred embodiment is to provide a B cell epitope+CRM197 conjugate covalently linked to β-glucan, more preferably a peptide+CRM197+linear β-(1,6)-glucan or a peptide+CRM197+linear pyruvic acid conjugate.

[0181] Therefore, the present invention also relates to improving and / or optimizing carrier proteins by covalently coupling the carrier protein (already containing one or more T cell antigens (as part of its polypeptide sequence, optionally in a post-translationally modified form)) to the CLEC polysaccharide adjuvant of the present invention, i.e. β-glucan or mannan, preferably covalently coupled to pyruvic lan, lichenan, laminarin, curdlan gum, β-glucan peptide (BGP), schizophyllan, scleroglucan, whole glucan particles (WGP), zymosan or lentinan. Therefore, the present invention relates to a β-glucan or mannan used as a C-type lectin (CLEC) polysaccharide adjuvant for a B cell and / or T cell epitope α-synuclein polypeptide, wherein the β-glucan or mannan is covalently coupled to the B cell and / or T cell epitope polypeptide to form a conjugate of the β-glucan or mannan and the B cell and / or T cell epitope polypeptide, wherein a carrier protein is covalently coupled to the β-glucan or mannan.

[0182] This improvement / optimization results in a significant reduction or elimination of B cell responses to CLEC and / or to the carrier protein, and / or an enhancement (or at least maintenance) of T cell responses to T cell epitopes of the carrier protein. This enables a reduction or elimination of antibody responses to CLEC and / or the carrier (the carrier then only transmits T cell responses), and a specific enhancement of antibody responses to the true target polypeptide coupled to the carrier and CLEC.

[0183] Therefore, a particularly preferred embodiment of the present invention is a conjugate consisting of or comprising

[0184] (a) β-glucan or mannan

[0185] (b) at least one B-cell or T-cell epitope polypeptide, and

[0186] (c) a carrier protein,

[0187] The three components (a), (b) and (c) are covalently bound to each other.

[0188] This combination of three components can be provided in any orientation or order, i.e. in the order of (a)-(b)-(c), (a)-(c)-(b) or (b)-(a)-(c), wherein (b) and / or (c) can be covalently coupled from the N-terminus to the C-terminus or from the C-terminus to the N-terminus, or coupled via functional groups within the polypeptide (e.g. functional groups in lysine, arginine, aspartic acid, glutamic acid, asparagine, glutamine, serine, threonine, tyrosine, tryptophan or histidine residues, in particular the ε-amino group of lysine residues). Of course, β-glucan or mannan can be coupled to one or more of components (b) and (c), preferably by the methods disclosed herein. Preferably, these components are coupled via a linker, in particular via a linker between all components (at least three). Preferred linkers are disclosed herein, such as cysteine ​​residues, or linkers comprising cysteine ​​or glycine residues, linkers derived from hydrazide-mediated coupling, coupling via heterobifunctional linkers (e.g., BMPH, MPBH, EMCH or KMUH), imidazole-mediated coupling, reductive amination, carbodiimide coupling -NH-NH2 linkers; NRRA, NRRA-C or NRRA-NH-NH2 linkers, peptide linkers (e.g., dimer, trimer, tetramer (or longer polymer) peptide groups, such as CG or CG). For existing carrier proteins, especially CRM, CRM197 and KLH, the preferred order of the at least three components is (a)-(c)-(b), that is, β-glucan or mannan and at least one B cell or one T cell epitope polypeptide are coupled to the carrier protein.

[0189] According to another preferred embodiment, the conjugate of the invention comprises T cell epitopes and does not contain B cell epitopes, wherein the conjugate preferably comprises more than one T cell epitope, in particular two, three, four or five T cell epitopes. The construct is particularly suitable for cancer vaccines. The construct is also particularly suitable for autoantigens, in particular autoantigens associated with autoimmune diseases. The therapeutic effect of the corresponding conjugate is comparable to the reduction of effector T cells and regulatory T cells (T reg The presence of T reg cells in the brain is associated with the development of a population of T cells, which results in the suppression of the corresponding disease (e.g., autoimmune or allergic diseases), as shown in multiple sclerosis. Remarkably, these T reg cells perform powerful bystander immunosuppression, thereby ameliorating diseases caused by both cognate and noncognate self-antigens.

[0190] Preferred CLECs for use as the polysaccharide backbone of the present invention are pyracantha or other β-(1,6) glucans (including synthetic forms of such glucans); others that may be used are: mannan, members of the β-glucan family, especially linear β-(1,3) (Saccharomyces cerevisiae β-glucan (e.g., 150 kDa), curdlan gum) or glucans containing branched β-(1,3) and β-(1,6), such as laminarin (4,5-7 kDa), scleroglucan, schizophyllan, more preferably linear glucans, (e.g., β(1,3): Saccharomyces cerevisiae β-glucan (150 kDa), curdlan gum (75-80 kDa or greater), β-(1,3) + β-(1,4) lichenan (22-250 kDa) β-(1 ,6) pyrenoids (20 kDa). Therefore, preferred CLECs according to the present invention are mannans and β-glucans, including linear and branched β-glucans characterized by having β-(1,3)-, β-(1,3)+β-(1,4)- and β(-1,6) main chains and attached side chains with β-(1,6) residues, more preferably linear β-glucans containing β-(1,3), β-(1,3)+β-(1,4) and β-(1,6) chains, more preferably linear β-(1,6) β-glucans, especially pyrenoids, their fragments or synthetic variants consisting of polymeric β-(1,6)-glucans (e.g. 4-mers, 5-mers, 6-mers, 8-mers, 10-mers, 12-mers, 15-mers, 17-mers or 25-mers).

[0191] Preferably, the minimum length of the CLEC of the present invention is 6-mer, since the oxidation reaction performed according to the present invention is problematic for smaller polysaccharides (ultimately other coupling mechanisms can be used for such smaller forms and / or end-linking by adding reactive forms). CLECs with 6 or more monomer units (i.e., 6-mers and larger) show good dectin binding. In general, the longer the CLEC, the better the dectin binding. A degree of polymerization (i.e., the number of individual glucose molecules within one glucan entity, DP) of 20-25 (i.e., DP20-25) certainly ensures good binding and in vivo efficacy (e.g., laminarin is a typical example of DP20-30).

[0192] The molecular weight of synthetic CLECs can also be smaller, for example, as low as 1-2 kDa, while the preferred molecular weight range of glucans and their fragments can be 1-250 kDa (for example, laminarin, lichenan, Saccharomyces cerevisiae β-glucan, pyruvate, curdlan gum and barley glucan, etc.), preferably 4.5-80 kDa (for example, laminarin, pyruvate, curdlan gum, low molecular weight lichenan, etc.), especially 4.5-30 kDa (for example, laminarin, pyruvate, low molecular weight lichenan, etc.).

[0193] Mannans are linear polymers of mannose. Plant mannans have β-(1,4) linkages. They are a storage form of sugar. Mannan cell wall polysaccharides found in yeast have an α-(1,6) linked backbone and α-(1,2) and α-(1,3) linked branches. It is serologically similar to the structure found on mammalian glycoproteins.

[0194] In order to produce the conjugates of the invention, CLECs, especially pyralidin, must be activated (e.g., by using mild periodate-mediated oxidation), the degree of oxidation being important for the immune response. As described above, a practical range of oxidation (particularly for pyralidin) is about 20-260% oxidation. In many cases, the optimal range of oxidation is between low / moderate oxidation (i.e., 20-60% oxidation) and high oxidation (i.e., 140-260% oxidation), i.e., in the range of 60-140% oxidation. Optimization of other CLECs can be readily adapted by those skilled in the art, e.g., for lichenan, more than 200% is required to obtain a similar amount of aldehyde groups.

[0195] Therefore, the range can also be alternatively defined as the reactivity with Schiff's red reagent, using agarose as an example, as follows: low / medium oxidation at a molar ratio (sugar monomer: periodate) of 0.2-0.6, the optimal range 0.6-1.4, and high oxidation at 1.4-2.6.

[0196] In any case, the degree of oxidation should be defined to meet the optimal range for each specific CLEC. Preferably, the linear β-glucan, more preferably β-(1,6)β-glucan, especially chrysanthemin, chrysanthemin fragments or synthetic variants thereof consisting of polymeric β(1,6)-glucans (e.g., 4-mers, 5-mers, 6-mers, 8-mers, 10-mers, 12-mers, 15-mers, 17-mers or 25-mers), is activated by mild periodate oxidation, resulting in the cleavage of vicinal OH groups to generate reactive aldehydes. Mild periodate oxidation refers to the use of sodium periodate (NaIO4), a well-known mild reagent that effectively oxidizes vicinal diols in carbohydrate sugars to generate reactive aldehyde groups. The carbon-carbon bonds between adjacent hydroxyl groups are cleaved. By varying the amount of periodate used, aldehydes can be introduced stoichiometrically into fewer or more numbers of sugar moieties of a given polysaccharide.

[0197] Other exemplary methods for activating carbohydrates are well known in the art and include cyanation of hydroxyl groups (e.g., by using organic cyanation reagents such as 1-cyano-4-(dimethylamino)-pyridinium tetrafluoroborate (CDAP) or N-cyanotriethylammonium tetrafluoroborate (CTEA)), reductive amination of carbohydrates, or activation and coupling using carboxylic acid reactive chemical groups such as carbodiimides.

[0198] The activated carbohydrate then reacts with the polypeptide to be conjugated to the activated CLEC to form a conjugate of CLEC and the B cell or T cell epitope polypeptide.

[0199] Therefore, the present invention also relates to a method for producing the conjugate of the present invention, wherein β-glucan or mannan is activated by oxidation, and the activated β-glucan or mannan is contacted with a B cell and / or T cell epitope polypeptide to obtain a conjugate of β-glucan or mannan and a B cell and / or T cell epitope polypeptide.

[0200] Preferably, the β-glucan or mannan is obtained by periodate oxidation, reductive amination or cyanation of hydroxyl groups at vicinal positions.

[0201] According to a preferred embodiment, the β-glucan or mannan is oxidized to a degree of oxidation, defined as a reactivity with Schiff's fuchsin reagent, corresponding to the degree of oxidation of an equivalent amount of pyrenoids oxidized by periodate, in a molar ratio of 0.2-2.6, preferably 0.6-1.4, especially 0.7-1.

[0202] Preferably, the conjugate is produced by coupling a hydrazide to a carbonyl (aldehyde) via a hydrazone-based coupling, or by coupling a sulfhydryl (e.g., cysteine) to a carbonyl (aldehyde) via a heterobifunctional maleimide-and-hydrazide linker (e.g., BMPH (N-β-maleimidopropionic acid hydrazide, MPBH (4-[4-N-maleimidophenyl]butyric acid hydrazide), EMCH (N-[ε-maleimidocaproic acid) hydrazide), or KMUH (N-[κ-maleimidoundecanoic acid] hydrazide).

[0203] The polypeptide to be coupled to the CLEC of the present invention is or comprises at least one B cell or at least one T cell epitope. Preferably, the polypeptide coupled to the CLEC comprises a single B cell or T cell epitope (even in embodiments where more than one polypeptide is coupled to the CLEC polysaccharide backbone). As shown in the Examples section, the preferred length of the alpha synuclein polypeptide is 5-29 amino acid residues, preferably 5-25, more preferably 7-20, even more preferably 7-15, especially 7-13 amino acid residues. In this regard, it is important to note that these length ranges are only for epitope sequences and do not include linkers, including peptide linkers, such as cysteine ​​or glycine or di-, tri-, tetra-(or longer) polypeptide groups, such as CG or CG, or cleavage sites, such as cathepsin cleavage sites; or combinations thereof (e.g., -NRRAC). Examples of epitopes have been tested in the Examples section; as can be seen from these results, the platform of the present invention is not limited to any particular polypeptide. Thus, nearly all possible epitopes are suitable for use in the present invention, including those known in the art, and especially those that have been described as being incorporable into presentation platforms (eg, with "classical" carrier molecules or adjuvants).

[0204] It is particularly preferred if the epitope can be coupled to the activated β-glucan based on existing coupling methods, including hydrazide-mediated coupling, coupling via heterobifunctional linkers (e.g., BMPH, MPBH, EMCH, KMUH, etc.), imidazole-mediated coupling, reductive amination, carbodiimide coupling, etc. (more to be added). The epitope used comprises a single peptide, which can be contained in a peptide or protein, or can be presented as a peptide-protein conjugate and then coupled to CLEC.

[0205] Thus, preferred coupling methods for providing conjugates of the invention are hydrazide coupling or coupling using thioester formation (e.g., maleimide coupling using BMPH (N-β-maleimidopropionic acid hydrazide), MPBH, EMCH, KMUH), especially wherein the pyruvic polysaccharide is coupled to BMPH via hydrazone formation and the polypeptide is coupled via thioester.

[0206] In this embodiment, it is preferred to provide a polypeptide with two preferred linkers, such as a hydrazide polypeptide / epitope for hydrazone coupling:

[0207] N-terminal coupling of the peptide: H2N-NH-CO-CH2-CH2-CO-polypeptide-COOH; preferably in combination with succinic acid or an alternative suitable linker, such as other suitable dicarboxylic acids, especially glutaric acid as a spacer / linker;

[0208] C-terminal coupling (preferred coupling direction of the present invention): NH2-polypeptide-NH-NH2.

[0209] Alternatively, unmodified α-synuclein polypeptides / epitopes may be used in the present invention, for example, polypeptides containing an (additional) cysteine ​​residue or another source of SH groups at the C- or N-terminus for heterobifunctional linker-mediated coupling (particularly BMPH, MPBH, EMCH, KMUH): NH2-Cys-Pep-COOH or NH2-Pep-Cys-COOH.

[0210] The length of the B cell polypeptide preferably used in the present invention is 5-19 amino acid residues, preferably 6-18, especially 7-15 amino acid residues. The B cell epitope is preferably a short linear polypeptide, a glycopeptide, a lipopeptide, other post-translationally modified polypeptides (e.g., phosphorylated, acetylated, nitrated, containing pyroglutamic acid residues, glycosylated, etc.), a cyclic polypeptide, etc.

[0211] The T cell polypeptide preferably used in the present invention has a length of 8-30 amino acid residues, preferably 13-29 amino acid residues, and more preferably 13-28 amino acid residues.

[0212] The preferred specificity of T cell epitopes used in the present invention is a linear short peptide suitable or known to be suitable for presentation through MHC I and II (as known to those skilled in the art), especially MHCII epitopes for CD4 effector T cells and CD4 Treg cells, MHC I epitopes for cytotoxic T cells (CD8+) and CD8 Treg cells, for example, can be used for cancer, autoimmunity or infectious diseases, and are known to be effective in humans or animals; a linear short peptide suitable for presentation through MHC I and II (as known to those skilled in the art), which adds a lysosomal protease cleavage site at the N-terminus or C-terminus, specifically a cathepsin family member-specific site, more specifically a site for cysteine ​​cathepsins, such as cathepsins B, C, F, H, K, L, O, S, V, X and W, especially cathepsin S- or L-, most preferably a cathepsin L cleavage site, promoting effective endo / lysosomal release of the peptide for MHC presentation, especially MHCII, with known efficacy in humans or animals. Cathepsin cleavage sites in various proteins have been identified and are well known in the art. This includes literature on sequences or methods for identifying such sequences: for example: Biniosek et al., J. Proteome Res. 2011, 10, 12, 5363-5373; Adams-Cioaba et al., Nature Comm. 2011, 2: 197; Ferrall-Fairbanks PROTEIN SCIENCE 2018 VOL 27: 714-724; Kleine-Weber et al., Scientific Reports (2018) 8: 1659, https: / / en.wikipedia.org / wiki / Cathepsin_S, etc. Specifically, the adaptation of the peptide sequence with an artificial protease cleavage site as shown in the present invention is based on the surprising effect of these sequence extensions: when the antigen is coupled to CLEC, the CLEC vaccine of the present invention induces a more effective immune response after skin administration. The vaccine of the present invention is taken up by dendritic cells, and then the peptide antigen is processed by lysosomes and presented to MHC.

[0213] Lysosomes are membrane-bound organelles within cells that are characterized by an acidic interior and carry a variety of hydrolases, including lipases, proteases, and glycosidases, which are involved in cellular catabolism. Among the various enzymes carried by lysosomes, cathepsins are a family of lysosomal proteases with a broad spectrum of functions. All cathepsins are divided into three different protease families: serine proteases (cathepsins A and G), aspartic proteases (cathepsins D and E), and 11 cysteine ​​cathepsins. In humans, 11 cysteine ​​cathepsins are known, which also have structures similar to papain: cathepsins B, C (J, dipeptidyl peptidase I or DPPI), F, H, K (O2), L, O, S, V (L2), X (P, Y, Z), and W (lymphoplasmin).

[0214] The various cathepsins show similarities in cellular localization and biosynthesis, but there are some differences in expression patterns. Among all lysosomal proteases, cathepsins L, B, and D are the most abundant, and their lysosomal concentrations are equivalent to 1 mM. Cathepsins B, H, L, C, X, V, and O are ubiquitously expressed, while cathepsins K, S, E, and W show cell- or tissue-specific expression. Cathepsin K is expressed in osteoclasts and epithelial cells. Cathepsins S, E, and W are mainly expressed in immune cells.

[0215] In addition to playing a major role in lysosomal protein recycling, cathepsins also play an important role in various physiological processes. Cathepsin S is the main protease involved in MHC II antigen processing and presentation. Mice without cathepsin S show significant differences in the generation of MHC II-bound li fragments and presentation, because where cathepsin S is abundantly expressed, li degradation in professional APCs is significantly reduced. In addition, endocytosis selectively targets exogenous substances to cathepsin S in human dendritic cells. Enrichment of MHC II molecules in late endocytic structures is also persistently seen in splenic DCs of mice lacking cathepsin S. Recent studies have shown that cathepsins B and D are both involved, but are not essential for MHC II-mediated antigen presentation. Cathepsin L also plays a role in a wide variety of cellular processes, including antigen processing, tumor invasion and metastasis, bone resorption, and turnover of intracellular and secreted proteins involved in growth regulation. Although cathepsin L is generally considered a lysosomal protease, it is also a secreted enzyme. This broad-spectrum protease can effectively degrade a variety of extracellular proteins (laminin, fibronectin, collagen I and IV, elastin, and other structural proteins of the basement membrane) as well as serum proteins, cytoplasmic proteins, and nuclear proteins.

[0216] As a novel means to enhance the potency of T cell epitopes in vaccines, especially CLEC-based vaccines, the addition of a lysosomal protease cleavage site at the N-terminus or C-terminus is a preferred embodiment of the present invention.

[0217] Such cleavage sites according to the invention may have the following characteristics:

[0218] Cathepsin L-like cleavage site:

[0219] The expected cathepsin L-like cleavage site is defined according to the protease cleavage site sequences known in the art, particularly those disclosed in Biniossek et al. (J. Proteome Res. 2011, 10, 5363-5373) and Adams-Cioaba et al. (Nature Comm. 2011, 2: 197). The orientation of the site can be N-terminal or C-terminal, preferably C-terminal. The preferred consensus sequence of the C-terminal cathepsin L site consists of the following formula:

[0220] X n -X1-X2-X3-X4-X5-X6-X7-X8

[0221] X n : 3-27 amino acids from an immunogenic peptide

[0222] X1: Any amino acid

[0223] X2: Any amino acid

[0224] X3: Any amino acid

[0225] X4: N / D / A / Q / S / R / G / L; preferably N / D, more preferably N

[0226] X5: F / R / A / K / T / S / E; preferably F or R, more preferably R

[0227] X6: F / R / A / K / V / S / Y; preferably F or R, more preferably R

[0228] X7: any amino acid, preferably A / G / P / F, more preferably A

[0229] X8: Cysteine ​​or linker like NHNH2

[0230] The most preferred sequence: X n -X1 X2 X3 NRRA-connector

[0231] Cathepsin S-like cleavage site:

[0232] The expected cathepsin S cleavage site is based on protease cleavage site sequences known in the art, in particular those disclosed in Biniossek et al. (J. Proteome Res. 2011, 10, 5363-5373) and https: / / en.wikipedia.org / wiki / Cathepsin_S, characterized by the consensus sequence:

[0233] X n -X1-X2-X3-X4-X5-X6-X7-X8

[0234] The characteristics of X are

[0235] X n : 3-27 amino acids from an immunogenic peptide

[0236] X1: Any amino acid

[0237] X2: Any amino acid

[0238] X3: any amino acid, preferably V, L, I, F, W, Y, H, more preferably V

[0239] X4: any amino acid, preferably V, L, I, F, W, Y, H, more preferably V

[0240] X5: K, R, E, D, Q, N, preferably K, R, more preferably R

[0241] X6: Any amino acid

[0242] X7: Any amino acid, preferably A

[0243] X8: Preferred A

[0244] X8: Cysteine ​​or linker like NHNH2

[0245] The most preferred sequence: X n -X1 X2 VVRAA-connector

[0246] T cell epitopes contained in proteins suitable for coupling to CLECs include carrier proteins, particularly toxic cross-reactive substances of diphtheria toxin (CRM), particularly CRM 197, KLH, diphtheria toxoid (DT), tetanus toxoid (TT), Haemophilus influenzae protein D (HipD), group B meningococcal outer membrane protein complex (OMPC), recombinant atoxic form of Pseudomonas aeruginosa exotoxin A (rEPA), flagellin, Escherichia coli heat-labile enterotoxin (LT), cholera toxin (CT), mutant toxins (such as LTK63 and LTR72), virus-like particles, albumin binding protein, bovine serum albumin, ovalbumin, synthetic peptide dendrimers, such as multiple antigenic peptides (MAP) or other commercially available carrier proteins, preferably CRM197 and KLH, most preferably CRM197, preferably in the conjugate The ratio of carrier protein to β-glucan or mannan is 1 / 0.1 to 1 / 50, preferably 1 / 0.1 to 1 / 40, more preferably 1 / 0.1 to 1 / 20, especially 1 / 0.1 to 1 / 10.

[0247] According to a preferred embodiment of the present invention, the CLEC conjugate of the present invention comprises (a) CLEC coupled to a single α-synuclein B-cell epitope and / or T-cell epitope, including a mixture of multiple B- or T-cell epitopes, especially these epitopes coupled to pyralidin; (b) CLEC coupled to a polypeptide-carrier protein conjugate, preferably a polypeptide-KLH or polypeptide CRM197 conjugate coupled to pyralidin, most preferably a polypeptide-CRM197 conjugate coupled to pyralidin; (c) CLEC coupled to a single α-synuclein B-cell epitope and T-cell epitope; coupled to CLEC, most preferably coupled to pyralidin; (d) CLEC individually ("individually"); Here, it is meant that the polypeptide chains are not present in the form of fusion proteins, tandem repeat polypeptides or peptide-protein conjugates, but as independent entities; i.e., an independent polypeptide containing B cell epitopes and an independent polypeptide containing T cell epitopes) are coupled to B cell epitopes and T cell epitopes contained in polypeptides or proteins, such as carrier proteins, self-proteins, foreign proteins from pathogens, allergens, etc.; (e) CLECs are individually ("individually" also has the same meaning as (d)) coupled to T cell epitopes representing linear MHC I and MHC II epitopes or T cell epitopes contained in proteins, such as carrier proteins or target proteins, for example, for the treatment of tumor diseases or autoimmune diseases.

[0248] In view of these advantageous properties of the conjugate of the present invention, the conjugate and vaccine of the present invention are particularly suitable for active anti-α-synuclein vaccines for the treatment and prevention of synuclein diseases.

[0249] According to another aspect, the present invention also relates to a pharmaceutical composition comprising the above-mentioned conjugate or vaccine and a pharmaceutically acceptable carrier.

[0250] Preferably, the pharmaceutically acceptable carrier is a buffer, preferably a phosphate or TRIS-based buffer.

[0251] According to a preferred embodiment of the present invention, the pharmaceutical composition is contained in a needle-based delivery system, preferably a syringe, a microneedle system, a hollow needle system, a solid microneedle system, or a system containing a needle adapter; an ampoule, a needle-free injection system, preferably a jet injector; a patch, a transdermal patch, a microstructured transdermal system, a microneedle array patch (MAP), preferably a solid MAP (S-MAP), a coated MAP (C-MAP) or a soluble MAP (D-MAP); an electrophoretic system, an iontophoretic system, a laser-based system, especially an erbium YAG laser system; or a gene gun system. The conjugate of the present invention is not limited to any form of production, storage or delivery state. Therefore, all traditional and typical forms are suitable for the present invention. Preferably, the composition of the present invention can contain the conjugate or vaccine of the present invention as a solution or suspension, a deep-frozen solution or suspension; a lyophilizate, a powder or granules.

[0252] The present invention is further illustrated by the following examples and drawings, but is not limited thereto. BRIEF DESCRIPTION OF THE DRAWINGS

[0253] Figure 1 : The binding activity of CLEC conjugates to ConA and DC receptor (ie, dectin-1) in vitro.

[0254] A) Pus binds dectin-1 more efficiently than lichenan (Lich); B) Oat β-glucan (oat_BG265, oat_BG391) and barley β-glucan (Barley_BG229) bind with limited efficacy compared to Pus. C) Different types of glucans (i.e., Pus, mannan, and barley glucan (229 kd)) retain high or moderate receptor binding activity after glucan oxidation, as assessed by competition binding assays. "20% and 40% oxidation" indicates the oxidation state of the glucan moieties used for coupling. % inhibition indicates the inhibition of binding of soluble dectin-1 receptor (Pus and Barley_BG229) or ConA (mannan) to plate-bound β-glucan or mannan in the presence of the indicated concentrations of the tested CLECs. D) Pseudomonas aeruginosa conjugates and E) Lichenan conjugates retain approximately 50% of dectin-1 binding capacity compared to unconjugated β-glucan, as assessed by competition binding assays. F) Pseudomonas aeruginosa conjugates generated via heterobifunctional linkers retain high binding potency for dectin-1. Data are shown as relative light units (RLU) of a luminol-doped ELISA. Pus70 conjugates 1-3 refer to three different CLEC peptide conjugates (SeqID2, SeqID10, and SeqID16), respectively. Pus 70% and Lich200% refer to pseudomonas aeruginosa and lichenan in their respective oxidation states. BMPH Pus refers to activated pseudomonas aeruginosa. BMPH conjugate 2 refers to the CLEC-SeqID10 conjugate.

[0255] Figure 2 : Flow cytometric analysis of dendritic cells activated by lipopolysaccharide (LPS) and different pyrin preparations.

[0256] Immature, bone marrow-derived mouse dendritic cells (BMDC) were generated in vitro with granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF-BMDC were stimulated for 24 hours with LPS (equivalent to the dose contained in oxidized chrysanthemum and in chrysanthemum conjugate preparations), SeqID2+SeqID7+chrysanthemum conjugate, or oxidized chrysanthemum alone. Dose escalation (up to 500 μg / mL) was started for chrysanthemum conjugate and chrysanthemum alone, each starting at 62.5 μg / mL. DCs were identified based on CD11c / CD11b expression, and surface expression of CD80 and major histocompatibility complex (MHC) class II was measured by flow cytometry by A) and C) SeqID2+SeqID7+chrysanthemum conjugate or B) and D) oxidized chrysanthemum alone. For DCs treated with the pyrenoid preparation (= measured values) and DCs treated with an equal amount of LPS (= expected values), the expression of activation markers was analyzed using the CytExpert software.

[0257] Figure 3 : The particle size of CLEC conjugates was determined by dynamic light scattering (DLS).

[0258] Particle size was determined by measuring the random variation in the intensity of light scattered from a suspension or solution using DLS. Regularisation analysis and the corresponding 24 h cumulative radius analysis are shown for A) SeqID5+SeqID7+Pseudomonas aeruginosa (80% oxidized state) conjugate, B) SeqID6+CRM+Pseudomonas aeruginosa conjugate and C) unmodified Pseudomonas aeruginosa, respectively.

[0259] Figure 4 : Comparison of the immunogenicity of different CLEC-based vaccines.

[0260] Female BALB / c mice aged 8-12 weeks were vaccinated intradermally for a total of 3 times at 2-week intervals. Blood samples were collected at the start of vaccination and after each vaccination to obtain information on the kinetics of the ensuing immune response. Samples were collected 2 weeks after the third vaccination and analyzed for A) anti-peptide (SeqID3) responses to mannan, barley and pyralidin-based vaccines (SeqID2+SeqID7+CLEC) and B) anti-peptide (SeqID3 and SeqID11) responses to pyralidin-based and lichenin-based vaccines (SeqID2+SeqID7+CLEC and SeqID10+SeqID7+CLEC).

[0261] Figure 5 : Comparative analysis of the immunogenicity of peptide-pastelan conjugates and vaccines consisting of unconjugated peptide and CLEC.

[0262] Female BALB / c mice aged 8-12 weeks received a total of 3 intradermal vaccinations at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. Samples were collected 2 weeks after the third vaccination and analyzed for anti-peptide responses (SeqID3). Vaccines used: SeqID2+SeqID7+CLEC or a mixture of unconjugated SeqID2, SeqID7, and CLEC.

[0263] Figure 6 : Comparative analysis of the immunogenicity of pyrifos polysaccharide conjugates containing both B-cell epitopes and T-cell epitopes and conjugates containing only B-cell epitopes or only T-cell epitopes.

[0264] Female BALB / c mice aged 8-12 weeks received a total of 3 intradermal vaccinations at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. Vaccines used: SeqID5+SeqID7+CLEC or SeqID5+CLEC, and SeqID7+CLEC. Samples were collected 2 weeks after the third vaccination and analyzed for anti-peptide responses (SeqID6).

[0265] Figure 7 :Comparative analysis of anti-pastosan antibody responses in mice after repeated immunization with peptide-pastosan conjugates or vaccines containing the respective unconjugated components

[0266] Female BALB / c mice, 8-12 weeks old, received a total of 3 intradermal vaccinations at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. Pre-plasma and t1-t3 represent the immune response detectable before vaccination (pre-plasma) or after the first vaccination (t1), the second vaccination (t2), or the third vaccination (t3). Samples were collected 2 weeks after the third vaccination and analyzed for anti-pasteuran responses. A) Analysis of anti-pasteuran responses induced by different vaccines. B) Kinetics of immune responses. C) Inhibition ELISA demonstrates the specificity of the ELISA system. Vaccines used: SeqID2+SeqID7+CLEC or a mixture of unconjugated SeqID2, SeqID7, and CLEC

[0267] Figure 8 : Comparative analysis of immune responses elicited by CLEC-based vaccines using differentiated peptide conjugation orientations.

[0268] Female BALB / c mice aged 8-12 weeks received a total of 3 intradermal vaccinations at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. Four different CLEC-based prototype vaccine candidates were tested (two different peptides, conjugated to pyralidin via their C-terminus or N-terminus). Samples were collected 2 weeks after the third vaccination and analyzed for A) anti-peptide and B) anti-aSyn protein responses. Vaccines used: SeqID1 / 2 / 4 / 5+SeqID7+CLEC

[0269] Fig. 9 : Comparative analysis of the immunogenicity of CLEC-based vaccines using different promiscuous T helper cell epitopes.

[0270] Female BALB / c mice aged 8-12 weeks received a total of 3 intradermal vaccinations at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. Nine different CLEC-based vaccines (vaccines 1-9) containing the same B cell epitope and different T helper epitopes (i.e., SeqID7, SeqID22-29) were evaluated for immune responses against the respective peptide-KLH conjugates (vaccine 10). Samples were collected 2 weeks after the third vaccination and analyzed for A) anti-peptide and B) anti-aSyn protein responses.

[0271] Fig.10 : Comparative analysis of target-specific and carrier protein-specific immunogenicity induced by CLEC-based vaccines using carrier protein KLH as a source of T helper cell epitopes and traditional peptide-protein conjugate vaccines.

[0272] Female BALB / c mice aged 8-12 weeks received a total of 3 intradermal or subcutaneous (sc) vaccinations at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. The immune responses elicited by two peptide-protein conjugate vaccines using KLH as a source of T helper epitopes in combination with CLEC modification (SeqID3+KLH+Alumin and SeqID6+KLH+Alumin, respectively) were evaluated and compared with conventional peptide-KLH conjugates (i.e., SeqID3+KLH and SeqID6+KLH) in combination with Alum / Responses elicited by subcutaneous vaccination (sc) or intradermal vaccination (id) without additional adjuvant were compared. Samples were collected 2 weeks after the third vaccination and analyzed by ELISA for A) anti-peptide and anti-aSyn protein responses and B) anti-KLH responses.

[0273] Fig.11 :Comparative analysis of target-specific and carrier protein-specific immunogenicity induced by CLEC-based vaccines with carrier protein CRM197 as the source of T helper cell epitopes and traditional peptide-protein conjugate vaccines

[0274] Female BALB / c mice aged 8-12 weeks received a total of 3 intradermal or subcutaneous vaccinations at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. Two different CRM-based vaccine types were used in this study. SeqID6+CRM+Pus represents a peptide-CRM conjugate that was subsequently coupled to pyruvic acid, while SeqID5+CRM+Pus represents a conjugate in which the peptide component and the carrier molecule were coupled to CLEC, respectively. The immune response induced by both types was evaluated against the respective conventional peptide-CRM conjugates (i.e., SeqID6+CRM adjuvanted with Alum / Alhydrogel, administered subcutaneously). Samples were collected 2 weeks after the third vaccination and analyzed by ELISA for A) anti-peptide and anti-aSyn protein responses and B) anti-CRM responses.

[0275] Fig.12 : Comparative analysis of the selectivity of immune responses elicited by CLEC-based vaccines against two different aSyn forms in vivo.

[0276] Female BALB / c mice aged 8-12 weeks received a total of 3 intradermal or subcutaneous vaccinations at 2-week intervals. CLEC-based vaccines (SeqID2+SeqID7+Pus and SeqID5+SeqID7+Pus; intradermal) and alternative CLEC-based vaccines (SeqID3+KLH+Pus and SeqID6+CRM+Pus; intradermal) were evaluated compared to traditional peptide-component vaccines (SeqID3+KLH+Alum and SeqID6+CRM+Alum, subcutaneous). Samples were collected 2 weeks after the third vaccination for aSyn selectivity assay (inhibition ELISA). Black line: monomeric aSyn for inhibition; dashed line: filamentous aSyn for inhibition.

[0277] Fig.13 : Comparative analysis of the avidity of immune responses elicited by CLEC-based vaccines.

[0278] Female BALB / c mice aged 8-12 weeks received a total of 3 intradermal or subcutaneous vaccinations at 2-week intervals. CLEC-based vaccines (SeqID2+SeqID7+Pus and SeqID5+SeqID7+Pus, intradermal) and alternative CLEC-based vaccines (SeqID3+KLH+Pus and SeqID6+CRM+Pus, intradermal) were evaluated compared to traditional peptide-component vaccines (SeqID3+KLH+Alum and SeqID6+CRM+Alum, subcutaneous). Samples were collected 2 weeks after the second immunization (T2) or 2 weeks after the third immunization (T3) to assess antibody affinity for aSyn by ELISA-based affinity assays.

[0279] Fig.14 : Comparative analysis of the affinity of immune responses elicited by CLEC-based vaccines.

[0280] Female BALB / c mice aged 8-12 weeks received a total of 3 intradermal or subcutaneous vaccinations at 2-week intervals. CLEC-based vaccines (SeqID2+SeqID7+Pus and SeqID5+SeqID7+Pus, intradermal vaccination) and alternative CLEC-based vaccines (SeqID3+KLH+Pus and SeqID6+CRM+Pus, intradermal vaccination) were evaluated compared to traditional peptide-component vaccines (SeqID3+KLH+Alum and SeqID6+CRM+Alum, subcutaneous vaccination). Samples were collected 2 weeks after the third vaccination and the antibody equilibrium dissociation constant (Kd) against aSyn was assessed by aSyn displacement ELISA assay.

[0281] Fig.15 : Comparative analysis of the in vitro functionality of immune responses elicited by CLEC-based vaccines.

[0282] Female BALB / c mice aged 8-12 weeks received a total of 3 intradermal and subcutaneous vaccinations at 2-week intervals. Samples were collected 2 weeks after the third vaccination and modulation of aSyn aggregation in the presence of aSyn-specific antibodies was assessed by ThT fluorescence assay. A) Aggregation of aSyn for 0-72 hours in the presence of CLEC vaccine-induced antibodies (SeqID2+SeqID7+Pus; intradermal vaccination), traditional peptide-component-induced antibodies (SeqID3+KLH+Alum, subcutaneous vaccination), or mouse plasma. B) Aggregation of aSyn or aSyn with preformed fibrils for 0-92 hours in the presence of CLEC vaccine-induced antibodies (SeqID5+SeqID7+Pus and SeqID6+CRM+Pus, both intradermal vaccination), traditional peptide-component-induced antibodies (SeqID6+CRM+Alum, subcutaneous vaccination), or mouse plasma. Kinetic curves were calculated by normalizing to the ThT fluorescence at t0, and the percentage inhibition of aSyn aggregation was calculated using the slope values ​​extracted from the linear regression analysis of the exponential growth phase of ThT kinetics.

[0283] Fig.16 : Comparative analysis of the effects of immunization route on immune responses elicited by CLEC-based vaccines.

[0284] Female BALB / c mice aged 8-12 weeks were vaccinated 3 times at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. Two alternative routes, including subcutaneous (sc) and intramuscular (im), were compared with intradermal (id) vaccination of CLEC vaccines. Three doses of CLEC-based vaccine (SeqID2+SeqID7+Pus) were administered per route. Samples were collected 2 weeks after the third vaccination and analyzed for A) anti-peptide and B) anti-aSyn protein responses.

[0285] Fig.17 :Comparative analysis of target-protein-specific immunogenicity induced by CLEC-based peptide-CRM197 conjugate vaccines using different peptide-CRM197 / CLEC ratios

[0286] Female BALB / c mice aged 8-12 weeks received a total of 3 intradermal vaccinations at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. Five different peptide-CRM-based vaccines were used in this study, which employed different peptide-CRM / Pus ratios (w / w). All 5 groups were immunized with SeqID6+CRM+Pus conjugates. 1:1, 1:2,5, 1:5, 1:10 and 1:20 represent conjugates, where the weight ratio (w / w) of peptide-CRM conjugate / CLEC was 1 / 1, 1 / 2,5, 1 / 5, 1 / 10 and 1 / 20. The induced immune response was evaluated using samples collected 2 weeks after the third vaccination, and the response against aSyn protein was analyzed by ELISA. Titer determination was based on OD 最大 Calculation of / 2.

[0287] Fig.18 : Comparative analysis of immune responses elicited by CLEC vaccines containing B cell epitopes derived from aSyn (aa1-8).

[0288] Female BALB / c mice aged 8-12 weeks were vaccinated 3 times (id and sc) at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. CLEC-based vaccines (SeqID12+SeqID7+Asterin, id) were evaluated in comparison to conventional peptide-component conjugate-based vaccines (SeqID13 conjugated with KLH and Alhydrogel (Alum), sc). Samples were collected 2 weeks after the third vaccination and analyzed for A) anti-peptide and anti-ASyn protein responses and A) aSyn selectivity (inhibition ELISA). Black line: monomeric aSyn for inhibition; dashed line: filamentous aSyn for inhibition.

[0289] Fig.19 Shown is a comparative analysis of the immune responses elicited by CLEC vaccines containing B cell epitopes derived from aSyn (aa100-108).

[0290] Female BALB / c mice aged 8-12 weeks were vaccinated 3 times (id and sc) at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. CLEC-based vaccines (SeqID16+SeqID7 and pyruvic acid, id) were evaluated in comparison to conventional peptide-component conjugate-based vaccines (SeqID17 conjugated with KLH and Alhydrogel (Alum), sc). Samples were collected 2 weeks after the third vaccination and analyzed for A) anti-peptide and anti-aSyn protein responses and B) aSyn selectivity (inhibition ELISA). Black line: monomeric aSyn for inhibition; dashed line: filamentous aSyn for inhibition.

[0291] Fig. 20 Comparative analysis of immune responses elicited by CLEC vaccines containing B-cell epitopes derived from aSyn (aa91-97) is shown. Female BALB / c mice aged 8-12 weeks were vaccinated 3 times (id and sc) at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. CLEC-based vaccines (SeqID14+SeqID7 and Pseudomonas polysaccharide, id) were evaluated in comparison to vaccines based on traditional peptide-component conjugates (SeqID15 conjugated with KLH and Alhydrogel (Alum), sc). Samples were collected 2 weeks after the third vaccination and analyzed for anti-peptide and anti-aSyn protein responses.

[0292] Fig.21 Comparative analysis of immune responses elicited by CLEC vaccines containing B-cell epitopes derived from aSyn (aa130-140) is shown. Female BALB / c mice aged 8-12 weeks were vaccinated a total of 3 times (id and sc) at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. CLEC-based vaccines (SeqID20+SeqID7 and pyruvic acid, id) were evaluated in comparison to vaccines based on traditional peptide-component conjugates (SeqID21 conjugate with KLH and Alhydrogel (Alum), sc). Samples were collected 2 weeks after the third vaccination and analyzed for A) anti-peptide and anti-aSyn protein responses and B) aSyn selectivity (inhibition ELISA). Black line: monomeric aSyn for inhibition; dashed line: filamentous aSyn for inhibition.

[0293] Fig. 22Comparative analysis of immune responses elicited by CLEC vaccines containing B-cell epitopes derived from aSyn (aa115-122) is shown. Female BALB / c mice aged 8-12 weeks were vaccinated a total of 3 times (id and sc) at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. CLEC-based vaccines (SeqID51+SeqID7 and pyrenoidin, id) and vaccines based on traditional peptide-component conjugates (SeqID52 conjugated with CRM and Alhydrogel (Alum), sc) were evaluated. Samples were collected 2 weeks after the third vaccination and analyzed for A) anti-peptide and anti-aSyn filamentous responses and B) aSyn selectivity (inhibition ELISA). Black line: monomeric aSyn for inhibition; dashed line: filamentous aSyn for inhibition.

[0294] Fig.23 Comparative analysis of immune responses elicited by CLEC vaccines containing B-cell epitopes derived from aSyn (aa115-124) is shown. Female BALB / c mice aged 8-12 weeks received a total of 3 vaccinations (id and sc) at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. CLEC-based vaccines (SeqID67+SeqID7 and pyrenoidin, id) were evaluated compared to vaccines based on traditional peptide-component conjugates (SeqID68 conjugated with CRM and Alhydrogel (Alum), sc). Samples were collected 2 weeks after the third vaccination and analyzed for A) anti-peptide and anti-aSyn filamentous responses and B) aSyn selectivity (inhibition ELISA). Black line: monomeric aSyn for inhibition; dashed line: filamentous aSyn for inhibition.

[0295] Fig.24 Comparative analysis of immune responses elicited by CLEC vaccines containing B-cell epitopes derived from aSyn (aa107-113) is shown. Female BALB / c mice aged 8-12 weeks were vaccinated a total of 3 times (id and sc) at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. CLEC-based vaccines (SeqID73+SeqID7 and pyrenoidin, id) were evaluated compared to vaccines based on traditional peptide-component conjugates (SeqID74 conjugated with CRM and Alhydrogel (Alum), sc). Samples were collected 2 weeks after the third vaccination and analyzed for A) anti-peptide and anti-aSyn filamentous responses and B) aSyn selectivity (inhibition ELISA). Black line: monomeric aSyn for inhibition; dashed line: filamentous aSyn for inhibition.

[0296] Fig.25 A comparative analysis of the in vitro functionality of the immune responses elicited by CLEC-based vaccines is shown.

[0297] Female BALB / c mice aged 8-12 weeks were vaccinated 3 times (id and sc) at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. Samples were collected 2 weeks after the third vaccination and evaluated for ThT kinetics (i.e., the fibrillar fraction of aSyn) in the presence of A) CLEC vaccine-induced antibodies (SeqID67 / 71 / 73 + SeqID7 and pyrenoidin, id) or conventional peptide-component-induced antibodies (SeqID68 / 72 / 74 coupled to CRM and Alhydrogel (Alum), sc) or D) aSyn-specific monoclonal antibody LB09 or untreated mouse plasma.

[0298] Fig.26 The in vitro binding activity of the CRM197-CLEC conjugate to the murine DC receptor (ie, dectin-1) is shown.

[0299] The figure shows a comparative analysis of dectin-1 binding capacity as determined by ELISA. A) Pus refers to unmodified pus oxi and pus oxi refers to activated pus oxi. CRM-pus conjugate 1 refers to SeqID6+CRM197+pus oxi conjugate and CRM conjugate 1 refers to CRM197+SeqID6 conjugate without β-glucan modification. Negative control refers to samples without inhibitors. B) SeqID52 / 66 / 68 / 70 / 72 refer to CRM197-pus oxi conjugates with the indicated B cell epitopes. C) Lich oxi refers to activated lichen oxi and CRM-Lich conjugate 1 refers to SeqID6+CRM197+lichen oxi conjugate. D) Lam oxi refers to activated laminarin and CRM-Lam conjugate 1 refers to SeqID6+CRM197+laminarin conjugate.

[0300] Fig. 27 The in vitro binding activity of the CRM197-CLEC-conjugate to the human DC receptor (ie, dectin-1) is shown.

[0301] The figure shows a comparative analysis of dectin-1 binding capacity determined by ELISA. Lich conjugate refers to SeqID6+CRM197+lichenin conjugate, Pus conjugate refers to SeqID6+CRM197+pastosan conjugate, Lam conjugate refers to SeqID6+CRM197+laminarin conjugate, and negative control refers to a sample without inhibitor added.

[0302] Fig.28 A comparison of the immunogenicity of different CRM-chalcone based vaccines is shown.

[0303] Female BALB / c mice aged 8-12 weeks received a total of 3 intradermal vaccinations at 2-week intervals. Blood samples were collected at the start of vaccination and after each vaccination to obtain information on the kinetics of the ensuing immune response. Samples were collected 2 weeks after the third vaccination and analyzed for A) anti-peptide responses and B) responses against aggregated aSyn filaments.

[0304] Fig.29 A comparative analysis of the selectivity of the immune responses elicited in vivo by vaccines based on peptide+CRM+pastosan for aSyn filaments is shown.

[0305] Female BALB / c mice aged 8-12 weeks received a total of 3 intradermal or subcutaneous vaccinations at 2-week intervals. CRM-chalcone-based vaccines were evaluated compared to conventional CRM vaccines. Samples were collected 2 weeks after the third vaccination and assayed for aSyn selectivity (inhibition ELISA). IC50 values ​​of antibodies inhibited with increasing doses of aSyn filaments are shown.

[0306] Fig.30 The avidity of antibodies induced by the peptide+CRM197+Aglabracan vaccine is shown.

[0307] Shown are the stability of aSyn-antibody complexes induced by peptide+CRM197+pastosan or peptide+CRM197 vaccines after challenge with different concentrations of the chaotropic agent sodium thiocyanate (NaSCN) and the determined avidity index.

[0308] Fig.31 A comparison of the immunogenicity of different CLEC-based vaccines is shown.

[0309] Female BALB / c mice aged 8-12 weeks received a total of 3 intradermal vaccinations at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. Samples were collected 2 weeks after the third vaccination and analyzed for responses against SeqID6 peptide (A) and aSyn filaments (B) induced by vaccines based on peptide+carrier+dextran or non-CLEC-modified, alum-adjuvanted vaccines; dose: 20 μg peptide equivalent / injection; pustulan refers to SeqID6+CRM+pustulan, lichenan refers to SeqID6+CRM+lichenan, laminarin refers to SeqID6+CRM+laminarin, sc+Alum refers to non-CLEC-modified, alum-adjuvanted vaccine SeqID6+CRM.

[0310] Fig.32 The binding activity of peptide-CLEC-conjugates to the murine (A) and human (B) DC receptor (ie dectin-1) in vitro is shown.

[0311] Comparative analysis of dectin-1 binding capacity determined by ELISA is shown. Lich conjugate refers to SeqID5+SeqID7+lichenin conjugate, Pus conjugate refers to SeqID5+SeqID7+pastosan conjugate, Lam conjugate refers to SeqID5+SeqID7+laminarin conjugate, and negative control refers to samples without inhibitors.

[0312] Fig.33 Comparison of the immunogenicity of different CLEC-based vaccines is shown. Female BALB / c mice aged 8-12 weeks received a total of 3 intradermal vaccinations at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. Samples were collected 2 weeks after the third vaccination and analyzed for anti-peptide responses (SeqID6, shown as peptide) and anti-aSyn responses (shown as protein) induced by peptide-glucan-based vaccines (i.e., SeqID5+SeqID7+CLEC, doses: 5 μg (A) and 20 μg / injection (B); lichenan refers to SeqID5+SeqID7+lichenan; laminarin refers to SeqID5+SeqID7+laminarin, and pustulan refers to SeqID5+SeqID7+pustulan).

[0313] Fig.34 It was shown that antibodies induced by SeqID5+SeqID7+Agar vaccine inhibited aSyn aggregation in the in vivo PFF model.

[0314] C57BL / 6 mice were injected with recombinant aSyn PFFs into the right substantia nigra under stereotaxic conditions and then immunized four times with SeqID5+SeqID7+Agar vaccine (vaccine) or unconjugated CLEC (vector) as control starting on the day of PFF inoculation. Plasma was collected after the third immunization. Brain, plasma and cerebrospinal fluid (CSF) were collected 126 days after PFF inoculation. (A) Titers of specific antibodies against the peptides used for vaccination in plasma collected two weeks after the third immunization (day 126). (B) Comparison of titers of specific antibodies against the B cell peptides of the vaccine in CSF and plasma at day 126. (C) Analysis of phosphorylated S129 aSyn positive aggregates in all brain regions of SeqID5-SeqID7-Agar vaccine-vaccinated and CLEC-treated mice. (D) Correlation between antibody response and synucleinopathy level in vaccine recipients (r = -0.9391; CI (95%) -0.9961 to -0.3318, p = 0.0179, R2 = 0.882). (EH) Representative pSer129aSyn staining of injected hemispheres at the level of (E, F) substantia nigra and (G, H) striatum. (E, G) Vehicle-treated mice and (F, H) vaccine-treated mice after injection of PFFs. Error bars represent mean ± SEM of n = 5-9 animals per group. Statistical differences were assessed by unpaired t-test; **p < 0.01; *p < 0.05.

[0315] Fig.35 Analysis of carrier-specific immunogenicity of peptide+CLEC and peptide+CRM+CLEC conjugates

[0316] Female BALB / c mice aged 8-12 weeks received intradermal / subcutaneous vaccinations for a total of 3 times at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. The immune response elicited by SeqID6+CRM197+Alumin was evaluated compared to the respective peptide+CRM197 conjugates adjuvanted with Alum. Samples were collected 2 weeks after the third vaccination to analyze the induced in vivo anti-CRM response.

[0317] Fig.36 Analysis showing CLEC-specific immunogenicity of peptide+CRM+CLEC conjugates

[0318] Female BALB / c mice aged 8-12 weeks received a total of 3 intradermal vaccinations at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. The immune responses elicited by the different CLEC-based vaccines were evaluated. Samples were collected 2 weeks after the third vaccination and analyzed for in vivo responses against chalcone; A) Samples: SeqID6+CRM197+chalcone, SeqID6+CRM197+lichenan; SeqID6+CRM197+laminarin; B) Sample SeqID6+CRM197+chalcone; chalcone conjugated at the indicated conjugate / chalcone ratios (w / w); pre-serum: sample before vaccination; positive control: sample from an animal immunized with non-oxidized chalcone only.

[0319] Fig.37 : Analysis of immunogenicity of peptide+carrier+dextran conjugates and vaccines consisting of peptide+carrier conjugates and unconjugated dextran.

[0320] Female BALB / c mice aged 8-12 weeks received a total of 3 intradermal vaccinations at 2-week intervals. Blood samples were collected at baseline and after each vaccination to obtain information on the kinetics of the ensuing immune response. Samples were collected 2 weeks after the third vaccination and analyzed for responses against SeqID6 peptide (A) and against ASyn monomer (B). Vaccines used: SeqID6-CRM197-Pus: SeqID6+CRM197+Pus, SeqID6-CRM197+Pus (no conjugation): SeqID6+CRM197 without adjuvant mixed with non-oxidized Pus and SeqID6-CRM197: SeqID6+CRM197 without CLEC modification and without adjuvant. Example:

[0321] Materials and Methods

[0322] 1) Oxidation of CLEC / dextran backbone

[0323] In order to form vaccine conjugates, polysaccharides, and in particular CLEC / β-glucans, need to be chemically modified to produce reactive groups that can be used for attachment to proteins / peptides. Two commonly used methods for polysaccharide activation are periodate oxidation of vicinal hydroxyls and cyanation of hydroxyls. Other methods for polysaccharide activation are possible and are well known in the art. The examples shown in this Examples section rely on mild periodate oxidation.

[0324] Depending on their solubility, CLEC and β-glucans (eg, mannan, lichenan, pyrifos or β-glucan from barley) can be oxidized using the periodate oxidation method in aqueous solution or DMSO.

[0325] The degree of oxidation was predetermined by adding periodate solution in a molar ratio (periodate:sugar subunit; 100% = 1 Mol periodate per Mol sugar monomer) ranging from 1:5 (ie 20% oxidation degree) to 2,6:1 (260% oxidation degree).

[0326] Briefly, sodium periodate was added at a molar ratio of 1:5 to 2,6:1 (periodate:sugar subunit, corresponding to oxidation degrees of 20% and 260%) to open the furanose ring between the vicinal diols of β-glucan, leaving two aldehyde groups as substrates for subsequent coupling reactions. 10% (v / v) 2-propanol was added as a free radical scavenger. The reactants were incubated on an orbital shaker (1000 rpm) at room temperature in the dark for 4 h. Subsequently, the reaction was performed using a Slide-A-Lyzer TM (Thermo Scientific) or Pur-A-Lyzer TM The oxidized dextran was dialyzed 3 times against water to remove sodium (perio)iodate and low molecular weight dextran impurities using a Sigma Aldrich (Sigma Aldrich) dark box (cutoff 20 kDa). The dialyzed dextran can be directly used for peptide coupling reactions or stored at -20°C or lyophilized and stored at 4°C for further use.

[0327] 2) Conjugated WISIT vaccine

[0328] 2a. Formation via hydrazone

[0329] The polypeptide contains a hydrazide group at the N-terminus or C-terminus for aldehyde coupling. If the coupling direction is through the N-terminus of the selected peptide to the aldehyde group of the dextran moiety, the peptide is designed to contain a suitable linker / spacer arm, such as succinic acid. Alternatively, the dextran coupling is performed with the intact protein (e.g., CRM197).

[0330] Typical examples of such peptides: N-terminal coupling of peptide: H2N-NH-CO-CH2-CH2-CO-peptide-COOH; C-terminal coupling: NH 2- Polypeptide-NH-NH2.

[0331] For coupling, a solution of active dextran (i.e. oxidized pyruvic acid) is stirred with dissolved hydrazide-modified peptides or intact proteins (e.g. CRM197) in coupling buffer (sodium acetate buffer at pH 5.4 or DMEDA at neutral pH (6.8) depending on the isoelectric point of the peptide). The free hydrazide groups in these peptides react with aldehyde groups to form hydrazone bonds leading to the final conjugate. For proteins, coupling with active dextran is based on the reaction of the amino groups of lysine residues with the active aldehydes on the dextran in the presence of sodium cyanoborohydride.

[0332] Subsequently, the conjugate is reduced by adding sodium borohydride in borate buffer (pH 8.5). This step reduces the hydrazine bond to a stable primary amine and converts the unreacted aldehyde group in the sugar backbone to a primary alcohol. The carbohydrate concentration in the conjugate is estimated by the anthrone method, and the peptide concentration is estimated by UV spectroscopy or determined by amino acid analysis.

[0333] 2b. Coupling using heterobifunctional linkers

[0334] The second coupling technique used relies on heterobifunctional linkers (e.g., BMPH (N-β-maleimidopropionic acid hydrazide, MPBH (4-[4-N-maleimidophenyl]butyric acid hydrazide), EMCH (N-[ε-maleimidocaproic acid) hydrazide), or KMUH (N-[κ-maleimidoundecanoic acid] hydrazide), maleimide-and-hydrazide cross-linkers are used to couple sulfhydryls (cysteine) to carbonyls (aldehydes)).

[0335] The peptide contains a cysteine ​​(Cys) at the N-terminus or C-terminus for maleimide coupling. Typical examples of such peptides: N-terminal coupling of peptide: Cys-peptide-COOH; C-terminal coupling: NH2-peptide-Cys-COOH.

[0336] For coupling, the active dextran solution (i.e., oxidized pyralidin) was reacted with BMPH overnight (the ratio used was BMPH:pyralidin 1:1 (w / w) to 2:1), and then dialyzed three times with PBS. The BMPH-activated dextran was then mixed with the dissolved Cys-modified peptide in a coupling buffer (e.g., phosphate-buffered saline, PBS). The maleimido group reacts with the sulfhydryl group in the peptide to form a stable thioether bond, and together with the hydrazone formed between the linker and the active aldehyde, leads to a stable conjugate. The carbohydrate concentration in the conjugate was estimated by the anthrone method, and the peptide concentration was determined by amino acid analysis or the Ellmann assay using Ellman's reagent (5,5'-dithio-bis-(2-nitrobenzoic acid), DTNB). DTNB reacts with thiol groups to form colored products, which provides a reliable method for measuring reduced cysteine ​​and other free thiol groups in solution by spectrophotometry (λmax = 412 nm; ε = 14,150 / M·cm).

[0337] 2c) Peptide KLH / CRM coupling

[0338] Peptides (containing N-terminal or C-terminal Cys residues, see above) were coupled to the carriers CRM-197 (e.g.: EcoCRM, Fina Biosolutions) or KLH (Sigma Aldrich) using the heterobifunctional crosslinkers GMBS or SMCC (ThermoFisher). Briefly, CRM-197 / KLH was mixed with excess GMBS or SMCC (according to the manufacturer's protocol) at room temperature to allow activation, and then excess GMBS was removed by centrifugation through a desalting column. Excess peptide was then added to the activated carrier for coupling (buffer: 200 mM sodium phosphate (pH = 6,8)), followed by dialysis 3 times against PBS. The coupling efficiency / peptide content was assessed using the Ellmann assay for quantification of free thiol groups in the solution (Ellmann reagent: 5,5'-dithio-bis-(2-nitrobenzoic acid). The peptide CRM-197 / KLH conjugate was further reacted with Alum ( When the CRM-197 / KLH vaccine was compared with other vaccines of the present invention, each mouse was injected with the same amount of the coupled polypeptide.

[0339] 2d) Formation of sugar-neocomplexes using peptides, KLH / CRM197 and dextran

[0340] Peptide-KLH and peptide-CRM197 conjugates prepared as described in 2c) were also coupled to activated dextran at different ratios of peptide-KLH and peptide-CRM197 to dextran (i.e., 1 / 1 (w / w), 1 / 2 (w / w), 1 / 5 (w / w), 1 / 10 (w / w), and 1 / 20 (w / w), respectively). After formation of the peptide conjugates, the Pep-KLH or Pep-CRM conjugates were reduced with dithiothreitol (DTT). The reduced carrier conjugates were coupled to activated dextran in the presence of an excess of the heterobifunctional linker BMPH. The coupling was achieved via the formation of a stable thioether bond between the maleimido group of BMPH and the sulfhydryl residue of the reduced KLH or CRM197 conjugate, and the coupling of the aldehyde group in the sugar to the hydrazide group of BMPH. After 2 hours at room temperature, the generated hydrazone was reduced to a stable primary amine by incubation with sodium cyanoborohydride overnight. Subsequently, glucose-neoconjugate was lysed using Slide-A-Lyzer TM (ThermoScientific) or Pur-A-Lyzer TM (Sigma Aldrich) cassettes were dialyzed three times against PBS or water to remove low molecular weight impurities (see also: Example 23).

[0341] 3) Determination of in vitro bioactivity of CLEC-conjugates

[0342] The in vitro bioactivity of mannan and glucan conjugates was analyzed by ELISA with soluble murine Fc-dectin-1a receptor (InvivoGen) or ConA as described by Korotchenko et al. 2020. Briefly, ELISA plates were coated with reference glucans (CLR agonists, CLECs), such as chalcone, lichenan, or mannan, and reacted with fluorescently labeled ConA (for mannan) or soluble murine Fc-dectin-1a receptor (for chalcone and other β-D-glucans), which could be detected by HRP-labeled secondary antibodies. Oxidized carbohydrates as well as glycoconjugates were tested in a competitive ELISA (increasing concentrations of CLEC or conjugates were added to the soluble receptor used in the assay to reduce receptor binding to the coated CLEC) to demonstrate their functionality. IC 50 The value determines the biological activity (ie, the potency of binding to the soluble receptor compared to the non-oxidized, unconjugated ligand).

[0343] 4) Activation analysis using bone marrow-derived dendritic cells

[0344] Bone marrow-derived dendritic cells (BMDCs) were harvested from mouse femurs and tibias and incubated with 20 ng / mL murine GM-CSF (Immunotools) as described by Korotchenko et al. 2020 with slight modifications. + MHCII + CD11b int GM-CSF-derived dendritic cells (GM-DC) were subjected to FACS analysis to evaluate the effect of various conjugates as well as a positive control (=LPS) on CD80 and MHCII expression.

[0345] 5) Determine the hydrodynamic radius

[0346] The hydrodynamic radius of the conjugate is analyzed by dynamic light scattering (DLS). In brief, the sample (i.e., the conjugate) is centrifuged at 10,000g for 15 minutes (Merck Millipore, Ultrafree-MC-VV Durapore PVDF). All sample wells are sealed with silicone oil to prevent evaporation, and data for about 24 hours are continuously collected. All measurements are carried out at 25°C in 1536-well plates (1536W SensoPlate, Greiner Bio-One) using WYATT DynaProPlateReader-II. Sample measurements are performed in triplicate. All measurements are filtered by a baseline value of 1.00 ± 0.005 so that only curves with values ​​returned between 0.995 and 1.005 are considered for further analysis (e.g., cumulants radius and regularization analysis). The sample analysis was performed according to https: / / www.wyatt.com / library / application-notes / by-technique / dls.html and the DYNAMICS User Guide (M1406 Rev. C, Version 7.6.0), Technical Notes TN2004 and TN2005 (both available at: www.wyatt.com).

[0347] 6) Animal experiments

[0348] Female BALB / c mice, n=5 per group, were immunized with different CLEC conjugates (id, im, sc), peptide-CRM-197 / KLH conjugates (id) or peptide-CRM-197 / KLH conjugates adsorbed to Alum (sc) and respective controls (e.g., unconjugated CLEC, mixture of CLEC and peptide, etc.) Animals were vaccinated 3 times every two weeks, and blood was collected regularly one day before each vaccination and two weeks after the last vaccination unless otherwise stated.

[0349] 7) Quantification of vaccine-induced antibodies in mouse plasma by ELISA

[0350] Whole blood was collected from mice using heparin as an anticoagulant and centrifuged to obtain plasma. Plasma samples were stored at -80°C. To detect anti-target specific antibodies, peptide-BSA conjugates or recombinant proteins / fragments (usually at a concentration of 1 μg / ml) were coated on ELISA plates (Nunc Maxisorb) with 50 mM sodium carbonate buffer at 4°C overnight. All anti-peptide ELISAs used in the examples were performed with Pep-BSA conjugates (e.g., SeqID3 (sequence: DQPVLPD) has a C-terminal C for coupling with maleimide-activated BSA; named: Pep1c (DQPVLPD-C, SeqID 3), which was used as bait for the detection of Pep1b (SeqID2; DQPVLPD-(NH-NH 2) )- and Pep1c-conjugate vaccines induce anti-Pep1-specific responses. The plates were blocked with 1% bovine serum albumin (BSA) and the plasma samples were serially diluted in the plates. The target-specific antibodies were detected with biotinylated anti-mouse IgG (Southern Biotech) and then developed with streptavidin-POD (Roche) and TMB. EC 50 The values ​​were calculated by nonlinear regression analysis (four-parameter logistic fit function) using GraphPad Prism software (Graph Pad Prism www.graphpad.com / scientific-software / prism / ).

[0351]

[0352] 8) Characterization of the binding preference of aSyn-specific antibodies by inhibition ELISA

[0353] ELISA plates (Nunc Maxisorb) were coated with aSyn monomer (Abcam) or aSyn filaments (Abcam) and blocked with 1% bovine serum albumin (BSA). Control antibodies and plasma samples were incubated with serial dilutions of aSyn monomer or aSyn filaments in low binding ELISA plates. Next, the pre-incubated antibody / plasma samples were added to the monomer / filament coated plates and binding was detected with biotinylated anti-mouse IgG (Southern Biotech), followed by color development with streptavidin-POD (Roche) and TMB. The logIC50 value was calculated as the concentration of monomer or filamentous aSyn required to quench half of the ELISA signal and used as an estimate of the selectivity of the Abs for the antigen being studied. logIC 50The values ​​were calculated using GraphPad Prism software (GraphPad Prism www.graphpad.com / scientific-software / prism / ) according to nonlinear regression analysis (four-parameter logistic fit function).

[0354] 9) Quantification of aSyn aggregation

[0355] Automated protein aggregation assays were performed in black flat-bottom 96-well plates (0.1 ml reaction volume) in a GENIOS microplate reader (Tecan, Austria) with continuous orbital shaking. Kinetics were monitored by reading the peak fluorescence intensity every 20 min using filters for 450 nm excitation and 505 nm emission. The absence and presence of antibodies (antibody / protein molar ratios from 6 × 10 -5 to 3×10 -3 unequal) when the fibril is formed.

[0356] Furthermore, fibril formation in the absence and presence of antibodies was also initiated by the presence of preformed fibrils. Briefly, aSyn preformed fibrils (1 μM) were aggregated for 0-24 hours in the presence of activated aSyn monomers (10 μM) and 10 μM ThT in 100 μl PBS.

[0357] For data analysis, the mean value of negative control samples (i.e., ThT background fluorescence) was calculated in, for example, Microsoft Excel, and each sample at a given time point was divided by the mean value. In order to compare different conditions / inhibitors in the aggregation assay, the fluorescence reading determined at the beginning of the assay was set to 1 (t0=1), and each sample was standardized against it.

[0358] To evaluate the kinetic curves, the Michaelis-Menten kinetic model was applied: Km (substrate concentration yielding half-maximal rate) and Vmax (maximum rate) values ​​under each condition were calculated by enzyme kinetic analysis (Michaelis-Menten) using GraphPad Prism software.

[0359] To compare different conditions / inhibitors in the aggregation assay, the slope values ​​of the exponential growth phase of ThT kinetics were calculated by linear regression using GraphPad Prism software.

[0360] 10) Determination of affinity and avidity

[0361] To determine Ab (antibody) affinity, a modification of the standard ELISA test was used in which replicate wells containing antibody bound to the antigen were exposed to increasing concentrations of chaotropic thiocyanate ions. Avidity was measured by resistance to thiocyanate elution, and different sera were compared using an index representing 50% effective antibody binding (avidity index). Briefly, plasma was diluted 1 / 500 in PBS and spread on coated and blocked ELISA plates (Nunc Maxisorb). After incubation for 1 hour, sodium thiocyanate (NaSCN, SIGMA; in PBS) was added to the samples at concentrations ranging from 0.25 to 3 M. The plates were incubated at room temperature for 15 minutes, then washed, probed, and developed with streptavidin-POD (Roche) and TMB. Subsequent absorbance readings in the presence of increasing concentrations of NaSCN were converted to the appropriate percentage of total bound antibody, assuming that the absorbance reading in the absence of NaSCN represented effective total binding of the specific antibody (100% binding). The data were fitted to a graph of (% binding) versus NaSCN (log) concentration and an affinity index representing the concentration of NaSCN required to reduce the initial optical density by 50% was estimated by linear regression analysis. Data were rejected if the correlation coefficient of the line fit was less than 0.88.

[0362] To determine the k D The value (binding affinity) was determined using a displacement ELISA, which allows for the simple determination of the k value of the complex formed by the antibody and its competing ligand. D Briefly, equal concentrations of antibodies were incubated with increasing concentrations of free aSyn filaments on plates immobilized with aSyn filaments, and free antibody titers were measured. Relative binding of antibodies was expressed as a percentage of the maximum binding observed for each sample in the assay; in displacement curves, competition with aSyn filaments (5 μg / ml) was defined as representing 0% binding (nonspecific binding), while the reaction without competition represented 100% (maximum) binding.

[0363] Competition binding curves were analyzed according to the one-site model using GraphPad computer-assisted curve fitting software.

[0364] 11) Inducing synuclein disease in mice

[0365] To induce synucleinopathy, preformed polymorphic fibrils (PFFs; i.e., preformed sonicated τ-polymorphic aSyn fibrils 1B) were stereotaxically injected into the right substantia nigra of nine-week-old male C57BL / 6 mice. The preparation and validation of PFFs are described in Sci. Adv. 2020, 6, eabc4364, doi: 10.1126 / sciadv.abc4364; DOI: 10.1126 / sciadv.abc4364. Briefly, each animal was injected unilaterally with 2 μL of PFFs 1B solution (concentration: 2.5 mg / ml) into the area just above the right substantia nigra (coordinates from bregma: -2.9AP, ±1.3L, and -4.5DV) at a flow rate of 0.4 μL / min [Sci. Adv. 2020, 6, eabc4364, doi:10.1126 / sciadv.abc4364; DOI:10.1126 / sciadv.abc4364], and the needle was left in place for 5 minutes and then slowly withdrawn from the brain.

[0366] Animals received three id immunizations (i.e., weeks 0, 2, and 4) biweekly, starting from the day of vaccination, with either the CLEC-based vaccine (n=5) or unconjugated CLEC (n=10) as a control, followed by a booster immunization at week 10. At the end of the study (day 126), cerebrospinal fluid (CSF) was collected by cisterna magna puncture, and the brain was carefully removed and fixed with paraformaldehyde (PFA; 4%). Coronal serial sections of the whole brain (from the rostral forebrain cortex to the medulla oblongata - i.e., bregma - 6.72 mm) were collected at 50 μm intervals using a cryostat and processed for immunohistochemical analysis.

[0367] 12) Immunohistochemistry (IHC)

[0368] IHC staining of phosphor-S129 aSyn (pS129 aSyn) on coronal serial sections was performed as described in [Sci.Adv.2020,6,eabc4364,doi:10.1126 / sciadv.abc4364;DOI:10.1126 / sciadv.abc4364]. Monoclonal rabbit anti-pS129 aSyn antibody EP1536Y (ab51253, Abcam) was used, followed by incubation with labeled polymer-HRP anti-rabbit (Dako EnVision+TM Kit, K4011). pS129 aSyn staining was visualized with DakoDAB (K3468), and sections were counterstained with Nissl staining. The actual number of pS129 aSyn aggregates in each structure (cerebral cortex, striatum, thalamus, substantia nigra, and brainstem) and the total number of pS129 aSyn aggregates were assessed using whole-slice data acquired with Panoramic Scan II (3DHISTECH, Hungary) and then processed with the specially developed (ad-hoc) QuPath algorithm.

[0369] Example 1: In vitro determination of the biological activity of CLEC-conjugates

[0370] PAMP-like CLECs are recognized by PRRs in APCs. Binding of CLECs to their cognate PRRs (e.g., dectin-1 for β-glucan) is necessary to control adaptive immunity at different levels, for example, by inducing downstream carbohydrate-specific signaling and cell activation, maturation and cell migration to draining lymph nodes or by crosstalk with other PRRs. Therefore, in order to provide the novel vaccine platform technology proposed in this application, it is crucial that the CLECs used retain their PRR binding ability, which demonstrates the biological activity of the selected CLECs and conjugates based on the CLECs.

[0371] Following these lines of thought, and ensuring that 1) the structure of the CLECs was not disrupted during mild periodate oxidation and 2) the polysaccharide remained bioactive after conjugation, binding to dectin-1 was assessed by ELISA. First, several different CLECs were oxidized by mild periodate oxidation to generate reactive sugar backbones for the proposed vaccines. These CLECs included: mannan, pyruvate (20 kDa), lichenan (245 kDa), barley β-glucan (229 kDa), oat β-glucan (295 kDa), and oat β-glucan (391 kDa). Subsequently, vaccine conjugates were generated by hydrazone conjugation using different B cell epitope peptides (SeqID2, SeqID10, SeqID16) and a T helper epitope peptide SeqID7, all containing a C-terminal hydrazide linker for conjugation. In addition, a peptide-pyruvate conjugate generated by coupling SeqID10 via the heterobifunctional linker BMPH was used.

[0372] The bioactivity of non-oxidized and oxidized CLECs and CLEC-based novel conjugates was then also evaluated using a competitive ELISA system based on competitive binding of soluble murine Fc-dectin-1a receptor (InvivoGen) or ConA as described by Korotchenko et al. 2020.

[0373] result:

[0374] The different CLECs tested showed different PRR binding potencies. In a series of ELISA experiments, the dectin-1 ligands pyruvate, lichenan, barley β-glucan, and oat β-glucan were evaluated for their binding potency to dectin-1. Subsequent experiments showed that the medium molecular weight (20 kDa) linear β-(1,6)-linked β-D-glucan pyruvate unexpectedly exhibited significantly higher (approximately 3-fold) binding potency to dectin-1 compared to the larger high molecular weight linear β-(1,3)β-(1,4)-β-D-glucan lichenan (approximately 245 kDa) (see Figure 1 ).

[0375] This difference was even more pronounced when pyralidin was compared to other linear β-(1,3)β-(1,4)-β-D-glucans from oats and barley (barley β-glucan (229 kDa), oat β-glucan: 265 and 391 kd), which showed only limited binding potency compared to pyralidin (e.g., barley β-glucan (229 kDa) had approximately 30-fold lower binding potency).

[0376] Mild periodate oxidation of the indicated CLECs resulted in a reduction in dectin-1 binding. Oxidation of mannan reduced its ability to bind to the lectin ConA to a similar extent as the reduction in oxidized cerebroside-dectin-1 binding after periodate oxidation. Similarly, oxidation of dextran resulted in a reduction in PRR binding in a similar proportion (see Figure 1 A).

[0377] Importantly, conjugate formation also resulted in a reduction in the PRR binding capacity of the peptide-CLEC conjugates compared to unconjugated CLEC, as shown for the mannan-containing conjugates as well as for the different pyruvic, lichenan, or barley and oat-β-glucan conjugates tested (see Figure 1 B).

[0378] The experiments showed that despite the small size of pyrenoids and the absence of β-(1,3) glycosidic bonds (note: β-(1,3)-containing glucans are described as the best ligands for dectin-1), the linear β-(1,6)-linked β-D-glucan pyrenoids exerted the highest binding potency, regardless of oxidation or conjugation. For example, pyrenoid-containing conjugates retained approximately 3-fold higher binding potency than lichenan-based constructs.

[0379] Regarding IC50 value, Figure 1 The binding results show the binding of various constructs to the soluble murine Fc-dectin-1a receptor. The IC50 values ​​obtained were ( Figure 1 ):

[0380] - Oat β-glucan 265: 860μg / ml

[0381] - Oat β-glucan 391: 820μg / ml

[0382] - Barley β-glucan 229: 145 μg / ml

[0383] -Lichenan ( Figure 1 E): 13 μg / ml

[0384] -Lichenan 200% conjugate ( Figure 1 E): 27 μg / ml (i.e., about half of the unconjugated lichenan)

[0385] -Agar: 3.5μg / ml ( Figure 1 B) and 5 μg / ml ( Figure 1 D) (at least 30-fold higher binding than 145 μg / ml of barley β-glucan 229)

[0386] -Pyricularia polysaccharide conjugate ( Figure 1D): 11, 14 and 15 μg / ml (i.e. about half of the uncoupled pyrifos)

[0387] -BMPH-conjugate ( Figure 1 F): 80 μg / ml (peptide coupled to pyrogallol via a heterobifunctional linker).

[0388] Figure 1 A and 1B further demonstrate that peptide conjugation via hydrazone formation or via a heterobifunctional linker is equally applicable to WISIT conjugates, as both types of conjugates retain high dectin-1 binding potency.

[0389] Example 2: Determination of activation of DCs after exposure to pyrifos in vitro

[0390] An important function of the proposed vaccines is their ability to activate DCs (dendritic cells) following PRR binding and uptake. To demonstrate that the CLEC-based conjugates not only bind to PRRs but also exert biological functions in their target cells (ie DCs), DC activation experiments were performed.

[0391] First, mouse bone marrow cells were incubated with mGM-CSF according to published protocols to generate BMDCs. These GM-CSF DCs were then exposed to peptide-glucan conjugates P SeqID2+SeqID7+ pyruvic acid or an equivalent amount of oxidized but unconjugated sugar. In each case, the conjugate / sugar was titrated from 500 μg to 62.5 μg / mL of the corresponding sugar. For comparison, the strong activator LPS was used as a control, starting at a concentration of 2 ng / ml. Importantly, the pyruvic acid preparations used for oxidation and conjugate formation also contained small amounts of LPS. Therefore, an equal dose of LPS was used to normalize the effects. DCs were then evaluated by FACS analysis for their expression of markers representing DC activation and maturation, including CD80 and MHCII.

[0392] result:

[0393] GM-CSF DCs stimulated in vitro with SeqID2-SeqID7-pastolan conjugates showed a significant increase in CD80 and MHCII expression (see Figure 2 ). Levels were significantly higher than those observed with an equivalent amount of LPS contained in the conjugate preparation. In contrast, an equivalent amount of oxidized but unconjugated sugar resulted in a slight decrease in CD80 expression, as expected from the level of LPS in the preparation, and induction of MHCII was far less pronounced than with the pyrenoidin conjugate.

[0394] In summary, upregulation of MHC-II indicates DC activation. In addition, the upregulation of CD80 exceeds the expected amount of LPS, which strongly suggests that the pyrifos polysaccharide conjugate contributes significantly to the maturation and activation of DC (beyond the effect explained by LPS exposure alone). Therefore, Examples 1 and 2 clearly demonstrate the biological activity of the pyrifos polysaccharide vaccine.

[0395] Example 3: Particle size determination by DLS

[0396] Separate experiments analyzing the particle size / hydrodynamic radius of different dextran conjugates were performed.

[0397] For DLS analysis, different peptide-dextran and peptide-carrier-dextran conjugates were analyzed separately and compared with unconjugated pyrenoidin. All analyses were performed in triplicate using a WYATT DynaPro PlateReader-II. The obtained results showed that the particle size distribution of all tested conjugates reached a maximum in the low nm spectrum.

[0398] Conjugates tested:

[0399]

[0400] result:

[0401] The current analysis showed that the average primary particle hydrodynamic radius (HDR) of the peptide-pastolan conjugate SeqID2+SeqID7+pastolan used in this assay was about 5 nm. A minor second peak detectable at about 60 nm indicated the presence of very small amounts of aggregates in the formulation (see Figure 3 A). However, the majority of conjugate preparations appeared to be in monomeric form. The prevalence of monomeric rather than cross-linked or aggregated conjugates is also strongly supported by the fact that monomeric pyruvate (about 20 kDa) was detectable at about 5 nm (as shown in the control sample, see also Figure 3 C), which also supports the prevalence of monomeric pyruvic acid conjugates (the HDR of monomeric pyruvic acid is about 5 nm). As shown by the cumulative radius analysis over 24 hours, the HDR of these conjugates is also very stable and does not re-aggregate, supporting the prevalence of monomeric conjugates.

[0402] To characterize vaccines based on peptide-carrier-dextran conjugates, SeqID6+CRM197 conjugates that had been additionally conjugated to pyralidin were analyzed. Again, DLS analysis showed an average HDR of 11 nm and a second small peak of approximately 75 nm, again indicating the presence of small amounts of aggregates (see Figure 3B). The slight increase to 11 nm likely reflects the increased MW of the resulting conjugate, as the size of CRM197 is approximately 60 kDa. No significant aggregation or cross-linking of the CRM conjugate was detected, and cumulative volume radius analysis across 24 hours also showed that the conjugate was HDR stable and not prone to aggregation. Similarly, DLS analysis of this alternative type of CLEC-based vaccine supports the prevalence of monomeric conjugates.

[0403] The HDR of the control sample (i.e., unoxidized pyrocalyx) is much larger, averaging about 600 nm, with two smaller peaks at 5 nm and 46 nm (see Figure 3 C). The HDR of the pyrogallol monomer is approximately 5 nm, which is in good agreement with the assumed MW 20 kD, larger aggregates can be easily detected, and most of the dextran exists as large high molecular weight particles. Importantly, the cumulative radius analysis across 24 hours also showed that unconjugated pyrogallol tended to aggregate strongly over time compared to pyrogallol conjugates, resulting in the prevalent formation of large particles, which is consistent with various literature reports.

[0404] Figure 3 Example graphs of these two conjugates and an unoxidized pyrogallol control are shown.

[0405] These results of the present example further demonstrate the unique properties of CLEC-based conjugates to date compared to examples well known in the art (e.g., Wang et al. 2019, Jin et al. 2018), showing small (i.e., 5-11 nm), predominantly monomeric sugar-based nanoparticles with HDRs well below 150 nm, a size generally considered to be the preferred size for immunotherapeutically active conjugate vaccines. This is primarily due to the PRR binding and activation properties of larger particles, including whole glucan particles. Larger particles (>150 nm to a maximum of 2-4 μm) are known to interact more effectively with their receptors and can initiate DC signaling, -activation, -maturation, and -migration to draining lymph nodes, whereas small, even soluble PRR-ligands are thought to bind to their receptors but prevent subsequent DC activation (Goodridge et al. 2011). However, these data, together with the data described in Examples 1, 2 and 3 and in other Examples provided below, demonstrate for the first time that novel small soluble peptidyl glucan conjugates based on monomeric β-glucans such as the linear β(1,6)-β-D glucan chrysanthemin (as a backbone) can effectively bind to PRR (dectin-1), activate corresponding APCs (as exemplified by GM-CSF DCs), and exhibit very high bioactivity and immunogenicity in a skin-specific manner, also significantly exceeding the effects of traditional conjugate vaccines.

[0406] Example 4: In vivo comparison of different CLEC-based vaccines

[0407] CLEC-based vaccines that bind to their DC receptors (e.g., dectin-1 or ConA) were tested for their ability to induce strong and specific immune responses after repeated immunization of n=5 BALB / c mice / group. Typical experiments were performed with 5 μg of net peptide content per dose of B cell epitope peptide.

[0408] In the first set of experiments, three different CLECs were compared. In this experiment, aSynuclein (α-synuclein) derived peptide SeqID2 or amyloid β42 (Aβ42) derived peptide SeqID10 and a promiscuous T helper cell epitope SeqID7 were coupled to oxidized pyruvic lan (oxidation 20%), mannan (oxidation 20%) or barley β-glucan (229 kDa, oxidation 20%) via a C-terminal hydrazide linker.

[0409] Vaccines used:

[0410]

[0411] Animals (female BALB / c mice) were vaccinated three times at two-week intervals (route: id) and the subsequent immune response to the injected peptides (i.e. SeqID2 and SeqID10, respectively) was analyzed using mouse plasma collected two weeks after the third vaccination.

[0412] result:

[0413] like Figure 4 As shown in A, all three CLEC vaccines (SeqID2+SeqID7+mannan, SeqID2+SeqID7+pastolan (linear β(1,6)β-glucan), and barley SeqID2+SeqID7+β-glucan (229 kDa)) induced detectable immune responses. Interestingly, immunization with the barley high molecular weight β-glucan-based vaccine induced only very low anti-peptide responses (OD max / 2 titer is about 1 / 100). In contrast, the pyrifos polysaccharide-based conjugate can induce a significantly higher response, with an average titer of about 1 / 11000. The mannan-based conjugate is about 7 times less immunogenic than the pyrifos polysaccharide-based conjugate, and the average titer after immunization in this experiment reached about 1 / 1500.

[0414] Figure 4B shows the results of a second set of experiments comparing the immunogenicity of two different variants of the dextran-based conjugates, using either the aSynuclein-derived peptide SeqID2 or the amyloid β42 (Aβ42)-derived peptide SeqID10 as B-cell epitopes, and the T-cell epitope SeqID7. The first variant also relied on pyrenoidin as the CLEC for conjugation, while the second variant was made with the linear β-(1,3)β-(1,4)-β-D-glucan lichenan (approximately 245 kDa). Figure 4 As shown in Figure B, both variants induced high-titer immune responses against the injected peptide (i.e., SeqID2 / 3 (SeqID3 = SeqID2 adapted for BSA conjugation) and SeqID10 / 11 (SeqID11 = SeqID10 adapted for BSA conjugation)). However, in these experiments, the peptide lichenin conjugates showed significantly lower immunogenicity than the peptide dactyl glucan conjugates (4-8 times higher anti-peptide titers at a dose of 5 μg), which is also consistent with the lower dectin-1 binding ability shown in Example 1. This suggests that in vitro dectin-1 binding efficacy can directly correlate with the in vivo immunogenicity and biological activity of the vaccine. This led to the identification of dactyl glucan or its fragments (i.e., linear β(1,6)-β-D glucan) as the most potent glucan variant proposed in this application. Vaccines carrying different peptides were also functional, demonstrating the platform potential of this vaccine type.

[0415] Example 5: In vivo comparison of peptidoglycan conjugates and unconjugated peptide vaccines

[0416] To evaluate whether the conjugation of CLEC to the peptide immunogen is necessary to elicit the superior immunogenicity of the vaccine of the invention, a set of experiments was initiated to compare the two conjugates (SeqID2+SeqID7+Pseudo-plasmin or SeqID2+SeqID7+mannan) with a vaccine formulation containing a mixture of all components but not conjugated (i.e., SeqID2 and SeqID7 plus unoxidized Pseudo-plasmin or mannan, respectively). Again, n=5 female BALB / c mice received a total of three id immunizations at two-week intervals, and subsequent immune responses to the injected peptide (i.e., SeqID3) were analyzed using mouse plasma collected two weeks after the third immunization.

[0417] Vaccines used:

[0418]

[0419]

[0420] result:

[0421] Figure 5A comparison of anti-peptide (SeqID3) specific immune responses detectable after three immunizations is shown. In this experiment, SeqID2+SeqID7+Pyrrolidone conjugate (20% oxidized) was able to induce a 4-fold higher immune response than that reported for a mixture of unconjugated peptide SeqID2, SeqID7, and unoxidized Pyrrolidone (i.e., 1 / 12000 vs. 1 / 3000). Similarly, SeqID2+SeqID7+Mannan conjugate (20% oxidized) was also more effective in inducing peptide-specific immune responses than a mixture of these components (1 / 7000 vs. 1 / 4000; 1.75-fold increase). These data suggest that conjugation of peptide immunogens to activated CLECs is required to induce a strong and sustainable immune response in vivo.

[0422] Example 6: In vivo comparison of SeqID2+ or SeqID7+ pyruvic acid and SeqID2+ or Seq-7+ pyruvic acid conjugates

[0423] To evaluate whether CLEC-based vaccines require both B-cell epitopes and T-cell epitopes to induce a sustainable anti-B-cell epitope-specific immune response in vivo, a set of experiments was initiated to compare three conjugates, SeqID5+SeqID7+Aglaucoma, SeqID5+Aglaucoma, and SeqID7+Aglaucoma. n=5 female BALB / c mice received a total of three id immunizations at two-week intervals, and subsequent immune responses to the injected peptide (i.e., SeqID6) were analyzed using mouse plasma collected two weeks after the third immunization.

[0424]

[0425] result:

[0426] like Figure 6 As shown, SeqID5+SeqID7+Aglaucoma conjugate (80% oxidized) was able to induce a high specific immune response against the injected peptide moiety (i.e., the α-synuclein derived peptide SeqID6), with an average titer of 1 / 36000 in these experiments. After three immunizations (route: id) with peptide-Aglaucoma conjugates containing either SeqID5 or SeqID7 alone (coupled to Aglaucoma via hydrazone coupling) at two-week intervals, SeqID5-Aglaucoma induced a 12-fold lower immune response (1 / 3000), and SeqID7-Aglaucoma conjugate did not induce a SeqID6-specific immune response (titer <1 / 100, below the detection limit).

[0427] These data indicate that conjugation of peptide immunogens to activated CLECs is required for the induction of strong and sustainable in vivo immune responses. However, it also shows that, in the absence of T-cell epitopes, conjugation of sphaerocarpin to a single short B-cell epitope (e.g., SeqID5 alone) allows the induction of T-cell-independent B-cell responses in vivo, but at a significantly lower potency than reported for CLEC conjugates containing both T- and B-cell epitopes.

[0428] Example 7: In vivo analysis of anti-Aglaucoma / glucan immune responses after peptide-Aglaucoma immunization

[0429] The analysis of anti-CLEC antibodies is important for the novelty and effectiveness of the CLEC vaccine proposed in the present invention on two levels:

[0430] 1) β-glucan is a major component of the cell walls of various fungi, lichens and plants, giving the cell walls the typical strength to resist intracellular osmotic pressure. Therefore, β-glucan is also considered to be a typical microbial pathogen-associated molecular pattern (PAMP) and the main target of high-titer circulating natural antibodies in healthy human subjects. PAMPs are molecular structures shared by many pathogens and are relatively invariant. They are powerful activators of the immune system. (Chiani et al., Vaccine 27 (2009) 513–519, Noss et al., Int Arch Allergy Immunol 2012; 157: 98–108, Dong et al., J Immunol 2014; 192: 1302-1312, Ishibashi et al., FEMS Immunology and Medical Microbiology 44 (2005) 99–109, Harada et al., Biol Pharm Bull. 2003 Aug; 26 (8): 1225-8). IgG against both –β-(1,3)- and –β-(1,6)-glucans can be found in normal human serum, and β-(1,6)-glucan appears to be a more potent antigen than the β-(1-3) variant. In addition, the β-(1→6)-β-glucan moiety has been identified as one of the typical microbial PAMPs, a focus for surveillance of immune malignancies, recognition and attack, and defense against microbial invasion. Psoralen is the preferred glucan backbone of the CLEC conjugates of the present invention, consisting of a linear β-(1-6)-β-glucan moiety, and several research groups have reported that anti-psoralen immune responses can be activated in immune naive cells that have not been immunized with psoralen. β-glucan antibodies can specifically interact with peptide-beta-glucan in vivo and lead to rapid clearance by forming antigen-antibody complexes, thereby preventing the induction of an effective immune response. Alternatively, the induction / boosting of anti-beta-glucan antibody responses after immunization may also enhance immunogenicity, as the potential cross-presentation of CLEC conjugates by anti-beta-glucan-specific IgG antibodies and uptake by APCs may also increase the efficacy of the applied vaccine.

[0431] No formal studies have been published on the presence of anti-scleroglucan antibodies in immunonaive mice. However, Ishibashi et al. and Harada et al. could demonstrate the presence of β-glucan IgG against soluble scleroglucan / β-glucan (i.e., 1,3 / 1,6-β-glucan) in the sera of immunonaive DBA / 2 mice.

[0432] 2) As previously reported (e.g., Torosantucci et al., Bromuro et al., Donadei et al., Liao et al.), CLEC-protein conjugates, such as CRM197-conjugated to laminarin, Curdlan or synthetic β(1,3)β-D-glucan, act as potent immunogens, inducing high titers not only against CRM197 but also against glucan, and also providing protection against fungal infections. Therefore, previous attempts to use such conjugates were aimed at using CLEC as a true disease / fungal infection specific immunogen, rather than using it as a carrier and immunologically inert backbone as proposed in this application.

[0433] Along these lines, in-depth analysis was initiated on plasma samples of BALB / c mice (n=5 / group) that were immunonaive and immunized with peptide-CLEC conjugates to detect the presence of anti-pastosan antibodies before and after repeated immunizations.

[0434] Vaccines used:

[0435]

[0436] result:

[0437] Therefore, samples from animals immunized with peptide-chalcone (SeqID2+SeqID7+chalcone (20%)) and peptide-mannan (SeqID2+SeqID7+mannan (20%)) were analyzed (all vaccines: 4 μg aSyn targeting peptide / dose). As controls, animals vaccinated with vaccines composed of unconjugated peptide and non-oxidized CLEC (i.e., SeqID2+SeqID7+non-oxidizedchalcone, SeqID2+SeqID7+non-oxidized mannan) were also used. Figure 7 As shown in A, the Balb / c animals analyzed showed a pre-existing low-level immune response against chalcone / β(1,6)-β-D-glucan. The two CLEC vaccines tested (SeqID2+SeqID7+chalcone (20%), and SeqID2+SeqID7+mannan (20%)) failed to induce a strong de novo immune response against the glucan backbone in vivo. In contrast, repeated vaccinations with unconjugated, unoxidized chalcone in the control group (receiving a mixture of all three components) resulted in the induction of a strong anti-glucan immune response, increasing antibody levels against chalcone by 18.5-fold (compared to pre-immunization plasma). Conjugates or mixtures containing mannan were unable to induce anti-chalcone titers, indicating the specificity of the anti-glucan response detected. Kinetic analysis of anti-chalcone antibody titers showed that in animals immunized with unconjugated and unoxidized chalcone, antibody titers increased steadily over time, with a strong increase occurring after the third immunization (see Figure 7 B) Competitive ELISA using increasing amounts of natural Psoralen also demonstrated the specificity of the antibody response detectable in the group receiving the mixture of the components ( Figure 7 C).

[0438] In summary, these analyses demonstrated that despite the presence of low levels of autoreactivity (IgG) against pyralidin in immunonaive BALB / c mice, immunization with various CLEC conjugates induced no or only a very low level of vaccination-dependent increase in anti-pyralidin immune reactivity. Thus, the CLEC used as peptide-CLEC conjugates according to the invention are indeed immunologically inert when used with the novel vaccine design of the invention. This is in stark contrast to previously published results and therefore constitutes a surprising and inventive novel feature of the carbohydrate backbones of the invention, such as β-glucan or mannan, and in particular pyralidin backbones.

[0439] Furthermore, pre-existing anti-Aglais serrata responses did not seem to preclude immune responses to the peptide component of the WISIT vaccine, since responses to injected peptides showed high anti-peptide titers in both experiments.

[0440] Example 8: Analysis of the immunogenicity of dextran conjugates with N-terminal or C-terminal peptide immunogens

[0441] To evaluate whether the orientation of the linker used for conjugation interferes with the immunogenicity of the vaccine, four different candidate vaccines were prepared: In this experiment, aSynuclein-derived peptides SeqID1 / 2 and SeqID4 / 5 were conjugated to oxidized pyruvic acid (80%) via an N-terminal or C-terminal hydrazide linker. In addition, each of the four vaccines carried the promiscuous T helper cell epitope SeqID7, which was conjugated to the CLEC backbone via a C-terminal hydrazide linker.

[0442] Vaccines used:

[0443]

[0444] Animals (female BALB / c mice) were vaccinated three times (route: id) at two-week intervals, and subsequent immune responses against the injected peptides (i.e., SeqID3 and SeqID6) and against the target protein (i.e., recombinant aSynuclein) were analyzed using mouse plasma collected two weeks after the third immunization.

[0445] result:

[0446] like Figure 8 As shown, all four CLEC vaccines using N-terminal or C-terminal conjugated B cell epitopes were able to induce B cell responses against the injected peptide portion ( Figure 8 A) and target protein aSynuclein ( Figure 8 B) a strong and highly specific immune response. Interestingly, the direction of coupling has different effects on immunogenicity. For example, the N-terminally coupled SeqID1+SeqID7+CLEC vaccine induced a 7-fold lower response against the injected peptide and a 10-fold lower response against recombinant aSyn compared to the C-terminally coupled SeqID2+SeqID7+CLEC vaccine. In contrast, the C-terminally coupled SeqID5+SeqID7+CLEC vaccine induced approximately a 4-fold lower response against the injected peptide compared to the N-terminally coupled SeqID4+SeqID7+CLEC vaccine, but an equivalent level of response against ASyn. Thus, the coupling direction can be varied based on the specific characteristics of the peptide without affecting the generation of a high titer immune response.

[0447] However, if Figure 8 As shown, by changing the conjugation orientation of the immunogenic peptide, the specificity of the subsequent reaction against the target protein can be significantly improved, which can be used to generate new and unprecedented immune responses:

[0448] For example, vaccination with SeqID1 resulted in a 4.5-fold higher response to the peptide than to the target protein, whereas vaccination with SeqID2 induced a 3.3-fold higher anti-peptide than anti-protein response.

[0449] In contrast, the SeqID4 vaccine induced an anti-peptide response that was 1.7-fold higher than the anti-protein response, while the SeqID5 vaccine reversed this ratio, resulting in an anti-protein-specific response that was 2.5-fold higher than the detectable anti-injected peptide response.

[0450] In summary, these data clearly demonstrate that vaccines using either conjugation orientation are biologically active and suitable for this application. They also demonstrate that a particularly preferred and unprecedentedly active vaccine can be selected using the conjugation orientation depending on the peptide and target being treated.

[0451] Example 9: Analysis of the immunogenicity of CLEC conjugates using different T helper cell epitopes

[0452] In this example, the immunogenicity of a CLEC-based vaccine containing a non-natural pan-DR epitope (PADRE containing an artificial cathepsin cleavage site, SeqID7) was compared with other well-known T helper cell epitopes. To this end, several hybrid epitopes were selected that were either adjusted using a new, artificially included cathepsin (Cathepsin) L cleavage site to facilitate efficient endosomal / lysosomal release after receptor-mediated uptake into APC / DC, or remained unchanged. The selected epitopes included:

[0453]

[0454] To evaluate whether peptide vaccines carrying these T helper cell epitope peptides can generate high-level immune responses after repeated immunizations and can induce immune responses superior to those induced by conventional conjugate vaccines, 10 different candidate vaccines were tested:

[0455] In this experiment, aSyn-derived peptide SeqID2 was used as a peptide-CLEC vaccine (i.e., SeqID2 combined different T helper epitopes conjugated to oxidized pyruvate (80%) via a C-terminal hydrazide linker), or SeqID3 containing a C-terminal cysteine ​​(for conjugation to GMBS-activated KLH) was used to generate a traditional peptide conjugate.

[0456] Vaccines used:

[0457]

[0458] Animals (female BALB / c mice) were vaccinated three times at two-week intervals (all vaccines: 5 μg aSyn targeting peptide / dose; route: CLEC-based vaccines id, KLH-based vaccines sc (adjuvanted with Alhydrogel), and subsequent immune responses to the injected peptide (i.e., SeqID3) as well as the target protein (i.e., recombinant human α-synuclein) were analyzed using mouse plasma collected two weeks after the third immunization.

[0459] result:

[0460] like Fig. 9 As shown, all nine CLEC vaccines and KLH conjugates using different T helper cell epitopes were able to induce resistance to the injected peptide portion (SeqID3, Fig. 9 A) and anti-target protein: recombinant α-synuclein ( Fig. 9 B) a strong and specific immune response.

[0461] All T helper epitopes induced anti-peptide titers similar to or better than the traditional SeqID3+KLH conjugate. For example, vaccine 1 (comprising SeqID2 and SeqID7 conjugated to pyralidin) induced a 60% higher response than the KLH control, while vaccine 8 (comprising SeqID28 (a T helper epitope known to be particularly suitable for Balb / c animals), SeqID2 and pyralidin) induced a 5.5-fold higher response than the control. Even the promiscuous T helper epitope SeqID24 (derived from diphtheria toxin, a weak T helper epitope suitable for Balb / c animals, see WO 2019 / 21355A1) induced a sustainable immune response, but it was weaker than the KLH control.

[0462] Similarly, all T helper epitopes induced anti-protein titers similar to or better than the traditional SeqID3-KLH conjugate. Importantly, for example, vaccine 1 (comprising SeqID2 and SeqID7 conjugated to pyralidin) induced a 2.5-fold higher response than the KLH control, while vaccine 8 (comprising SeqID28 (a T helper epitope known to be particularly suitable for Balb / c animals), SeqID2 and pyralidin) induced a 3-fold higher response than the control, which again supports the fact that the CLEC-based vaccines of the present invention can induce superior anti-target responses.

[0463] This example also demonstrates that the introduction of an additional Cathepsin L cleavage site on a well-described T-helper epitope leads to a more effective induction of immune responses than conventional vaccines and CLEC-based vaccines lacking this artificial sequence.

[0464] For example, SeqID25, a modified variant of the weak T helper epitope SeqID24 containing the cleavage site, induced 7.5 times higher anti-peptide and 3.6 times higher anti-protein responses than the unmodified peptide (vaccine 5 vs. vaccine 4). In addition, this change also resulted in a 40% increase in anti-protein titers over the KLH control. SeqID27, a modified variant of the Cathepsin L cleavage site of SeqID26 (an epitope derived from measles virus fusion protein, see WO 2019 / 21355A1), can also significantly increase titers compared to the SeqID26-CLEC vaccine, with an increase of 1.8 times in anti-peptide and 3.2 times in anti-protein titers (i.e., vaccine 7 vs. vaccine 6). Vaccine 7 also induced an anti-peptide response 2.2 times higher than the KLH control and an anti-protein response 1.6 times higher. The SeqID7-based CLEC vaccine also induced higher anti-protein titers (20% increase) than the unmodified variant (eg: SeqID22), and both peptides resulted in approximately a one-fold increase in titers against the SeqID2 peptide and anti-aSyn, respectively, compared to the KLH control.

[0465] Addition of a cathepsin cleavage site results in the formation of peptide variants with an additional N (e.g., a C-terminus that is released upon cleavage). For example: SeqID22, PADRE, is released as AKFVAAWTLKAAA, whereas SeqID7, a modified PADRE, is released as AKFVAAWTLKAAA-N. This N can also have a negative impact on further processing and MHCII presentation and can therefore reduce the potency of the corresponding peptide. This phenomenon can be seen in the example of the very potent OVA-derived epitopes SeqID28 and SeqID29. The unmodified peptide induced a very high immune response, whereas the modified variant pep17 induced 75% lower anti-peptide titers and 98% lower anti-protein titers than the unmodified variant.

[0466] Example 10: Analysis of the immunogenicity of CLEC conjugates using the carrier protein KLH as a T helper cell epitope

[0467] In this case, the immunogenicity of a CLEC-based conjugate vaccine containing the well-known carrier protein KLH was compared with that of a conventional KLH vaccine. For this purpose, two aSyn-derived epitopes (SeqID3 and SeqID6) were selected and conjugated to GMBS-activated KLH. Subsequently, the Pep-KLH conjugate was coupled to the reactive aldehyde of oxidized pepto-glycan using BPMH cross-linker to form a CLEC-based conjugate vaccine with KLH as the source of T helper cell epitopes to induce a sustainable immune response.

[0468] Vaccines used:

[0469]

[0470]

[0471] Animals (female BALB / c mice) were vaccinated three times at two-week intervals (all vaccines: 20 μg aSyn targeting peptide / dose; route: id for CLEC-based vaccines and non-adjuvanted KLH vaccines, sc for KLH-based vaccines adjuvanted with Alhydrogel), and then the immune responses against the injected peptides (i.e., SeqID3 and SeqID6) and against the target protein (i.e., recombinant human aSynuclein) were analyzed using mouse plasma collected two weeks after the third immunization.

[0472] result:

[0473] like Fig.10 As shown in A, all six vaccines using KLH as a source of T helper epitopes were able to induce strong and specific immune responses against the injected peptide parts (SeqID3 and SeqID6) and the target protein: recombinant aSynuclein.

[0474] CLEC modification of KLH conjugates resulted in very superior immune responses using two peptides, SeqID3 and SeqID6, respectively. SeqID3+KLH+pastelan induced an anti-peptide response 2.3-fold higher than SeqID3+KLH with Alhydrogel adjuvant and 14-fold higher than that obtained with id vaccination of unadjuvanted SeqID3+KLH. Similarly, anti-protein titers were increased by 8.5-fold (compared with SeqID3+KLH with Alhydrogel adjuvant) and 17-fold compared with unadjuvanted material. SeqID6+KLH+pastelan was also 2-fold (injected peptide) to 4.6-fold (α-synuclein) more effective than adjuvanted SeqID6+KLH and 8.7-fold (injected peptide) and 11-fold (α-synuclein) more immunogenic than unadjuvanted SeqID6+KLH vaccine.

[0475] In addition to the general increase in immunogenicity of the CLEC modified vaccines, these results also indicate that the CLEC modification of the present invention results in a significant increase in the relative amount of induced antibodies that bind to the target molecule (i.e., protein), thereby significantly improving the target specificity of the subsequent immune response. Thus, in terms of the relative amount of antibodies detecting α-synuclein in the induced response (i.e., total titer against the injected peptide compared to specific titer against α-synuclein), SeqID3+KLH+Pyrrolidone was 3.7 times higher than adjuvanted SeqID3+KLH, and SeqID6+KLH+Pyrrolidone was 2.2 times higher than the adjuvanted conjugate.

[0476] In a second set of experiments, the ability of the same vaccines used (all vaccines: 5 μg aSyn targeting peptide / dose; route: id for CLEC-based vaccines, sc for KLH-based vaccines adjuvanted with Alhydrogel) to induce anti-vector-specific antibody responses was compared. As expected, the conventional SeqID3+ and SeqID6+KLH-based vaccines induced high titers against KLH (SeqID3+KLH: 1 / 2100, SeqID6+KLH: 1 / 7700), while the CLEC-based SeqID3+KLH+Pyricularia polysaccharide and SeqID6+KLH+Pyricularia polysaccharide vaccines were essentially unable to induce sustainable anti-vector antibodies. The titers obtained were close to the detection limit, 1 / 150 for SeqID3+KLH+Pyricularia polysaccharide and less than 1 / 100 for SeqID6+KLH+Pyricularia polysaccharide, thus establishing a new, undescribed strategy for optimizing peptide-coupled vaccines to increase target-specific titers while reducing unwanted anti-vector responses.

[0477] Example 11: Analysis of the immunogenicity of CLEC conjugates using the carrier protein CRM197 as a T helper cell epitope

[0478] In this example, the immunogenicity of a CLEC-based conjugate vaccine containing the well-known carrier protein CRM197 was compared to a conventional CRM197 vaccine. To this end, the α-synuclein derived epitope SeqID6 has been conjugated to maleimide-activated CRM197. Subsequently, the SeqID6+CRM197 conjugate was conjugated to activated pyralidin using the heterobifunctional linker BPMH to form a CLEC-based conjugate vaccine with CRM197 as the source of T helper cell epitopes to induce a sustainable immune response. Alternatively, SeqID5-(NH-NH2; SeqID5) and CRM197 were conjugated to activated pyralidin separately. This was achieved by reacting the C-terminal hydrazide of SeqID5 with the reactive aldehyde on activated pyralidin via the lysin in CRM197.

[0479] Vaccines used:

[0480]

[0481] Animals (female BALB / c mice) were vaccinated three times at two-week intervals (all vaccines: 20 μg α-synuclein targeting peptide / dose; route: CLEC-based vaccines id, CRM197-based vaccines sc with Alhydrogel as adjuvant), and the immune responses against the injected peptide (i.e., SeqID6) and against the target protein (i.e., recombinant human α-synuclein and α-synuclein filaments) were analyzed using mouse plasma collected two weeks after the third immunization.

[0482] result:

[0483] like Fig.11 As shown in A, all three vaccines using CRM197 as a source of T helper epitopes were able to induce strong and specific immune responses against the injected peptide portion (SeqID6) and the target protein recombinant α-synuclein.

[0484] Again, CLEC modification of the CRM197 conjugate resulted in a very superior immune response. SeqID6+CRM197+Agarin induced a 28-fold higher anti-peptide response than Alhydrogel-adjuvanted SeqID6+CRM197. Likewise, anti-protein titers against recombinant aSyn were increased 15-fold (compared to Alhydrogel-adjuvanted SeqID6+CRM197), and titers against aggregated forms of α-synuclein (α-synuclein filaments) were increased 11-fold.

[0485] The vaccine generated by independently coupling SeqID5 and CRM197 to styraxan also induced 1.7-fold higher titers of injected peptide than the conventional Alhydrogel-adjuvanted SeqID6+CRM197. Reactivity to recombinant α-synuclein was also increased by 6.6-fold and anti-filamentous responses by 4.25-fold.

[0486] Comparison of anti-vector specific antibody responses revealed that the conventional SeqID6+CRM197-based vaccine induced high titers of anti-CRM197 (1 / 6600), while the CLEC-based SeqID6+CRM197+Pyricularia polysaccharide vaccine was basically unable to induce sustainable anti-vector antibodies. The titers obtained were close to the detection limit, which was less than 1 / 100 for SeqID6+CRM197+Pyricularia polysaccharide.

[0487] Therefore, these experiments demonstrate that CLEC modification of conventional peptide-protein conjugates significantly impairs the generation of anti-carrier responses and leads to greatly enhanced target specificity of the subsequent immune response, thus providing an unprecedented new strategy to optimize current conjugate vaccines based on KLH, CRM197, or other carrier proteins.

[0488] Independent conjugation of CRM197 and SeqID6 to pyruvic acid resulted in a sustained response to B cell epitopes present on CRM197, although at levels as low as those detected with conventional non-CLEC modified conjugates (titer approximately 1 / 400). This suggests that the CLEC scaffolds of the present invention are also suitable for providing B cell epitopes from CLEC-conjugated immunogenic proteins for use as vaccines.

[0489] Example 12: Analysis of the selectivity of immune responses elicited by CLEC-based vaccines in vivo

[0490] Aggregation of the presynaptic protein aSyn is thought to be the main pathological culprit in synucleinopathies such as Parkinson's disease, and monomeric, non-aggregated aSyn has important neuronal functions. Therefore, it is believed that reducing / removing aggregated aSyn without affecting the existing pool of non-aggregated molecules is crucial for treating (e.g., through active or passive immunotherapy) synucleinopathies.

[0491] To further characterize the immune responses elicited by CLEC-based vaccines containing aSyn targeting peptides SeqID2 and SeqID3 and SeqID5 and SeqID6 compared to traditional peptide vector vaccines (i.e., SeqID3+KLH and SeqID6+CRM197), a set of experiments was performed to analyze the selectivity of the subsequent immune response against two different forms of the presynaptic protein aSyn: non-aggregated, predominantly monomeric aSyn and aggregated aSyn filaments.

[0492] Vaccines used:

[0493]

[0494] Animals (female BALB / c mice) were vaccinated three times at two-week intervals (all vaccines: 20 μg aSyn targeting peptide / dose; route: CLEC-based vaccines id, KLH and CRM197-based vaccines sc with Alhydrogel adjuvant), and the subsequent immune response against the target protein (i.e., recombinant human α-synuclein and aSyn filaments) was analyzed using mouse plasma collected two weeks after the third immunization. Plasma samples were subjected to aSyn-specific inhibition ELISA and IC50 values ​​were determined.

[0495] result:

[0496] In brief, compared with the traditional peptide conjugate vaccines (i.e. SeqID3+KLH and SeqID6+CRM, see Fig.12 ), all CLEC-based conjugates used in this experiment showed excellent immunogenicity and aSynuclein aggregate-specific target selectivity.

[0497] Conventional peptide-coupled vaccines induced antibody responses with slightly increased selectivity for aSyn aggregates (i.e., filaments) over monomeric / recombinant aSyn. SeqID3+KLH adjuvanted with Alhydrogel induced an immune response to aSyn aggregates with 9-fold selectivity over recombinant aSyn. SeqID6+CRM197 adjuvanted with Alhydrogel induced a less selective immune response with 3.5-fold higher binding selectivity for aggregates over the primary monomeric, recombinant aSyn.

[0498] In contrast, antibodies induced by CLEC-based peptide-coupled vaccines were characterized by several-fold higher binding selectivity than KLH or CRM197-coupled vaccines. Plasma induced by SeqID2+SeqID7+Agar and SeqID5+SeqID7+Agar showed approximately 97-fold higher (i.e., 14-fold higher than SeqID3+KLH, Alhydrogel vaccine) and 50-fold higher aggregate selectivity (i.e., 14-fold higher than SeqID6+CRM, Alhydrogel vaccine). SeqID3+KLH+Agar and SeqID6+CRM197+Agar also achieved 40-fold higher (i.e., 5-fold higher than SeqID3+KLH) and 50-fold higher (i.e., 14-fold higher than SeqID6+CRM) selectivity for aSyn aggregates.

[0499] Thus, these experiments demonstrate that CLEC modification of peptide conjugates as well as peptide-protein conjugates leads to greatly enhanced target specificity of the subsequent immune response, thus providing an unprecedented new strategy for optimizing current conjugate vaccines.

[0500] Example 13: Analysis of the affinity and avidity of immune responses elicited by CLEC-based vaccines

[0501] To further characterize the immune responses elicited by CLEC-based vaccines containing aSyn targeting peptides SeqID2 and SeqID3 and SeqID5 and SeqID6 compared to traditional peptide vector vaccines (i.e., SeqID3+KLH and SeqID6+CRM197), a set of experiments were performed to analyze the affinity and avidity of antibodies against aSyn.

[0502] Vaccines used:

[0503]

[0504]

[0505] Animals (female BALB / c mice) were vaccinated three times at two-week intervals (all vaccines: 20 μg aSyn targeting peptide / dose; route: CLEC-based vaccines id, KLH and CRM197-based vaccines sc with Alhydrogel adjuvant) and the subsequent immune response against the target protein (i.e., recombinant human aSyn as well as aSyn filaments) was analyzed using mouse plasma collected two weeks after each immunization. To determine the affinity of the induced antibodies to recombinant aSyn, a modification of the standard ELISA test was used, in which duplicate wells containing antibodies bound to the antigen were exposed to increasing concentrations of chaotropic thiocyanate ions. The ability to withstand elution with thiocyanate was used as a measure of affinity, and plasma samples (between treatment groups and between time points) were compared using an index representing 50% of effective antibody binding (avidity index).

[0506] In addition, the k of the antibody against aSyn filaments was determined 2 weeks after the last immunization based on aSyn competition ELISA. D Value (affinity of the antibody for aSyn filaments).

[0507] result:

[0508] like Fig.13 As shown, the conventional SeqID3+KLH conjugate (with Alhydrogel adjuvant) showed only limited affinity maturation for aSyn binding when comparing immunized samples obtained two weeks after the second (T2) immunization or two weeks after the third immunization (affinity maturation (AM, comparing IC values ​​of T2 and T3 samples)). 50 In contrast, CLEC-based vaccines (e.g., SeqID2+SeqID7+Pseudomonas aeruginosa) were able to induce a strong maturation of the anti-aSyn response, shown as AI 2,2, with a strong increase in the avidity of the T3 samples for aSynuclein. Samples obtained from animals immunized with SeqID3+KLH+Pseudomonas aeruginosa also showed significantly higher avidity and slightly increased maturation than SeqID3+KLH alone.

[0509] Similarly, the antibodies induced by SeqID5+SeqID7+Agar and SeqID6+CRM197+Agar vaccines also had significantly higher avidity for the aSyn protein than those induced by SeqID6+CRM197-based vaccines (analyzed at T3; i.e., 3-3.8-fold higher chaotropic salt levels were required to reduce binding), and the affinity maturity was increased compared to the values ​​of T2 and T3, respectively. SeqID6+CRM197 did not result in an increase in avidity for aSyn compared to T2 and T3, and both CLEC-based vaccines resulted in a substantial increase in aSyn-specific binding compared to T2 and T3.

[0510] aSyn filamentous K on immune responses elicited by CLEC-based vaccines as well as conventional benchmark vaccines D Quantitative experiments showed that the overall affinity of antibodies induced by CLEC-based vaccines for aSyn was significantly increased (see Fig.14 SeqID2+SeqID7+Aglaucoma and SeqID3+KLH+Aglaucoma conjugates showed 6-9 times higher affinity than the benchmark vaccine SeqID3+KLH adjuvanted with Alhydrogel (i.e., Kd: 110 nM and 160 nM, compared to K DSeqID5+SeqID7+Aglabra and SeqID6+CRM+Aglabra conjugates showed 12-15 times better Kd values ​​than the benchmark control SeqID6+CRM197 with Alhydrogel adjuvant (i.e., Kd: 50 nM and 60 nM, compared to Kd: 1 mM). D 750nM).

[0511] Thus, the experiments demonstrate that CLEC modification of peptide conjugates as well as peptide-protein conjugates leads to greatly enhanced target specificity and affinity of the subsequent immune response, thus providing an unprecedented new strategy for optimizing current conjugate vaccines.

[0512] Example 14: Analysis of the in vitro function of immune responses elicited by CLEC-based vaccines

[0513] To analyze whether aSyn-specific antibodies elicited by the CLEC-based vaccine (containing aSyn targeting peptides SeqID2 / 3 and SeqID5 / 6) were biologically active, a set of experiments was performed to analyze the ability of the antibodies to inhibit aSyn aggregation in vitro.

[0514] Vaccines used:

[0515]

[0516] Animals (female BALB / c mice) were vaccinated three times at two-week intervals (all vaccines: 20 μg aSyn targeting peptide / dose; route: CLEC-based vaccines id, KLH and CRM197-based vaccines adjuvanted with Alhydrogel sc). Mouse plasma samples collected two weeks after each immunization and corresponding control samples (e.g., non-aSyn binding antibodies or pre-immune plasma obtained before immunization) were analyzed for their ability to inhibit aggregation in vitro.

[0517] result:

[0518] like Fig.15 As shown in A, control antibodies or plasma collected from animals before immunization had no significant effect on the aggregation kinetics of aSyn, confirming the specificity of the test. Antibodies induced by the traditional SeqID3+KLH conjugate (with Alhydrogel adjuvant) were able to significantly reduce aSyn aggregation, as shown by a 40% decrease in slope values ​​(aSyn monomer only: 100%; KLH: 60%). Antibodies induced by the SeqID2+SeqID7+Agar vaccine strongly inhibited aSyn aggregation, as shown by an 85% decrease in slope values ​​in this test (aSyn monomer only: 100%; CLEC: 15%), indicating a significantly higher inhibitory capacity than antibodies induced by traditional vaccines.

[0519] The antibodies induced by the vaccines based on SeqID5+SeqID7+Agar and SeqID6+CRM+Agar showed 86-92% inhibition of the formation of aggregates starting from recombinant aSyn (low aggregate content) and 67-82% inhibition of the formation of aggregates starting from preformed fibrils (= true aggregates), compared to 68% and 57% induced by the benchmark vaccine SeqID6+CRM, Alhydrogel (see Fig.15 B).

[0520] Example 15: Analysis of the effect of immunization route on immune response induced by CLEC-based vaccines

[0521] A series of immunizations were performed to compare id administration with other routes including subcutaneous (sc) and intramuscular (im).

[0522] Vaccines used:

[0523]

[0524] Animals (female BALB / c mice) were vaccinated three times at two-week intervals (all vaccines: 1 μg, 5 μg and 20 μg aSyn targeting peptide / dose), and subsequent immune responses against the injected peptide and target protein (i.e., recombinant human α-synuclein and aSyn filaments) were analyzed using mouse plasma collected two weeks after the third immunization.

[0525] result:

[0526] Tables 1 and 2 and Fig.16 It was shown that SeqID2+SeqID7+Agar vaccine administered via im or sc route could induce resistance to injected peptide ( Fig.16 A) and anti-aSyn response ( Fig.16 B) high immune response. At all tested doses, the maximum titer achieved was significantly lower than the maximum titer after id administration. sc administration showed a dose response behavior similar to id, and im showed no significant difference at 5-20 μg, indicating that saturation was achieved at these doses / application amounts. Similar results were obtained for the reactivity of monomeric and aggregated aSyn, respectively. These results indicate that the CLEC framework proposed by the present invention is highly selective for application in the skin rather than in other pathways / tissues.

[0527]

[0528] Table: Antibody responses induced by anti-SeqID2 / 3 after WISIT vaccine administration via different routes

[0529]

[0530] Table: Anti-aSyn induced antibody responses after WISIT vaccine administration via different routes

[0531] Example 16: Analysis of the immunogenicity of CLEC conjugates using carrier proteins as T helper cell epitopes: different conjugate / CLEC ratios

[0532] In this example, the immunogenicity of CLEC-based conjugate vaccines containing the well-known carrier protein CRM197 using different peptide-CRM / CLEC ratios was compared. To this end, the aSyn-derived epitope SeqID6 has been conjugated to maleimide-activated CRM197. Subsequently, the SeqID6+CRM197 conjugate was conjugated to activated pyralidin using the heterobifunctional linker BPMH at different weight ratios (w / w) to form CLEC-based conjugate vaccines with CRM197 as the source of T helper cell epitopes to induce a sustainable immune response.

[0533] Vaccines used:

[0534]

[0535] Animals (female BALB / c mice) were vaccinated three times at two-week intervals (all vaccines: 5 μg aSyn targeting peptide / dose; route: CLEC-based vaccine id), and subsequent immune responses against the injected peptide (i.e., SeqID6) and target protein (i.e., recombinant human aSynuclein and aSyn filaments) were analyzed using mouse plasma collected two weeks after the third immunization.

[0536] result:

[0537] like Fig.17 As shown, all five vaccines using CRM197 as a source of T helper epitopes were able to induce strong and specific immune responses against the injected peptide portion (SeqID6) and the target protein: recombinant aSynuclein.

[0538] The CLEC modification of the CRM197 conjugate produced efficient immune responses at all w / w conjugate / CLEC ratios tested. SeqID6-CRM197-pastosan (w / w 1 / 10) produced the highest anti-aSyn specific immune response compared to the other tested variants. Thus, SeqID6+CRM197 conjugates with medium / high conjugate / CLEC ratios were particularly suitable for inducing the best immune responses (e.g., 1 / 5, 1 / 10, and 1 / 20).

[0539] Thus, our experiments demonstrate that CLEC modification of conventional peptide-protein conjugates results in a subsequent immune response with strong target specificity, providing an unprecedented new strategy to optimize current conjugate vaccines constructed on KLH, CRM197, or other carrier proteins.

[0540] Example 17: Analysis of the immunogenicity of CLEC conjugates and peptide conjugates using the N-terminus of the carrier protein aSyn (aa1-10) as a T helper cell epitope

[0541] In this example, it was evaluated whether the CLEC-based conjugate vaccine of the present invention could induce a superior immune response against aSyn aggregates compared to the corresponding peptide conjugate using existing carrier proteins as the source of T cell epitopes.

[0542] Therefore, a set of experiments was performed to compare two conjugates, both containing epitopes considered suitable as aSyn targeting epitopes. The experiments made it possible to demonstrate the selectivity of the immune response elicited against the injected peptide and aSyn protein, and subsequently against two different forms of the presynaptic protein aSyn: non-aggregated, mainly monomeric aSyn and aggregated aSyn filaments.

[0543] For example, Weihofen et al. (2019, aa1-10 as epitope for Cinpanemab) and WO2016 / 062720 (aa1-8 as epitope in VLP-based immunotherapy) suggested the N-terminal aSyn sequence from aa1-10 as a potentially suitable epitope for aSyn-targeted immunotherapy. To assess whether CLEC modification indeed leads to a better immune response, we therefore compared a CLEC-based vaccine containing aSyn sequence aa1-8 (SeqID12+SeqID7+Alum) with the corresponding conventional peptide-KLH vaccine (SeqID13+KLH adjuvanted with Alum).

[0544] Vaccines used:

[0545]

[0546] Animals (female BALB / c mice) were vaccinated three times at two-week intervals (all vaccines: 5 μg aSyn targeting peptide / dose; route: CLEC-based vaccines id, KLH-based vaccines adjuvanted with Alhydrogel sc), and the subsequent immune responses to the injected peptides and target proteins were determined by ELISA and EC50 values. In addition, to assess the selectivity of the immune response, plasma samples were subjected to aSyn-specific inhibition ELISA, expressed as a percentage of maximal binding.

[0547] result:

[0548] The CLEC-based conjugate vaccine targeting the N-terminus of aSyn used in this experiment (SeqID12+SeqID7+Pus) is different from the traditional peptide-conjugate vaccine (i.e., SeqID13+KLH, see Fig.18 A), showed superior immunogenicity to aSyn protein. The CLEC-based vaccine induced a 1.8-fold increase in anti-aSyn titers compared to the control group, while the ratio of anti-peptide to anti-protein responses increased by 3-fold. This strongly supports the teaching of the present invention that CLEC modification leads to superior immune responses than similar conventional vaccines.

[0549] In addition, conventional peptide-KLH conjugate vaccines induce antibody responses to aSyn monomers rather than aggregates (i.e., filaments, see Fig.18 In contrast to this finding and quite unexpectedly, the CLEC-based conjugates resulted in a completely different selectivity: the selectivity of the antibodies induced by SeqID12+SeqID7+pastolan for aSyn aggregates over recombinant aSyn was significantly increased by about 10-fold, completely changing the characteristics of the induced antibodies (see Fig.18 B).

[0550] Thus, the experiments showed that conventional peptide vaccines using aSyn aa1-8 were poorly suited to generate an effective and selective immune response in vivo, suggesting that this epitope is not suitable for aggregate-selective immunotherapy. Importantly, the results also showed that CLEC modification of the peptide conjugates led to greatly enhanced target specificity of the subsequent immune response and altered selectivity for aggregates, thus providing an unprecedented new conjugate vaccine targeting aSyn.

[0551] Example 18: Analysis of the immunogenicity of CLEC conjugates and peptide conjugates using the carrier protein aSyn aa100-108 as a T helper cell epitope

[0552] Here, a set of experiments was initiated to compare two conjugates, both containing an epitope thought to be suitable as aSyn targeting epitope, by analyzing the immune response against the injected peptide and aSyn protein, and the subsequent selectivity of the immune response for two different forms of the presynaptic protein aSyn: non-aggregated, predominantly monomeric aSyn and aggregated aSyn filaments.

[0553] For example, WO 2011 / 020133 and WO 2016 / 062720 suggest aSyn sequences derived from aa100-108 / 109 (either native sequences or mimotopes, i.e., 100-108) as potentially suitable epitopes for aSyn targeted immunotherapy. To assess whether CLEC modification indeed leads to a better immune response with this epitope region, we therefore compared aSyn aa100-108-containing CLEC-based vaccines (SeqID16+SeqID7+Pyrrolidone) with the corresponding conventional peptide-KLH vaccine (SeqID17+KLH adjuvanted with Alum).

[0554] Vaccines used:

[0555]

[0556] Animals (female BALB / c mice) were vaccinated three times at two-week intervals (all vaccines: 5 μg aSyn targeting peptide / dose; route: CLEC-based vaccines id, KLH-based vaccines adjuvanted with Alhydrogel sc), and the subsequent immune responses to the injected peptides and target proteins were determined by ELISA and EC50 values. In addition, to assess the selectivity of the immune response, plasma samples were subjected to aSyn-specific inhibition ELISA, expressed as a percentage of maximal binding.

[0557] result:

[0558] The CLEC-based conjugate vaccine targeting aSyn used in this experiment (SeqID16+SeqID7+Pus) showed an overall very low anti-aSyn protein response, which was comparable to the conventional peptide-conjugate vaccine (i.e., SeqID17+KLH, see Fig.19 A). The immune response induced by the conventional vaccine was characterized by a 2.1-fold increase in anti-aSyn titers compared to the CLEC-based vaccine, but at the same time a 2-fold decrease in the ratio of anti-peptide / anti-protein titers. The latter finding supports the teaching of the present invention that CLEC modification leads to a superior anti-target protein response, even in the case of lower overall immunogenicity compared to a similar conventional vaccine.

[0559] Furthermore, both vaccines (conventional peptide conjugates and CLEC-based vaccines) were poorly suited to induce aggregate-selective immune responses (see Fig.19 B). Thus, the experiments presented indicate that CLEC-based vaccines and conventional peptide vaccines targeting the aa100-108 region are not well suited to generate an effective and selective immune response in vivo, suggesting that this epitope may not be the best choice for the aggregate-selective immunotherapy of the present invention.

[0560] Example 19: Analysis of the immunogenicity of CLEC conjugates and peptide conjugates using the carrier protein aSyn aa91-100 as a T helper cell epitope

[0561] In this example, a set of experiments was initiated to compare two conjugates, both containing an epitope thought to be suitable as a targeting epitope for aSyn, by analyzing the immune response to the injected peptide and aSyn protein.

[0562] For example, US2014 / 0377271 A1 suggests that epitope aa91-99 acts as a self-epitope in PD patients and should therefore constitute a potentially suitable epitope for aSyn-targeted immunotherapy. To assess whether CLEC modification indeed leads to a superior immune response using this epitope, we therefore compared aSyn aa91-100-containing CLEC-based vaccine (SeqID14+SeqID7+Alum) with the corresponding conventional peptide-KLH vaccine (SeqID15+KLH adjuvanted with Alum).

[0563] Vaccines used:

[0564]

[0565] Animals (female BALB / c mice) were vaccinated three times at two-week intervals (all vaccines: 5 μg aSyn targeting peptide / dose; route: CLEC-based vaccines id, KLH-based vaccines adjuvanted with Alhydrogel sc), and subsequent immune responses to the injected peptides and target protein aSyn were determined by ELISA and EC50 values.

[0566] result:

[0567] Unexpectedly, both vaccines induced relevant anti-peptide titers but were less successful in inducing detectable anti-aSyn protein titers (see Fig. 20 ). Thus, the experiments presented indicate that CLEC-based vaccines and conventional peptide vaccines targeting the aa91-100 region are not well suited to generate an effective and selective immune response in vivo, suggesting that this epitope may not be the best choice for the aggregate-selective immunotherapy of the present invention.

[0568] Example 20: Analysis of the immunogenicity of CLEC conjugates and peptide conjugates using the carrier protein aSyn C-terminal region aa131-140 as a T helper cell epitope

[0569] In this case, a set of experiments was initiated to compare two conjugates, both containing an epitope thought to be suitable as aSyn targeting epitope, by analyzing the immune response against the injected peptide and aSyn protein. In addition, the selectivity of the subsequent immune response against two different forms of the presynaptic protein aSyn was evaluated.

[0570] For example, US2015 / 0232524 and WO2016 / 062720 suggest C-terminal aSyn sequences derived from aa-126-140 and 131-140 as potential suitable epitopes for aSyn-targeted immunotherapy. To evaluate whether CLEC modification indeed results in a better immune response, we compared aSyn aa131-140-containing CLEC-based vaccine (SeqID20+SeqID7+Alum) with the corresponding traditional peptide-KLH vaccine (SeqID21+KLH adjuvanted with Alum).

[0571] Vaccines used:

[0572]

[0573] Animals (female BALB / c mice) were vaccinated three times at two-week intervals (all vaccines: 5 μg aSyn targeting peptide / dose; route: CLEC-based vaccines id, KLH-based vaccines adjuvanted with Alhydrogel sc), and the subsequent immune responses to the injected peptides and target proteins were determined by ELISA and EC50 values. In addition, to assess the selectivity of the immune response, plasma samples were subjected to aSyn-specific inhibition ELISA, expressed as a percentage of maximal binding.

[0574] result:

[0575] The aSyn-targeted CLEC-based conjugate vaccine (SeqID20+SeqID7+Pus) used in this experiment is different from the conventional peptide-conjugate vaccine (i.e., SeqID21+KLH, see Fig.21 A), showed an overall lower anti-aSyn protein response compared to the conventional vaccine. The immune response induced by the conventional vaccine was characterized by a 1.8-fold increase in anti-aSyn titers, but a 45% decrease in the ratio of anti-peptide / anti-protein titers compared to the CLEC-based vaccine. The latter finding supports the teaching of the present invention that CLEC modifications lead to superior anti-target protein responses, even when the overall immunogenicity is lower than that of a similar conventional vaccine.

[0576] Furthermore, conventional peptide conjugates are not well suited for inducing aggregate-selective immune responses (see Fig.21 B). In contrast, antibodies elicited by CLEC-based vaccines showed approximately 10-fold greater selectivity for monomeric aSyn and decreased selectivity for aggregated aSyn (see Fig.21B). Thus, the experiments presented indicate that CLEC-based vaccines and conventional peptide vaccines targeting the aa131-140 region are not well suited to generate an effective and selective immune response to aggregated aSyn in vivo, suggesting that this epitope may not be the best choice for the aggregate-selective immunotherapy of the present invention.

[0577] Example 21: Analysis of the immunogenicity of CLEC conjugates and peptide conjugates using the carrier protein aSyn C-terminal region aa103-135 as a T helper cell epitope

[0578] In this example, we evaluated whether the CLEC-based conjugate vaccine of the present invention induced a superior immune response against aSyn than the corresponding peptide conjugate when using a prior art carrier protein as a source of T cell epitopes.

[0579] Therefore, a set of experiments was initiated to compare several conjugates from epitope regions considered suitable as aSyn targeting epitopes. These experiments allowed to demonstrate the immune response against the injected peptide and aSyn protein, and the selectivity of the subsequent immune response against two different forms of the presynaptic protein aSyn: non-aggregated, mainly monomeric aSyn and aggregated aSyn filaments.

[0580] Several studies have suggested that the C-terminal aSyn sequence derived from aa103-135 is a potentially suitable epitope for aSyn-targeted immunotherapy, either as a source of self-epitopes or as a source of peptides containing the original sequence or its mimics. To assess whether CLEC modification indeed generates a superior immune response using this region in aSyn, we therefore compared several CLEC-based vaccines (using peptides within region 107-126) with the corresponding conventional peptide-CRM vaccines (adjuvanted with Alum).

[0581] Vaccines used:

[0582]

[0583] Animals (female BALB / c mice) were vaccinated three times at two-week intervals (all vaccines: 5 μg aSyn targeting peptide / dose; route: CLEC-based vaccines id, KLH-based vaccines adjuvanted with Alhydrogel sc), and the subsequent immune responses to the injected peptides and target proteins were determined by ELISA and EC50 values. In addition, to assess the selectivity of the immune response, plasma samples were subjected to aSyn-specific inhibition ELISA, expressed as a percentage of maximal binding.

[0584] result:

[0585] vaccine Peptide titer (x1000) aSyn filamentous titer (x1000) SEQ ID 56+SEQ ID 7+Pus 0,1 0,1 SEQ ID 58+CRM+Alum 9,781 0,1 SEQ ID 53+SEQ ID 7+Pus 0,1 0,1 SEQ ID 55+CRM+Alum 17,647 0,8 SEQ ID 51+SEQ ID 7+Pus 19,694 1,687 SEQ ID 52+CRM+Alum 13,115 1,594 SEQ ID 65+SEQ ID 7+Pus 9,04 3,256 SEQ ID 66+CRM+Alum 7,984 1,108 SEQ ID 67+SEQ ID 7+Pus 12,016 7,335 SEQ ID 68+CRM+Alum 18,126 1,864 SEQ ID 69+SEQ ID 7+Pus 28,125 3,523 SEQ ID 70+CRM+Alum 37,88 1,054 SEQ ID 71+SEQ ID 7+Pus 7,783 5,788 SEQ ID 72+CRM+Alum 14,603 2,429

[0586] Table 1: Immune responses elicited by vaccines covering aa107-126

[0587] The CLEC-based vaccine and CRM-based vaccine containing 5- and 6-peptides were not suitable for inducing high anti-aSyn filamentous titers in this experiment. The CLEC-based conjugate vaccine (7-12 peptides) targeting the C-terminus of aSyn used in this experiment (see Tables 1 and Fig. 22 A, 23A and 24A) all showed superior immunogenicity against aSyn filaments than conventional peptide-coupled vaccines (see Table 1, up to 4-fold increase). This strongly supports the teaching of the present invention that CLEC modification leads to an immune response superior to similar conventional vaccines using epitopes derived from 103-135, especially 107-126.

[0588] This teaching is further supported by the analysis of the selectivity of aggregated aSyn. Fig. 22 As shown in Figures B and 23B, CLEC vaccines containing epitopes derived from sequence aa115-126 were unexpectedly effective in eliciting high levels of aggregate-selective immune responses. Fig. 22 As shown in B, the CLEC-based vaccine SeqID51+SeqID7+Pus containing 8-mer aSyn targeting epitopes induced nearly 10-fold higher selectivity for aSyn aggregates, while the corresponding conventional vaccine (SeqID52+CRM+Alum) failed to induce aggregate-selective antibodies. Similarly, the CLEC-based vaccine SeqID67+SeqID7+Pus containing 10-mer aSyn targeting epitopes induced 10-fold higher selectivity for aSyn aggregates than monomers, while the corresponding conventional vaccine (SeqID68+CRM+Alum) elicited antibodies that were approximately 3-fold more selective for monomers than for aggregates (see Fig.23 B).

[0589] For vaccines containing epitopes aa107-114 (SeqID73+SeqID7+Pus and SeqID74+CRM+Alum, see Fig.24 B) The selectivity analysis surprisingly revealed that, although the CLEC-based vaccine induced high anti-aSyn filamentous titers (i.e., excellent immunogenicity), neither the CLEC vaccine nor the traditional vaccine was able to induce aggregate-selective antibodies, indicating that only highly selected peptide sequences within aa103-135 are suitable as immunotherapeutic agents specifically targeting aggregated aSyn.

[0590] It should also be noted that, as shown above (see Figure 18-20 ), epitopes derived from aa91-100, aa100-108, and aa131-140 are not suitable as potential immunotherapeutic regions specifically targeting aggregated aSyn.

[0591] Example 22: Analysis of the in vitro functionality of immune responses elicited by CLEC-based vaccines

[0592] To analyze whether aSyn-specific antibodies elicited by the CLEC-based vaccine (containing an aSyn targeting peptide from the epitope region aa103-135) were biologically active, a set of experiments was performed analyzing the ability of the antibodies to inhibit aSyn aggregation in vitro.

[0593] Vaccines used:

[0594]

[0595] Animals (female BALB / c mice) were vaccinated three times at two-week intervals (all vaccines: 20 μg aSyn targeting peptide / dose; route: CLEC-based vaccines id, CRM197-based vaccines adjuvanted with Alhydrogel sc). Mouse plasma samples collected two weeks after each immunization and corresponding control samples (e.g., aSyn binding antibody LB509, epitope aa115-122 or pre-immune plasma obtained before immunization) were analyzed for in vitro aggregation inhibition capacity.

[0596] result:

[0597] like Fig.25 As shown in D, plasma collected from animals prior to immunization had no significant effect on the aggregation kinetics of aSyn, confirming the specificity of the assay.

[0598] Antibodies induced by the SeqID67+SeqID7+Agar vaccine (containing 10 aSyn-derived peptides) strongly inhibited aSyn aggregation, as shown by a 40% reduction in aggregation over time in this test, while the corresponding CRM-conjugate vaccine showed only minimal effects, indicating a significantly improved inhibitory capacity compared to antibodies induced by conventional vaccines ( Fig.25 A). Similar results were seen in the analysis of antibodies induced by SeqID71+SeqID7+Agar (containing 12-mer aSyn derived peptides), which reduced aggregation more strongly (70-80% inhibition) and had a 2-2.5-fold higher inhibitory capacity than antibodies induced by the traditional CRM vaccine (SeqID72+CRM+Alhydrogel). Fig.25 C shows that antibodies induced by CLEC-based vaccines based on epitope aa107-114 (containing 8-mer aSyn-derived peptides) and traditional vaccines failed to inhibit aSyn aggregation.

[0599] like Fig.25 The aSyn-specific antibody LB509 failed to inhibit aSyn aggregation as shown in D. Instead, a slight increase in aggregation could be detected in this assay.

[0600] Considering the teachings of the present invention (see Examples 14 and Fig.15 (analyzed epitopes derived from aSyn sequences aa115-126 and particularly aa115-121), and Tables 1 and Figure 22-25 (described a vaccine covering epitopes 115-126)), which is a very unexpected effect, since monoclonal LB509 (epitope aa: 115-122) is known to bind to a different form of aSyn (Jakes et al., Neurosci. Lett. 1999 Jul 2;269(1):13-6) and has the same epitope as the biologically effective vaccine of the present invention (see Fig.25 D) Therefore, the biologically superior effects obtained with the CLEC-based vaccine are indeed surprising and suggest that the highly selected peptide sequences contained within aa115-126 are preferentially present within the aa103-135 region as immunotherapeutic agents specifically targeting aggregated aSyn.

[0601] Example 23: Determination of the biological activity of peptide-CRM197-CLEC-conjugates on the mouse dectin-1 receptor in vitro

[0602] In a series of ELISA experiments, the binding effect of conjugates containing the dectin-1 ligands pyruvicin, lichenan and laminarin on mouse dectin-1 was evaluated. The biological activity of the peptide+CRM197+CLEC conjugates was represented by their PRR binding ability. Along these lines, and to ensure that the structure of CLEC (pyruvicin, lichenan, laminarin) remained bioactive after conjugation, the binding to mouse dectin-1 was evaluated. Then, the bioactivity of non-oxidized and oxidized pyruvicin, lichenan and laminarin as well as the CRM conjugate vaccine and the novel conjugate based on peptide+CRM197+CLEC was evaluated using a competitive ELISA system based on competitive binding to the soluble mouse Fc-dectin-1a receptor (InvivoGen) as described by Korotchenko et al. 2020.

[0603] result:

[0604] Subsequent experiments showed that the median molecular weight (20 kDa), linear β-(1,6)-linked β-D-glucan laminarin and the linear β(1-3)-glucan with β(1-6)-links laminarin bind to mouse dectin-1 significantly more potently (approximately 10-fold) than the larger, higher molecular weight, linear β-(1,3)β-(1,4)-β-D-glucan lichenan (approximately 245 kDa) (see Fig.26 ).

[0605] like Fig.26As shown in A, the binding potency of the dectin-1 ligand chalcone, oxidized chalcone, SeqID6+CRM conjugate (CRM conjugate 1), and SeqID6+CRM+chalcone conjugate (CRM-Pus conjugate 1) to mouse dectin-1 was evaluated by ELISA analysis. Subsequent experiments showed that the binding potency of the peptide+CRM197+chalcone conjugate to mouse dectin-1 was similar to that of oxidized chalcone. In contrast, the traditional CRM conjugate 1 did not show specific mouse dectin-1 binding. The five novel CRM-chalcone conjugates (SeqID52 / 66 / 68 / 70 / 72) also showed high binding potency to mouse dectin-1 ( Fig.26 B). Subsequent experiments showed that peptide-CRM197-Pus pyrenoidosa conjugates with different B cell epitopes, from 7 B cell epitopes (SeqID6+CRM+Pus; Fig.26 A) to 12 somatic B cell epitopes (SeqID71+CRM+Pus; Figure 1 B), both showed similar binding potency to rat dectin-1 as oxidized pyruvate. Fig.26 As shown in Figure 2, the high molecular weight (approximately 22-245 kDa) linear β-(1,3)β-(1,4)-β-D-glucan laminarin, whether oxidized or conjugated, exhibited lower binding potency than the linear β-(1,6)-linked β-D-glucan laminarin-based constructs. For example, laminarin containing CRM197-peptide conjugates retained approximately 10-fold higher binding potency than the laminarin-based constructs. High binding potency to mouse dectin-1 was also observed with the linear β(1-3)-glucan laminarin ( Fig.26 D) Subsequent experiments showed that the peptide+CRM197+laminarin conjugate exhibited murine dectin-1 binding potency similar to that of the pyrifos-based construct, independent of oxidation or conjugation.

[0606] The experiments showed that the peptide+CRM197+CLEC conjugate exhibited biological activity on dendritic cells by binding to dectin-1 in the mouse system.

[0607] Example 24: Determination of the biological activity of peptide-CRM197-CLEC-conjugates on human dectin-1 receptor in vitro

[0608] In a series of ELISA experiments, the dectin-1 ligands pyruvicin, lichenan and laminarin have been evaluated for their binding potency to human dectin-1. The bioactivity of the peptide+CRM197+CLEC conjugates is represented by their PRR binding capacity. Along these lines, and to ensure that the structure of CLEC (pyruvicin, lichenan, laminarin) remains bioactive after conjugation, binding to human dectin-1 was evaluated by a competitive ELISA system based on competitive binding to the soluble human Fc-dectin-1a receptor (InvivoGen).

[0609] result:

[0610] like Fig. 27 As shown, the binding potency of SeqID6+CRM conjugates conjugated to lichenan (Lich conjugate), pulexan (Pus conjugate) or laminarin (Lam conjugate) to human dectin-1 was evaluated by ELISA analysis.

[0611] Subsequent experiments showed that the peptide + CRM197 + lichenin vaccine had a significantly higher (about 30-fold) binding potency against human dectin-1 than the lichenin-coupled vaccine (see Fig. 27 In contrast, the peptide+CRM197+laminarin vaccine had weaker binding to human dectin-1.

[0612] Example 25: In vivo comparison of different peptides + CRM197 + Psoralea corylifolia polysaccharide-based vaccines

[0613] The novel CRM197-Agar vaccines with different B cell epitopes, ranging from 8 to 11, that bind to their DC receptors (e.g., dectin-1) were tested for their ability to induce strong and specific immune responses after repeated vaccination in n=5 BALB / c mice / group. Typical experiments were performed with 5 μg of net peptide content of B cell epitope peptides per dose.

[0614] In this experiment, aSyn derived peptides SeqID52+CRM197 and SeqID66 / 68 / 70+CRM conjugates were conjugated to oxidized pyruvic acid. Animals (female BALB / c mice) were vaccinated three times at two-week intervals with β-glucan modified or unmodified peptide-CRM conjugates (route: id), and the subsequent immune responses against the injected peptides (i.e. SeqID52 / 66 / 68 / 70, respectively) and against aggregated aSyn filaments were analyzed using mouse plasma collected two weeks after the third immunization.

[0615] Vaccines used:

[0616]

[0617] result:

[0618] like Fig.28 As shown in A, all four CRM-chalcone-based vaccines (SeqID52 / 66 / 68 / 70 / 72) were able to induce significantly higher responses against the injected peptide portion (e.g., SeqID52 / 66 / 68 / 70) and against aggregated aSyn filaments compared to the unmodified peptide-CRM-based vaccine (adjuvanted with Alhydrogel).

[0619] Compared with the unmodified peptide-CRM based vaccine, the peptide+CRM+Aglabracan based conjugates could induce 2-5 times higher anti-corresponding peptide titers (maximum titer was 1 / 190.000) and 3-13 times higher anti-aSyn filamentous titers (maximum titer was 1 / 29.000).

[0620] Example 26: Analysis of the selectivity of the immune response elicited by a vaccine based on peptide + CRM + pyrifos in vivo

[0621] To further characterize the immune response elicited by the peptide+CRM197+Agroin vaccine containing different B cell epitopes compared to the traditional peptide+CRM197 vaccine, a set of experiments was performed to analyze the selectivity of the elicited immune response to aggregated aSyn filaments.

[0622] Animals (female BALB / c mice) were vaccinated three times at two-week intervals (all vaccines: 5 μg aSyn targeting peptide / dose; routes: 4 peptides + CRM197 + CLEC-based vaccine (SeqID52 / SeqID66 / 68 / 70-CRM197-pus) as id, 4 peptides + CRM197-based vaccine (SeqID52 / SeqID66 / 68 / 70-CRM197 adjuvanted with Alhydrogel) as sc, and subsequent immune responses against target proteins (i.e., recombinant human α-synuclein and aSyn filaments) were analyzed using mouse plasma collected two weeks after the third immunization. Plasma samples were subjected to aSyn-specific inhibition ELISA and IC50 values ​​were determined.

[0623] Vaccines used:

[0624]

[0625] result:

[0626] In brief, all CLEC-based conjugates used in this experiment showed superior aSyn aggregate-specific target selectivity compared to the conventional peptide-CRM197 conjugate vaccine, as determined by much lower anti-aSyn filament IC50 values ​​(see Fig.29 ).

[0627] All four conventional peptide-CRM197 conjugate vaccines tested in this experiment induced antibodies showing very weak selectivity for aSyn filaments, exhibiting very high IC50 values: 400 - 1.700 ng / ml.

[0628] In contrast, all antibodies induced by the peptide+CRM197+Aglabracan-based conjugate vaccine were characterized by much lower IC50 values ​​against aSyn filaments (ranging from 3.5 to 15 ng / ml).

[0629] Our results therefore demonstrate that CLEC modification of CRM197 conjugates greatly enhances the target specificity of the subsequent immune response, regardless of the epitope used, thereby providing an unprecedented new strategy for optimizing existing conjugate vaccines.

[0630] Example 27: Analysis of the affinity of the immune response induced by peptide + CRM197 + pyrifos polysaccharide-based vaccine

[0631] To further characterize the immune response elicited by the peptide-CRM197-chalcone vaccine containing different B cell epitopes compared to the conventional peptide-CRM197 vaccine, a set of experiments was performed analyzing the affinity of the elicited antibodies for aSyn filaments.

[0632] Animals (female BALB / c mice) were vaccinated three times at two-week intervals (all vaccines: 5 μg aSyn targeting peptide / dose; route: id for CLEC-based vaccines (SeqID52 / 66 / 68 / 70+CRM197+Agaricin), sc for CRM197-based vaccines adjuvanted with Alhydrogel (SeqID52 / 66 / 68 / 70-CRM197)) and subsequent immune responses against the target protein (i.e. aSyn filaments) were analyzed using mouse plasma collected two weeks after each immunization. To determine the affinity of the induced antibodies to aSyn filaments, a modification of the standard ELISA test was used, in which duplicate wells containing antibodies bound to the antigen were exposed to increasing concentrations of chaotropic thiocyanate ions. Resistance to thiocyanate elution was used as a measure of affinity, and an index representing 50% effective antibody binding (avidity index) was used to compare plasma samples.

[0633] Vaccines used:

[0634]

[0635] result:

[0636] like Fig.30As shown, all conventional peptide-CRM197 conjugates tested (with Alhydrogel as adjuvant) induced antibodies with limited binding strength to aSyn filaments, with very low avidity indices ranging from 0.25 to 0.85. In contrast, all novel peptide+CRM197+Auricularia polysaccharide-based vaccines induced antibodies with significantly higher binding strength to aSyn filaments, with AI (avidity index) ranging from 0.5 to 2.2.

[0637] Thus, the experiments demonstrated that CLEC modification of peptide-CRM197 conjugates can significantly enhance target-specific immune responses (titers), as well as significantly enhance the target specificity and avidity of induced antibody responses, regardless of the epitope used, providing an unprecedented new strategy to optimize existing protein-conjugated vaccines, including CRM197.

[0638] Example 28: In vivo comparison of different peptide + CRM197 + CLEC-based vaccines

[0639] aSyn derived peptide SeqID6+CRM197 conjugates coupled to pyruvican, lichenan or laminarin were tested for their ability to induce a strong and specific immune response after repeated application in n=5 BALB / c mice / group. A typical experiment was performed using 5 μg of net peptide content of B cell epitope peptide per dose. Animals (female BALB / c mice) were vaccinated 3 times at two week intervals (route: id) and the subsequent immune response against the injected peptide (i.e. SeqID6) and against aggregated aSyn filaments was analyzed using mouse plasma collected two weeks after the third immunization.

[0640] Vaccines used:

[0641]

[0642]

[0643] result:

[0644] The tested vaccines induced significant immune responses against the injected peptides (such as SeqID6) and against aggregated aSyn filaments after repeated immunization of mice. Peptide+CRM+Agarin-based conjugates induced high titers against the corresponding peptides and against aSyn filaments compared to conventional peptide-CRM-based vaccines and peptide-CRM-based vaccines conjugated to laminarin or lichenan (see Fig.31 ).

[0645] Specifically, SeqID6+CRM197+Aglabra induced 1.6-fold higher titers against the injected peptide SeqID6 than SeqID6+CRM197+Lichenan and 12-fold higher titers than SeqID6+CRM197+Laminarin. SeqID6+CRM197+Lichenan induced 7.5-fold higher titers than SeqID6+CRM197+Laminarin.

[0646] Similarly, SeqID+CRM197+Agarin induced titers against aSyn aggregates (filaments) 3.1-fold higher than SeqID6+CRM197+Lichenin, 7.6-fold higher than SeqID6+CRM197+laminarin, and 6-fold higher than SeqID6+CRM197 without CLEC modification adjuvanted with Alum. SeqID6+CRM197+Lichenin induced titers 2.4-fold higher than SeqID6+CRM197+Laminarin, and 2-fold higher than SeqID6+CRM197 without CLEC modification adjuvanted with Alum.

[0647] CLEC modification of peptide-CRM197 conjugates provides an unprecedented new strategy to optimize existing protein-conjugate vaccines, including CRM197.

[0648] Example 29: Determination of the biological activity of peptide-CLEC-conjugates at mouse and human dectin-1 receptors in vitro

[0649] In a series of ELISA experiments, the dectin-1 ligands trachytan, lichenan, and laminarin were evaluated for their binding potency to mouse and human dectin-1. The bioactivity of the peptide-CLEC conjugates is indicated by their PRR binding capacity. Along these lines, and to ensure that the CLEC (trachytan, lichenan, laminarin) constructs were still bioactive after conjugation, binding to mouse and human dectin-1 was assessed using a competitive ELISA system based on competitive binding to soluble mouse and human Fc-dectin-1a receptors (InvivoGen).

[0650] result:

[0651] like Fig.32 As shown, the potency of SeqID5+SeqID7+CLEC conjugates conjugated to lichenan (Lich conjugate), pulexan (Pus conjugate) or laminarin (Lam conjugate) for binding to murine and human dectin-1 was assessed by ELISA analysis.

[0652] Subsequent experiments showed that the peptide-lichenin vaccine had significantly higher binding potency against mouse and human dectin-1 than the lichenin-coupled vaccine (see Fig.32 A+B). In contrast, the peptide-laminarin vaccine had very high binding levels to mouse dectin1 ( Fig.32 A), but only weakly binds to human dectin-1 ( Fig.32 B).

[0653] Example 30: In vivo comparison of different peptide + CLEC-based vaccines

[0654] CLEC-based vaccines that can be combined with murine and / or human dectin-1 were tested for their ability to induce a strong and specific immune response after repeated administration in n=5 BALB / c mice / group. Typical experiments were performed using B cell epitope peptides at 5 μg and 20 μg of net peptide content per dose.

[0655] In this experiment, the α-synuclein derived peptide SeqID5 and the promiscuous T helper cell epitope SeqID7 were coupled to oxidized pyrogallol, lichenan or laminarin via a C-terminal hydrazide linker.

[0656] Vaccines used:

[0657] B cell epitope T cell epitope CLEC

[0658] SEQ ID 5 SEQ ID 7 Pyrrolidone

[0659] SEQ ID 5 SEQ ID 7 Lichenin

[0660] SEQ ID 5 SEQ ID 7 laminarin

[0661] Animals (female BALB / c mice) were vaccinated three times at two-week intervals (doses: 5 μg (A) and 20 μg (B); route: id), and the subsequent immune response against the injected peptide (i.e., SeqID6) was analyzed using mouse plasma collected two weeks after the third immunization.

[0662] result:

[0663] like Fig.33As shown, all three CLEC vaccines (SeqID5+SeqID7+pastosan, SeqID5+SeqID7+lichenan, and SeqID5+SeqID7+laminarin) were able to induce detectable immune responses. Interestingly, immunization with laminarin-based vaccines induced only very low anti-peptide and anti-aSyn responses. In contrast, the pastosan-based conjugates were able to induce significantly higher responses. The lichenan-based conjugates showed lower immunogenicity than the pastosan-based conjugates, but were able to induce higher titers than the laminarin-based conjugates in this experiment.

[0664] This suggests that in vitro dectin-1 binding potency, especially to human dectin-1, can be directly correlated with the in vivo immunogenicity and biological activity of the vaccine. This led to the identification of pyruvic polysaccharide or a fragment thereof (i.e., linear β(1,6)-β-D glucan) as the most potent glucan variant of the present application.

[0665] Example 31: Analysis of the in vivo function of immune responses elicited by CLEC-based vaccines

[0666] To determine whether aSyn-specific antibodies elicited by CLEC-based vaccines could inhibit aSyn fibril formation in vivo, a proof-of-concept experiment was initiated using an established synucleinopathy vaccination model [Sci. Adv. 2020, 6, eabc4364, doi:10.1126 / sciadv.abc4364; DOI:10.1126 / sciadv.abc4364].

[0667] Vaccines used:

[0668]

[0669] In this model, C57BL / 6 mice were stereotaxically injected with α-syn preformed fibrils (PFFs) at the level of the right substantia nigra, subsequently causing a widespread synucleinopathy characterized by phosphorylated synuclein immunopositive Lewy-like neurites and intracytoplasmic aggregates along anatomical connections. Animals were immunized four times at weeks 0, 2, 4, and 10 with SeqID5+SeqID7+Agar vaccine or unconjugated CLEC as control, starting with the first immunization on the day of PFF inoculation. 126 days after PFF injection, animals were sacrificed and brains were analyzed for the presence of phosphorylated S129 aSyn-positive aggregates in selected brain regions including the cerebral cortex, striatum, thalamus, substantia nigra, and brainstem.

[0670] result:

[0671] Subsequent immune responses were analyzed using plasma and CSF (cerebrospinal fluid) obtained at sacrifice. High titers of anti-injected peptide antibodies were detected in the plasma of animals treated with SeqID5+SeqID7+Pyrrolidone vaccine. In contrast, no signal above background was detected in the CLEC-only treatment group ( Fig.34 Analysis of anti-peptide titers in CSF also showed that SeqID5+SeqID7+ pyruvate vaccine induced high levels of antibodies, while no signal above background was detected in vehicle-treated animals ( Fig.34 ). Immunohistochemistry of brain sections revealed numerous phosphorylated-S129 aSyn-positive aggregates in all analyzed areas of the vehicle-treated group, indicating a strong spread of aSyn pathology. In contrast, synucleinopathy was significantly reduced in mice vaccinated with SeqID5+SeqID7+A. Fig.34 ). Notably, there was a strong and significant correlation between the magnitude of the antibody response and the level of synucleinopathy in vaccine recipients ( Fig.34 ).

[0672] Example 32: Analysis of the immunogenicity of peptide+CRM+CLEC conjugates

[0673] In this example, the vector-specific immunogenicity of a CLEC-based conjugate vaccine was compared with that of a conventional vector vaccine.

[0674] To this end, the α-synuclein derived epitope SeqID6 was conjugated to maleimide-activated CRM197. Subsequently, the peptide-CRM197 conjugate was coupled to activated pyruvic acid using the heterobifunctional linker BPMH to form a CLEC-based conjugate vaccine with CRM197 as a source of T helper cell epitopes to induce a sustainable immune response.

[0675] Vaccines used:

[0676]

[0677] Animals (female BALB / c mice) were vaccinated three times at two-week intervals, and the subsequent immune response to the carrier protein CRM197 was analyzed using mouse plasma collected two weeks after the third immunization. Doses of vaccines containing SeqID6: 20 μg and 100 μg α-synuclein targeting peptide / dose; routes: CLEC-based vaccines id, CRM197-based vaccines adjuvanted with Alhydrogel sc ( Fig.35 ).

[0678] result:

[0679] Comparison of anti-vector-specific antibody responses showed that the conventional SeqID6+CRM197-based vaccine induced high titers of anti-CRM197 in a dose-dependent manner. In contrast, the CLEC-based SeqID6+CRM197+Aglabra polysaccharide vaccine induced significantly lower anti-CRM responses after repeated immunization with 20 μg and 100 μg doses (reduction: 4.5-5-fold; Fig.35 ).

[0680] Therefore, the experiments show that covalent CLEC modification of traditional peptide-protein conjugates significantly impairs the generation of anti-carrier responses, thus providing an unprecedented new strategy for optimizing existing conjugate vaccines based on carrier proteins such as KLH and CRM197.

[0681] Example 33: In vivo analysis of anti-Agar / glucan immune responses after immunization

[0682] As already described in Example 7, the analysis of anti-CLEC antibodies induced by CLEC-based immunogens is important for the novelty and effectiveness of the CLEC vaccine proposed in the present invention at two levels.

[0683] Along these lines, anti-paucidan antibodies were analyzed in depth in plasma samples of immunonaive BALB / c mice (n=5 / group) immunized with peptide+CRM+CLEC conjugates before and after repeated immunizations.

[0684] Vaccines used:

[0685]

[0686] result:

[0687] This example analyzes different types of samples:

[0688] Fig.36 A shows anti-Aglaiscan immune reactivity of samples obtained from animals repeatedly vaccinated with SeqID6+CRM+Aglaiscan, SeqID6+CRM+Lichenan or SeqID6+CRM+laminarin (all vaccines: 20 μg aSyn targeting peptide / dose). Fig.36 B shows anti-A. truncatum immunoreactivity of samples obtained from animals repeatedly vaccinated with SeqID6+CRM+A. truncatum using vaccines containing different w / w peptide+CRM conjugate / CLEC ratios: i.e., conjugate / CLEC ratios of 1 / 1, 1 / 2.5, 1 / 5, 1 / 10 and 1 / 20 (all vaccines: 5 μg aSyn targeting peptide / dose).

[0689] For control, samples obtained from pre-immunized animals and from animals treated with non-oxidized CLEC were used.

[0690] like Fig.36 As shown, the Balb / c animals analyzed exhibited a pre-existing low level immune response to glucan / pastelan / β(1,6)-β-D glucan.

[0691] All CLEC vaccines tested failed to significantly increase pre-existing anti-glucan responses or to induce high immune responses against the glucan backbone de novo in vivo. In contrast, repeated vaccination of the control group with unconjugated, non-oxidized pyruvic acid resulted in the induction of a strong anti-glucan immune response, increasing the anti-pyruvic acid antibody levels more than 5-fold (compared to pre-immunization plasma). Non-CLEC modified peptide + CRM conjugates and conjugates containing lichenan and laminarin failed to induce anti-pyruvic acid titers above pre-immunization levels, indicating the specificity of the anti-glucan responses detected.

[0692] In summary, these analyses could demonstrate that despite low levels of pre-existing autoreactivity (IgG) against β-glucan in immunonaive BALB / c mice, no or only very low vaccination-dependent changes were detected with regard to anti-β-glucan immune responses after immunization with various CLEC conjugates. This indicates that the immunogenicity of the glucan was significantly reduced using the novel vaccine design of the present invention. This is in stark contrast to previously published results and therefore constitutes a surprising and inventive novel feature of the carbohydrate backbones, such as β-glucans, and in particular β-glucan backbones, according to the present invention.

[0693] Furthermore, pre-existing anti-pachysan responses did not appear to preclude immune responses to the peptide component of the WISIT vaccine, as responses to the injected peptide in all experiments showed high anti-peptide titers.

[0694] Example 34: In vivo comparison of the effect of dextran conjugation on the immunogenicity of peptide + carrier vaccines

[0695] To evaluate whether conjugation of CLEC to the peptide+carrier immunogen is necessary to induce the superior immunogenicity of the vaccine of the present invention, a set of experiments was initiated comparing three vaccine formulations: a peptide+carrier conjugate covalently modified with β-glucan, a vaccine formulation containing a mixture of peptide+carrier conjugate and β-glucan but not conjugated, and an unmodified, Alum-free peptide+carrier vaccine.

[0696] Again, n=5 female BALB / c mice were immunized three times id at two-week intervals, and subsequent immune responses to the injected peptide and aSyn filaments (ie, SeqID6) were analyzed using mouse plasma collected two weeks after the third immunization.

[0697] Vaccines used:

[0698]

[0699] result:

[0700] Fig.37 Comparison of anti-peptide (SeqID6) and anti-aSyn monomer specific immune responses detectable after three immunizations is shown. In this experiment, SeqID6+CRM197+pastosan conjugate induced an approximately 10-fold higher anti-injected peptide immune response than reported for a mixture of SeqID6+CRM197 and non-oxidized pastosan ( Fig.37 A) and anti-aSyn titers were nearly 4 times higher ( Fig.37 B), aSyn titers were approximately 10-fold higher than reported for SeqID6+CRM197 (no adjuvant). Interestingly, the mixture of SeqID6+CRM197 and non-oxidized psammonium sulphate did not result in a significantly different immune response than conventional SeqID6+CRM197.

[0701] These data indicate that coupling the peptide-carrier immunogen to activated CLEC according to the present invention is necessary to induce a superior immune response in vivo.

[0702] The B cell epitope sequences disclosed in the examples are as follows:

[0703]

[0704]

[0705] Based on this disclosure and these examples of the present invention, the following are preferred embodiments of the present invention:

[0706] 1. A conjugate consisting of at least one β-glucan or mannan and at least one B cell or T cell epitope polypeptide, or comprising at least one β-glucan or mannan and at least one B cell or T cell epitope polypeptide, wherein the β-glucan or mannan is covalently coupled to the B cell and / or T cell epitope polypeptide to form a conjugate of the β-glucan or mannan and the B cell and / or T cell epitope polypeptide, wherein the B cell and / or T cell epitope polypeptide is an α-synuclein polypeptide; or

[0707] A conjugate, which consists of or contains at least one β-glucan or mannan and at least one α-synuclein B cell epitope polypeptide, wherein the β-glucan or mannan is covalently coupled to the B cell epitope polypeptide to form a conjugate of the β-glucan or mannan and the B cell epitope polypeptide.

[0708] 2. The conjugate according to embodiment 1, wherein the β-glucan is predominantly linear β-(1,6)-glucan, wherein the ratio of (1,6)-conjugated monosaccharide moieties to non-β-(1,6)-conjugated monosaccharide moieties is at least 1:1, preferably at least 2:1, more preferably at least 5:1, and in particular at least 10:1.

[0709] 3. The conjugate according to embodiment 1 or 2, wherein the β-glucan is a dectin-1 binding β-glucan, preferably pyralidin, lichenan, laminarin, curdlan gum, β-glucan peptide (BGP), schizophyllan, scleroglucan, whole glucan particles (WGP), zymosan or lentinan, more preferably pyralidin, laminarin, lichenan, lentinan, schizophyllan or scleroglucan, especially pyralidin; and / or the β-glucan is a potent dectin-1 binding β-glucan, preferably

[0710] - β-glucan having an IC50 value for binding to soluble murine Fc-dectin-1a receptor as determined by competitive ELISA of less than 10 mg / ml, more preferably less than 1 mg / ml, even more preferably less than 500 μg / ml, in particular less than 200 μg / ml; and / or

[0711] - the conjugate has an IC50 value of less than 1 mg / ml for binding to soluble murine Fc-dectin-1a receptor as determined by competitive ELISA, more preferably less than 500 μg / ml, even more preferably less than 200 μg / ml, especially less than 100 μg / ml; and / or

[0712] - β-glucan having an IC50 value for binding to soluble human Fc-dectin-1a receptor as determined by competitive ELISA of less than 10 mg / ml, more preferably less than 1 mg / ml, even more preferably less than 500 μg / ml, in particular less than 200 μg / ml; and / or

[0713] - wherein the IC50 value of the conjugate binding to soluble human Fc-dectin-1a receptor as determined by competitive ELISA is lower than 1 mg / ml, more preferably lower than 500 μg / ml, even more preferably lower than 200 μg / ml, in particular lower than 100 μg / ml.

[0714] 4. A conjugate according to any one of embodiments 1 to 3, wherein the polypeptide comprises at least one alpha synuclein B cell epitope and at least one T cell epitope, preferably a B cell epitope + CRM197 conjugate covalently linked to β-glucan, in particular a peptide + CRM197 + linear β-(1,6)-glucan or a peptide + CRM197 + linear pyruvate conjugate.

[0715] 5. A conjugate according to any one of embodiments 1 to 4, wherein the ratio of β-glucan or mannan to B-cell and / or T-cell epitope polypeptides, in particular the ratio of pyruvic acid to peptides in the conjugate is 10:1 (w / w) to 0.1:1 (w / w), preferably 8:1 (w / w) to 2:1 (w / w), in particular 4:1 (w / w), but if the conjugate comprises a carrier protein, the preferred ratio of β-glucan or mannan to B-cell epitope + carrier polypeptide is 50:1 (w / w) to 0.1:1 (w / w), in particular 10:1 to 0.1:1.

[0716] 6. The conjugate according to any one of embodiments 1-5, wherein the B-cell epitope and the pan-specific / heterogamous T-cell epitope are independently conjugated to β-glucan.

[0717] 7. The conjugate according to any one of embodiments 1 to 6, wherein the B-cell epitope polypeptide has a length of 5-20 amino acid residues, preferably 6-19 amino acid residues, in particular 7-15 amino acid residues; and / or wherein the T-cell epitope polypeptide has a length of 8-30 amino acid residues, preferably 13-29 amino acid residues, in particular 13-28 amino acid residues,

[0718] Wherein, the B cell epitope and / or T cell epitope is preferably connected to β-glucan or mannan and / or to a carrier protein via a linker, and the linker is more preferably a cysteine ​​residue or the linker comprises a cysteine ​​or glycine residue, and the linker is obtained by hydrazide-mediated coupling, obtained by coupling via a heterobifunctional linker (e.g., N-β-maleimidopropionic acid hydrazide (BMPH), 4-[4-N-maleimidophenyl]butyric acid hydrazide (MPBH), N-[ε-maleimidohexanoic acid] hydrazide (EMCH) or N -[kappa-maleimidoundecanoic acid]hydrazide (KMUH)), from imidazole-mediated coupling, from reductive amination, from carbodiimide coupling -NH-NH2 linker; NRRA, NRRA-C or NRRA-NH-NH2 linker, peptide linker, such as dimer, trimer, tetramer (or longer) peptide group, such as CG or CG, or cleavage site, such as cathepsin cleavage site; or a combination thereof, in particular cysteine ​​or NRRA-NH-NH2 linker;

[0719] wherein the T cell epitope is preferably a polypeptide comprising the amino acid sequence AKFVAAWTLKAAA, optionally linked to a linker, such as a cysteine ​​residue or a linker comprising a cysteine ​​residue, NRRA, NRRA-C or NRRA-NH-NH2 linker; or a variant of the amino acid sequence AKFVAAWTLKAAA, wherein the variant includes the amino acid sequence AKFVAAWTLKAA, a variant in which the first residue alanine is substituted by an aliphatic amino acid residue (e.g. glycine, valine, isoleucine and leucine), a variant in which the third residue phenylalanine is substituted by L-cyclohexylalanine, a variant in which the thirteenth amino acid residue alanine is substituted by an aliphatic amino acid residue (e.g. glycine, valine, isoleucine and leucine) A variant comprising aminocaproic acid, preferably coupled to the C-terminus of the amino acid sequence AKFVAAWTLKAA, having a variant of the amino acid sequence AX1FVAAX2TLX3AX4A, wherein X1 is selected from the group consisting of W, F, Y, H, D, E, N, Q, I and K; X2 is selected from the group consisting of F, N, Y and W, X3 is selected from the group consisting of H and K, X4 is selected from the group consisting of A, D and E, but the oligopeptide sequence is not AKFVAAWTLKAAA; in particular, wherein the T cell epitope is selected from AKFVAAWTLKAAANRRA-(NH-NH2), AKFVAAWTLKAAAN-C, AKFVAAWTLKAAA-C, AKFVAAWTLKAAANRRA-C, aKXVAAWTLKAAaZC, aKXVAAWTLKAAaZCNRRA, aKXVAAWTLKAAa, aKXVAAWTLKAAaNRRA, aA(X)AAAKTAAAAa, aA(X)AAATLKAAa, aA(X)VAAATLKAAa, aA(X)IAAATLKAAa, aK(X)VAAWTLKAAa, and aKFVAAWTLKAAa, wherein X is L-cyclohexylalanine, Z is aminocaproic acid, and a is an aliphatic amino acid residue selected from alanine, glycine, valine, isoleucine and leucine; and / or

[0720] Wherein the T cell epitope is an alpha synuclein polypeptide selected from the group consisting of: GKTKEGVLYVGSKTK

[0721] (aa31-45), KTKEGVLYVGSKTKE (aa32-46), EQVTNVGGAVVTGVT (aa61-75), VTGVTAVAQKTVEGAGNIAAATGFVK (aa71-86), DPDNEAYEMPSE (aa116-130), DNEAYEMPSEEGYQD (aa121-135), and EMPSEEGYQDYEPEA (aa126-140).

[0722] 8. The conjugate according to any one of embodiments 1 to 7, wherein the conjugate further comprises a carrier protein, preferably a non-toxic cross-reactive substance of diphtheria toxin (CRM), in particular CRM 197 , KLH, diphtheria toxoid (DT), tetanus toxoid (TT), Haemophilus influenzae protein D (HipD), serotype B meningococcal outer membrane protein complex (OMPC), recombinant avirulent form of Pseudomonas aeruginosa exotoxin A (rEPA), flagellin, Escherichia coli heat-labile enterotoxin (LT), cholera toxin (CT), mutant toxins (e.g. LTK63 and LTR72), virus-like particles, albumin binding protein, bovine serum albumin, ovalbumin, synthetic peptide dendrimers such as multiple antigenic peptides (MAP), especially in the conjugate, the ratio of carrier protein to β-glucan or mannan is 1 / 0.1-1 / 50, preferably 1 / 0.1-1 / 40, more preferably 1 / 0.1-1 / 20, especially 1 / 0.1-1 / 10,

[0723] Preferably, the conjugate consists of or comprises the following substances

[0724] (a) β-glucan or mannan

[0725] (b) an alpha synuclein polypeptide as the at least one B cell or T cell epitope polypeptide, and

[0726] (c) a carrier protein,

[0727] wherein the three components (a), (b) and (c) are covalently bound to each other in the order (a)-(b)-(c), (a)-(c)-(b) or (b)-(a)-(c), in particular in the order (a)-(c)-(b); and

[0728] Preferably, all of these components (a), (b) and (c) are coupled via a linker.

[0729] 9. A conjugate according to any one of embodiments 1-8, wherein the polypeptide is or comprises at least one α-synuclein B-cell or T-cell epitope polypeptide, wherein the conjugate further comprises a non-α-synuclein B-cell or T-cell epitope.

[0730] 10. The conjugate according to any one of embodiments 1 to 8, wherein the α-synuclein polypeptide is a native α-synuclein or comprises or consists of the native human α-synuclein amino acid sequence MDVFMKGLSK AKEGVVAAAE KTKQGVAEAAGKTKEGVLYV GSKTKEGVVH GVATVAEKTK EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQLGKNEEGAPQE GILEDMPVDP DNEAYEMPSE a polypeptide consisting of amino acid residues 1-5, 1-8, 1-10, 60-100, 70-140, 85-99, 91-100, 100-108, 102-108, 102-109, 103-129, 103-135, 107-130, 109-126, 110-130, 111-121, 111-135, 115-121, 115-122, 115-123, 115-124, 115-125, 115-126, 118-126, 121121-127, 121-140 or 126-135,

[0731] Preferably, a polypeptide comprising or consisting of amino acid residues 1-8, 91-100, 100-108, 103-135, 107-130, 110-130, 115-121, 115-122, 115-123, 115-124, 115-125, 115-126, 118-126, 121-127 or 121-140; or a mimotope selected from DQPVLPD, DQPVLPDN, DQPVLPDNE, DQPVLPDNEA, DQPVLPDNEAY, DQPVLPDNEAYE, DSPVLPDG, DHPVHPDS, DTPVLPDS, DAPVTPDT, DAPVRPDS, and YDRPVQPDR.

[0732] 10. The conjugate according to any one of embodiments 1-9, wherein the conjugate comprises T-cell epitopes and does not contain B-cell epitopes, wherein the conjugate preferably comprises more than one T-cell epitope, in particular two, three, four or five T-cell epitopes.

[0733] 11. The conjugate according to any one of embodiments 1-10 for use as an active vaccine for the treatment and prevention of synucleinopathies, preferably Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), Parkinson's disease dementia (PDD), neuroaxonal dystrophy, Alzheimer's disease with amygdala restricted dementia with Lewy bodies (AD / ALB).

[0734] 12. The conjugate according to any one of embodiments 1 to 11, for use in inducing a target-specific immune response while inducing no or only a very limited CLEC- or carrier protein-specific antibody response; and / or

[0735] Used in diseases with reduced or dysfunctional Treg cell populations to enhance the number and activity of weakened / reduced Tregs, thereby reducing the autoimmune responsiveness of disease-specific T effector cells and inhibiting the patient's autoimmune response, wherein T cell epitopes suitable as Treg epitopes are used, or in combination with Treg inducers, such as rapamycin, low-dose IL-2, TNF receptor 2 (TNFR2) agonists, anti-CD20 antibodies (such as rituximab), prednisolone, inositol planobex, glatiramer acetate or sodium butyrate; and / or

[0736] Used in treatment to increase or maintain the number of T cells (especially the number of T effector cells) and T cell function in PD patients, which preferably includes a combination of checkpoint inhibitors or vaccines, using anti-immune checkpoint inhibitor epitopes to induce anti-immune checkpoint inhibitor immune responses to increase or maintain the number of T cells (especially the number of T effector cells) and T cell function in PD patients, wherein the CD3+ cells (especially CD3+CD4+ cells) of the selected PD patients are preferably reduced overall, which is a typical feature of PD patients at all stages of the disease; preferably the patient is in H+Y 1-4 stage, more preferably H+Y1-3, and most preferably H+Y 2-3.

[0737] 13. The conjugate according to any one of embodiments 1 to 12, wherein β-glucan or mannan is used as a C-type lectin (CLEC) polysaccharide adjuvant, preferably for enhancing the T cell response to a given T cell epitope polypeptide, more preferably wherein the T cell epitope is a linear T cell epitope, especially wherein the T cell epitope is a polypeptide comprising or consisting of the amino acid sequence SeqID7, 8, 22-29, 87-131, GKTKEGVLYVGSKTK, KTKEGVLYVGSKTKE, ​​EQVTNVGGAVVTGVT, VTGVTAVAQKTVEGAGNIAAATGFVK, MPVDPDNEAYEMPSE), DNEAYEMPSEEGYQD, EMPSEEGYQDYEPEA or a combination thereof.

[0738] 14. The conjugate according to any one of embodiments 1 to 13, for use in increasing affinity maturation against a specific alpha synuclein polypeptide antigen or for inducing an enhanced immune response against the human autoantigen alpha synuclein.

[0739] 15. The conjugate according to any one of embodiments 1 to 14, further comprising a carrier protein comprising a T cell epitope for reducing or eliminating a B cell response to CLEC and / or to the carrier protein and / or enhancing a T cell response to a T cell epitope of the carrier protein, preferably wherein the carrier protein is a non-toxic cross-reactive material (CRM) of diphtheria toxin, in particular CRM197, KLH, diphtheria toxoid (DT), tetanus toxoid (TT), Haemophilus influenzae protein D (HipD), serogroup B meningococcal outer membrane protein complex (OMPC), a recombinant non-toxic form of Pseudomonas aeruginosa ...CRM), a Toxin A (rEPA), flagellin, Escherichia coli heat-labile enterotoxin (LT), cholera toxin (CT), mutant toxins (e.g. LTK63 and LTR72), virus-like particles, albumin binding protein, bovine serum albumin, ovalbumin, synthetic peptide dendrimers, such as multiple antigenic peptides (MAPs), in particular, wherein the T cell epitope potency in vaccines comprising linear T cell epitopes is enhanced, for example by adding a lysosomal protease cleavage site at the N-terminus or C-terminus, such as a cathepsin L-like cleavage site or a cathepsin S-like cleavage site, wherein the cathepsin L-like cleavage site is preferably defined by the following consensus sequence:

[0740] X n -X1-X2-X3-X4-X5-X6-X7-X8

[0741] X n : 3-27 amino acids from an immunogenic peptide

[0742] X1: Any amino acid

[0743] X2: Any amino acid

[0744] X3: Any amino acid

[0745] X4: N / D / A / Q / S / R / G / L; preferably N / D, more preferably N

[0746] X5: F / R / A / K / T / S / E; preferably F or R, more preferably R

[0747] X6: F / R / A / K / V / S / Y; preferably F or R, more preferably R

[0748] X7: any amino acid, preferably A / G / P / F, more preferably A

[0749] X8: Cysteine ​​or linker such as NHNH2,

[0750] The most preferred sequence is X n -X1 X2 X3 NRRA-connector;

[0751] and wherein the cathepsin S-like cleavage site is preferably defined by the following consensus sequence:

[0752] X n -X1-X2-X3-X4-X5-X6-X7-X8

[0753] X n : 3-27 amino acids from an immunogenic peptide

[0754] X1: Any amino acid

[0755] X2: Any amino acid

[0756] X3: any amino acid, preferably V, L, I, F, W, Y, H, more preferably V

[0757] X4: any amino acid, preferably V, L, I, F, W, Y, H, more preferably V

[0758] X5: K, R, E, D, Q, N, preferably K, R, more preferably R

[0759] X6: Any amino acid

[0760] X7: Any amino acid, preferably A

[0761] X8: Preferred A

[0762] X8: Cysteine ​​or linker such as NHNH2, wherein the most preferred sequence is X n -X1X2VVRAA- connector.

[0763] 16. A method for preparing a conjugate according to any one of embodiments 1 to 15, wherein the β-glucan or mannan is activated by oxidation, and wherein the activated β-glucan or mannan is contacted with a B cell and / or T cell epitope polypeptide, thereby obtaining a conjugate of β-glucan or mannan and a B cell and / or T cell epitope polypeptide.

[0764] 17. The method of embodiment 16, wherein the β-glucan or mannan is obtained by periodate oxidation at the ortho-hydroxyl groups, as a reductive amination, or as a cyanation of the hydroxyl groups.

[0765] 18. The method according to embodiment 16 or 17, wherein the β-glucan or mannan is oxidized to a certain degree of oxidation, wherein the degree of oxidation is defined as the reactivity with Schiff fuchsin reagent corresponding to the degree of oxidation of an equivalent amount of pyrenoids by periodate in a molar ratio of 0.2-2.6, preferably 0.6-1.4, especially 0.7-1.

[0766] 19. A method according to any one of embodiments 16-18, wherein the conjugate is produced by a hydrazone-based coupling for coupling hydrazides to carbonyls (aldehydes) or by coupling sulfhydryls (e.g., cysteine) to carbonyls (aldehydes) using heterobifunctional maleimide-and-hydrazide linkers (e.g., BMPH (N-β-maleimidopropionic acid hydrazide, MPBH (4-[4-N-maleimidophenyl]butyric acid hydrazide), EMCH (N-[ε-maleimidocaproic acid) hydrazide), or KMUH (N-[κ-maleimidoundecanoic acid] hydrazide).

[0767] 20. A vaccine product designed for vaccinating an individual against a specific antigen, wherein the product comprises a compound comprising β-glucan or mannan as a C-type lectin (CLEC) polysaccharide adjuvant covalently coupled to the specific antigen.

[0768] 21. The vaccine product according to embodiment 20, wherein the product comprises a conjugate according to any one of embodiments 1-16 or a conjugate obtainable or obtained by a method according to any one of embodiments 16-19.

[0769] 22. The vaccine product according to embodiment 20 or 21, wherein the antigen comprises at least one B c...

Claims

1. A conjugate consisting of at least one β-glucan or mannan and at least one B cell or T cell epitope polypeptide, or comprising at least one β-glucan or mannan and at least one B cell or T cell epitope polypeptide, wherein the β-glucan or mannan is covalently coupled to the B cell and / or T cell epitope polypeptide to form a conjugate of the β-glucan or mannan and the B cell and / or T cell epitope polypeptide, and wherein the B cell and / or T cell epitope polypeptide is an alpha synuclein polypeptide.

2. The conjugate according to claim 1, wherein the β-glucan is a dectin-1-binding β-glucan, preferably pyralidin, lichenan, laminarin, curdlan gum, β-glucan peptide (BGP), schizophyllan, scleroglucan, whole glucan particles (WGP), zymosan or lentinan, more preferably pyralidin, laminarin, lichenan, lentinan, schizophyllan or scleroglucan, especially the β-glucan is pyralidin; and / or the β-glucan is a potent dectin-1 binding β-glucan, preferably determined by competitive ELISA The IC50 value of the conjugate for binding to the soluble mouse Fc-dectin-1a receptor is lower than 10 mg / ml, more preferably lower than 1 mg / ml, even more preferably lower than 500 μg / ml, and especially lower than 200 μg / ml of β-glucan; and / or the IC50 value of the conjugate for binding to the soluble mouse Fc-dectin-1a receptor as determined by competitive ELISA is lower than 1 mg / ml, more preferably lower than 500 μg / ml, even more preferably lower than 200 μg / ml, and especially lower than 100 μg / ml.

3. The conjugate according to claim 1 or 2, wherein the β-glucan is a predominantly linear β-(1,6)-glucan and the ratio of (1,6)-conjugated monosaccharide moieties to non-β-(1,6)-conjugated monosaccharide moieties is at least 1:1, preferably at least 2:1, more preferably at least 5:1, and especially at least 10:

1.

4. The conjugate according to any one of claims 1 to 3, wherein the alpha synuclein polypeptide comprises at least one B cell epitope.

5. The conjugate according to any one of claims 1 to 4, wherein a B cell epitope and a pan-specific / heterogamous T cell epitope are independently conjugated to the β-glucan or mannan.

6. The conjugate according to any one of claims 1 to 5, wherein the length of the B cell epitope polypeptide is 5 to 20 amino acid residues, preferably 6 to 19 amino acid residues, in particular 7 to 15 amino acid residues.

7. The conjugate according to any one of claims 1 to 6, wherein the length of the T cell epitope polypeptide is 8 to 30 amino acid residues, preferably 13 to 29 amino acid residues, in particular 13 to 28 amino acid residues.

8. The conjugate according to any one of claims 1 to 7, wherein the conjugate further comprises a carrier protein, preferably a non-toxic cross-reactive substance of diphtheria toxin (CRM) (especially CRM 197 ), KLH, diphtheria toxoid (DT), tetanus toxoid (TT), Haemophilus influenzae protein D (HipD), outer membrane protein complex (OMPC) of meningococcal serogroup B, recombinant avirulent Pseudomonas aeruginosa exotoxin A (rEPA), flagellin, Escherichia coli heat-labile enterotoxin (LT), cholera toxin (CT), mutant toxins (e.g., LTK63 and LTR72), virus-like particles, albumin binding protein, bovine serum albumin, ovalbumin, synthetic peptide dendrimers such as multi-antigenic peptides (MAP).

9. The conjugate according to any one of claims 1 to 8, wherein the polypeptide is or comprises a B cell epitope polypeptide or a T cell epitope polypeptide, preferably the polypeptide is or comprises a B cell epitope and a T cell epitope.

10. The conjugate according to any one of claims 1 to 8, wherein the conjugate comprises a T cell epitope, preferably a T cell epitope comprising the amino acid sequence AKFVAAWTLKAAA, optionally linked to a linker, preferably AKFVAAWTLKAAANRRA-(NH-NH2), AKFVAAWTLKAAAN-C, AKFVAAWTLKAAA-C, AKFVAAWTLKAAANRRA-C; or a linker selected from aKXVAAWTLKAAaZC, aKXVAAWTLKAAa Variants of ZCNRRA, aKXVAAWTLKAAa, aKXVAAWTLKAAaNRRA, aA(X)AAAKTAAAAa, aA(X)AAATLKAAa, aA(X)VAAATLKAAa, aA(X)IAAATLKAAa, aK(X)VAAWTLKAAa, and aKFVAAWTLKAAa, wherein X is L-cyclohexylalanine, Z is aminocaproic acid, and a is an aliphatic amino acid residue selected from alanine, glycine, valine, isoleucine and leucine.

11. The conjugate according to any one of claims 1 to 10, wherein the ratio of β-glucan or mannan to B cell and / or T cell epitope polypeptide in the conjugate is 10:1 (w / w) to 0.1:1 (w / w), preferably 8:1 (w / w) to 2:1 (w / w), especially 4:1 (w / w).

12. Use of the conjugate according to any one of claims 1 to 11 as an active anti-alpha synuclein vaccine for the treatment and prevention of synucleinopathies, preferably Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), Parkinson's disease dementia (PDD), axonal dystrophy, amygdala restricted Lewy body AD (AD / ALB).

13. A method for preparing a conjugate according to any one of claims 1 to 12, wherein the β-glucan or mannan is activated by oxidation, and wherein the activated β-glucan or mannan is contacted with a B cell epitope polypeptide and / or a T cell epitope polypeptide, thereby obtaining a conjugate of β-glucan or mannan and a B cell epitope polypeptide and / or a T cell epitope polypeptide.

14. The method according to claim 13, wherein the β-glucan or mannan is obtained by periodate oxidation on the ortho-hydroxyl groups, by reductive amination, or by cyanation of the hydroxyl groups.

15. The method according to claim 13 or 14, wherein the β-glucan or mannan is oxidized to a degree of oxidation defined as the reactivity with Schiff's fuchsin reagent corresponding to the degree of oxidation of an equivalent amount of β-glucan with periodate in a molar ratio of 0.2-2.6, preferably 0.6-1.4, especially 0.7-1.